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ABSTRACT 
Critically ill patients are known to experience stress-induced hyperglycemia. Inhibiting the 
physiological response to increased glycemic levels in these patients are factors such as 
increased insulin resistance, increased dextrose input, absolute or relative insulin 
deficiency, and drug therapy. Although hyperglycemia can be a marker for seveIity of 
illness, it can also worsen outcomes, leading to an increased risk of further complications. 
Hyperglycemia has been quantified in critically ill patients showing the need for glucose 
control. The development of a relatively simple system model and the verification of both 
genenc and patient specific parameters have been successful in control trials and 
simulations over a range of critically ill patients. Stepwise reduction of blood glucose 
values by adaptive control was shown to be accurate to within 20 %, and average long-tenn 
fitting errors are within the measureIllent error of the glucose sensor. 
A control algorithm capable of tight regulation for a glucose intolerant ICU patient would 
thus reduce mortality, as well as the burden on medical resources and time with current 
experience-based control approaches used in most critical care units. Overall, the research 
presented is a significant step towards fully automated adaptive control of hyperglycaemia 
in critically ill patients. 
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INTRODUCTION AND OVERVIEW 
1.1 MOTIVATION 
Critically ill patients often experience stress-induced hyperglycemia and high levels of 
insulin resistance (Bloomgarden, 2003; Capes, et aI., 2000; Christensen, 2001; Coursin and 
Murray, 2003; Esposito, et a1., 2003; Finney, et aI., 2003; I<rinsley, 2003; McCowen, et aI., 
2001; Mizock, 2001; Ousman, 2002; Peck, 2004; Umpierrez, et aI., 2002; Van den Berghe, 
et aI., 2001; 2003). Nutritional support regimes with a high dextrose content often 
compound the counter-regulatory response, induce insulin resistance, and did not suppress 
endogenous glucose production as with a prandial input (McCowen, et aI., 2001; Mizock, 
2001; Patino, et aI., 1999; Weissman, 1999). Inhibiting the physiological response to 
increased glycemic levels are factors such as increased insulin resistance, absolute or 
relative insulin deficiency, and dmg therapy. Although hyperglycemia can be a marker for 
severity of illness, it can also worsen outcomes, leading to an increased risk of further 
complications, such as severe infections (Bistrian, 2001), myocardial infarctions (Capes, et 
aI., 2000), polyneuropathy and multiple-organ failure (Van den Berghe, et aI., 2001). Tight 
2 and Control of HunPrcrl in Clitical Care Patients 
glucose control has been shown to reduce Intensive Care Unit (lCU) patient mortality by as 
much as 45% (Van den Berghe, et aI., 2001; 2003) if kept to a glucose level less than 6.1 
mmollL for a cardiac care population. Krinsley (2003) showed a 6 % total reduction in 
mortality over a broader critical care populations at a glucose limit of7.75 mmol/L. 
The aim of this research is to quantifY hyperglycemia in critically ill patients, and then 
introduce a system model that captures the mechanisms involved and provides a means of 
developing control protocols. The focus on critically ill patients arises because emerging 
glucose sensors are still in their infancy, so it is likely that the first area for implementation 
of an automated approach to controlling glycemic levels is in a clinical environment. A 
number of recent studies have also shown reduction in mortality in critically ill patients 
when their glucose levels were lowered (Krinsley, 2003; Van den Berghe, et aI., 2001; 
2003). A control algorithm capable of tight regulation for a glucose intolerant ICU patient 
would thus reduce mortality, as well as the burden on medical resources and time with 
current experience-based control approaches used in most critical care units. 
A retrospective data analysis is performed to determine how high blood glucose levels are 
in critical care patients and the impact of hyperglycemia on mortality, for the Christchurch 
Hospital ICU. Short-tenn and long-term analysis are presented, showing the range of 
applications for the control algorithm and in verifYing the system model of glucose-insulin 
kinetics. Short-term targeted control has been clinically triaIled and used to verifY the 
system model, showing extremely good results in achieving the sub-targets set out. Long-
term data fitting and predictions of retrospective data show the promise of the system 
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model, when teamed with a suitable controller, in both clinical situations and, eventually, 
for ambulatory diabetic individuals. 
1.2 THE GLUCOSE-INSULIN SYSTEM 
After food is consumed, the body reduces the complex carbohydrate and sugar molecules to 
the simple six-carbon sugar known as glucose. Glucose is the body's fuel, and upon the 
reduction by the body, it is either utilised or stored. Sensing glucose in the bloodstream 
leads the p-cells in the pancreas to produce insulin. The concentration of insulin acts as the 
body's signal as to how to manage its storage and transportation needs, and hence 
determines the utilisation rate of the glucose. 
1.2.1 The Role of Insulin in the Body 
Insulin is a small protein, which consists of 51 amino acids in two closely connected 
chains. Insulin molecules and their connecting fragments are then packed together in small 
granules in the P-cells, which are secreted through the islets of Langerhans in the pancreas. 
Along with p-cells, the 1 to 2 million islets of Langerhans contain alpha and delta cells 
which secrete glucagons and somatostatin respectively, which act as additional blood 
glucose regulatory honnones. The alpha, beta and delta cells are approximately 25%, 60% 
and 10% of the total islets and are all very closely related (Guyton and Hall, 1996; Joslin, 
1985). 
<4 Modelling and Control of Hyperglycemia in Critical Care Patients 
Upon stimulation by glucose, the granules are pulled to the surface of the ~-cells and the 
insulin molecules are released into the blood, also releasing the C-peptide connector. 
Therefore, C-peptide measurements are an accurate indicator of endogenous insulin 
production. In the blood, insulin travels in an almost entirely unbound form to the tissue 
receptors. A great deal of insulin is cleared from circulation within 10 - 15 minutes, with 
the only exception being insulin that has combined with receptors in the target cells and the 
small amount which is degraded by the liver, kidneys, muscle and other tissues. The rapid 
removal of insulin from the bloodstream is very important, quickly relaying the insulin 
signal to stop production of insulin as a prompt form of control. 
The level of insulin in the bloodstream is the signal that facilitates the metabolic response 
to produce the desired effect. A high insulin level promotes storage of glucose, and a low 
insulin level signals the need for the release of glucose fuels, currently in storage, back into 
the blood stream, as shown by Figure 1.1. A meal results in an increase of insulin 
concentration in the blood, due to the increased secretion of insulin by the ~-cells, and 
signals the liver and muscles to consume the extra fuel (glucose) available. The liver stores 
glucose as glycogen or fat, and the muscles utilise glucose primarily to repair damaged 
muscle cells, for energy storage as glycogen and lastly storage in the fat cells. 
Glooagcm~ 
by Alpha Cells 
off 
Aohleve 
Normal Blood 
GI~UweIs 
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FIGURE 1.1: EFFECT OF HIGH AND LOW BLOOD GLUCOSE LEVELS ON THE 
BODY (ENDOCRINEWEB.COM, 2002) 
When insulin levels are too high, counter regulatory honnones, such as glucagons and 
adrenaline, signal the liver to release glucose. If the insulin levels are significantly too 
high, then too much glucose is removed from the blood-stream, sometimes resulting in 
dangerously low blood glucose levels. When the glucose available is not sufficient to 
supply the brain's requirements, hyperglycemic symptoms include hunger, anxiousness, 
restlessness, agitation, perspiration, tachycardia (racing pulse) and palpitation (irregular 
and/or forced heart-beats). These symptoms are partly a result of the release of adrenalin 
by the body as a counter regulatory measure to restore nonnal blood glucose levels. 
6 Modelling and Control of Hyperglycemia in Critical Care Patients 
When there is a deficit in the amount of insulin released, the signal is not available to the 
body to indicate it should remove glucose from the blood stream. The blood-glucose level 
therefore rises and remains higher than the body's natural basal glucose level for an 
extended period, resulting in hyperglycemia. If the deficit in insulin is slight, it is probable 
that sufficient insulin levels will be available to control glucose in the fasting state. 
However, when fuel is ingested, the blood glucose level will become hyperglycemic. As 
the body is able to function with deficient insulin levels only in the fasting state, it is said to 
be lacking in glucose tolerance or glucose intolerant. 
In the body's fasting state the organs must be supplied fuel (glucose) from the reserves in 
storage in the liver to retain function. The need for glucose reserves is indicated by a low 
insulin concentration in the blood. The brain is the body's priority for supply and 
continuously requires glucose. If the glucose is not available to supply all major organs, 
the energy requirement of the brain is still met by the liver's stored glycogen reserves. 
These priorities are shown in Figure 1.2. As the concentration of insulin signals the amount 
of glucose available, its role in directing glucose to the brain is vitally important. Insulin 
also increases the activity of other enzymes, primarily those involved in glycogen, lipid and 
protein synthesis, and inhibits the activity of those that catalyse glucose degradation. All 
major functions of insulin in the body are outlined in Figure 1.3. 
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FIGURE 1.2: MAJOR ORGANS IN THE INSULIN-GLUCOSE DYNAMICS SYSTEM 
(SALTIEL AND KAHN, 2001) 
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FIGURE 1.3: PHYSIOLOGICAL EFFECTS OF INSULIN. 
(A '+' indicates an increase, while -' indicates a decrease in level) 
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1.2.2 Diabetes Mellitus 
Diabetes is a disorder of the metabolism where little or no insulin is produced by the p-
cells, and as such blood glucose cannot be transported out of the blood. Diabetes is 
generally divided into two broad categories labelled Type 1 and Type 2. However, the two 
categories can be thought of as defining a continuum of insulin deficiency. 
Type 1 Diabetes Mellitus 
Type 1 diabetes is also known as juvenile onset diabetes, insulin dependent diabetes, or 
sometimes known as ketosis prone diabetes. The tenn juvenile onset diabetes arises as 
most people diagnosed with Type 1 diabetes are identified at a young age, as a result of 
contraction of an immune-disorder disease. Both of the other terms for Type I diabetic 
individuals come from the person's insulin dependency, as without insulin death due to 
ketoacidosis may occur. Type 1 diabetic individuals have little or no p-ce1ls or p-cell 
function, and therefore no ability to produce insulin. 
Type 2 Diabetes Mellitus 
Type 2 diabetes is known as stable diabetes, maturity onset diabetes, or non-insulin 
dependent diabetes. Generally, Type 2 diabetic individuals are diagnosed in their forties or 
later. Although they may require small doses of insulin, it is not always completely 
essential for body functions. Type 2 diabetes that is not too severe can be controlled 
through diet and lifestyle alone. 
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Post-prandial glucose measurements can often be used to determine the extent of a person's 
~-cell function. A normal person's glucose levels should retum to normal within 2 - 3 
hours in response to a glucose challenge, where a Type 1 diabetic individual will not 
naturally return to basal and an exogenous insulin input is required. The blood glucose 
level of a Type 2 diabetic individual will eventually return to basal, but may require 
external insulin to aid in this mechanism. Each of these responses are shown schematically 
in Figure 1.4. 
Blood Glucose 
over Basal Level 
2-3 
hours 
Type I 
IGT, Type II 
Back to Fasting 
Level 
FIGURE 1.4: BLOOD GLUCOSE RESPONSE TO A GLUCOSE CHALLENGE 
Complications of Diabetes 
Lack of insulin results in blood glucose levels remaining dangerously high, which untreated 
over time can lead to costly complications. The risks of complications increase with the 
duration of the disease. Diabetic individuals are more likely to develop eye diseases such 
as retinopathy and cataracts, and skin disorders such as ulcers and infections, than non-
diabetic individuals. Diabetic individuals also have an increased risk of heart disease, 
peripheral vascular (outer blood vessel) disease and cerebrovascular disease (stroke), as 
well as increased neuropathy (nervous system disease). 
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Many of the complications due to diabetes are a result of protein cross-linking that occurs 
in the presence of elevated blood glucose levels. Protein containing collagen fibres 
surround blood vessels. When these proteins form cross-links in the presence of excess 
glucose, the fibres loose much of their elasticity, resulting, for example, in hardening of the 
arteries around the heart or atherosclerosis. Atherosclerosis facilitates the formation of 
plaques which, when they break off, can obstruct the blood vessel resulting in heart attack. 
Pathologic changes in blood vessels are a large contributor to many of these complications. 
The immune system also fails to function optimally in the presence of high blood glucose 
levels. At 8 mmol/L, the immune response is only 50 % effective, and at 10 mmol/L, the 
immune response is essentially completely ineffective. An ineffective immune response 
can have the obvious significant consequences in terms of fighting off bacterial or viral 
infections. 
Current Treatment of Diabetes 
Current treatment of Type 1 and severe Type 2 diabetes involves constant monitoring of the 
plasma glucose level and injecting insulin into the subcutaneous tissue as required and best 
practice was laid out by the Diabetes Control and Complications Trial Research Group 
(1993). Using a glucose monitoring system and an insulin pump or syringe injections, all 
current treatments are performed manually by the patients or, in a hospital setting, under 
professional care. Therefore, diabetic individuals are required to monitor food intake and 
daily activity to maintain blood glucose levels at an acceptable level. For ease of 
management, subjects are encouraged to stick to strict routines and diets to keep manual 
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monitoring and injections to a minimum, reducing intervention and difficulty. This regime 
can lead to severe limitation of the subjects' lifestyle and is prone to error. As a result, 
many diabetic individuals do not, or cannot, maintain tight blood glucose control, resulting 
in regular and continuous exposure to elevated blood glucose levels. Hence, the primary 
problem with current treatment is that there is no interface between the monitoring system 
and insulin pump to automate the treatment with stability and robustness. 
1.2.3 Stress-induced Hyperglycemia 
Medical illness and surgery can cause a state of increased insulin resistance and 
consequently decreased insulin sensitivity, in both diabetic and non-diabetic patients 
(Bloomgarden, 2003; Capes, et aI., 2000; Christensen, 2001; Coursin and Murray, 2003; 
Esposito, et aI., 2003; Finney, et aI., 2003; Krinsley, 2003; McCowen, et aI., 2001; Mizock, 
2001; Ousman, 2002; Umpierrez, et aI., 2002; Van den Berghe, et aI., 2001; 2003). Given 
the stress-induced insulin resistance, hyperglycemia is exacerbated by the administration of 
intravenous fluids containing dextrose (McCowen, et aI., 2001; Mizock, 2001; Patino, et 
aI., 1999; Weissman, 1999). Increases in glucagons, growth hormones and 
neurotransmitters such as adrenaline, diminish the effects of insulin, decrease the insulin 
secretion, and stimulate hepatic glucose production (Coursin and Murray, 2003; Finney, et 
aI., 2003; Hanson, et aI., 2000; Mizock, 2001; Ratner, 2001; Thorsteinsson, 1990; Toffolo, 
et aI., 1980; Turnheim and Waldhausl, 1988; Van den Berghe, et aI., 2001; Zierler, 1999). 
As a result, a critical care patient has increased blood glucose production and input, 
combined with decreased ability to reduce blood glucose levels. 
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Maintaining normal basal blood glucose levels becomes increasingly important in surgical 
and critically ill patients. Treatment, typically with insulin, must compensate for caloric 
intake, as well as the increased stress the body is subject to as it excretes adrenalin and 
other stress honnones. To avoid serious medical predicaments such as ketosis, white blood 
cell dysfunction, infection, and slowed wound healing, tight blood glucose control should 
be maintained. In particular, tight glucose control in surgical cardiac critical care patients 
has been shown to reduce mortality as much as 45 % (Van den Berghe, et aI., 2001; 2003) 
and 6 - 10 % in general critical care populations (Krinsley, 2003). 
Current Treatment of Hyperglycemia in the lCU 
In hospital situations, the most common management of blood glucose levels is to use a 
'sliding-scale' protocol to administer insulin (Albisser, et aI., 1974; Chee, et aI., 2002; 
Woolf son, 1980). An example of this method is shown in Table 1.1. However, this 
method is often unused by medical staff, or used only as a guide, and medical staff intuition 
and experience are used instead in the art of medicine. There are also many problems with 
the sliding scale approach, as it is strictly reactive to blood glucose levels, rather than 
proactive so, it can result in large swings between hypoglycemia and hyperglycemia for 
some patients. It has also received a measurable amount of resistance by physicians and 
researchers that have considered the sliding scale and found the approach to be less than 
satisfactory (Kletter, 1998; Queale, et aI., 1997; Radack, 1997; Sawin, 1997). 
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TABLE 1.1: AN EXAMPLE OF A SLIDING SCALE INSULIN PROTOCOL 
Bloon (ljlucose Slitling Scale Insulin 
CmmoI1'Th) Infusion ~m%Iir) 
<8 0 
8 -10 1 
10-12 2 
12 -14 3 
>15 6 
1.3 RESEARCH OBJECTIVES 
The overall objective of this research is to further studies towards the ultimate goal of 
automating insulin infusions in critically ill patients. To reach this goal, a number of 
avenues are considered. The research presented focuses on: 
1. quantifying the need for automated insulin infusion in the ICU 
2. improving the system model 
3. identifying patient specific parameters 
4. verifying the system model and patient specific parameters 
5. applications of the system and controllers developed 
1.3.1 Retrospective Data Audit 
The retrospective data audit considers the blood glucose and insulin profiles of all patients 
with a stay greater than 72 hours in the Christchurch Hospital ICU over a period of 12 
and Control of .... " ... "..·nl in Critical Care Patients 
months. This data allowed a wide range of aspects to be considered, and gave quantitative 
values to concepts that had previously been assumed on the basis of qualitative 
observations. The study also provided a database of patient information for use in model 
verification. 
1.3.2 System Modelling 
The system model used in this research has evolved over the previous 3 years from the 
original three compartment minimal model (Bergman, et a1., 1985). It now comprises 2 
non-linear differential equations which can be decomposed into 3 linear equations. 
Michaelis-Menten saturation of two different insulin kinetics is then added to these 
equations. The evolution from Bergman's three compartment model to the current model 
has been an iterative process, aiming to capture all essential dynamics while minimising 
complexity. This approach minimises computational effort and increases the opportunity 
for the model to be used in control design and by medical staff in a clinical environment 
where patient condition and patient specific parameters are often highly variable. 
1.3.3 Pal'ametel' Identification 
As each research group modelling the glucose-insulin system has a dif1erent model, 
parameter values, their definition, and their defined effects change between models. Values 
from the medical literature were converted into parameters relevant to the model 
developed, and used as initial estimates of time-varying parameters, or as approximations 
to generic, constant parameters. 
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1.3.4 Model and Parameter Verification 
Parameter values were researched and physiologically valid ranges identified from the 
extensive literature on the subject (Araujo-Vilar, et aI., 1998; Avogaro, et aI., 1989; Baura, 
et aI., 1993; Bergman, et aI., 1985; 1981; 1987; Bettini, et aI., 1995; Caumo, et aI., 1999; 
Cobelli, et aI., 1998; Duckworth and Kitabchi, 1981; Duncan, et aI., 2003; Ellemann, et aI., 
1987; Furler, et aI., 1985; Kobayashi, et aI., 1983; Kraegen and Chisholm, 1984; 
McDonald, et aI., 2000; Natali, et aI., 2000; Nestler, et aI., 1988; Pacini and Bergman, 
1986; Pillonetto, et aI., 2002; Prigeon, et aI., 1996; Thorsteinsson, 1990; 1986; Transberg, 
et aI., 1981; Turnheim and Waldhausl, 1988; Vicini, et aI., 1997; 1999). These values were 
used as bounds with retrospective patient data to verify the ability of the model to capture 
the dynamics observed using physiologically valid values 
1.3.5 Control Applications 
The clinical trials and retrospective data fitting presented show the efficacy of the control 
algorithm and system models in achieving sub-target control and effectively capturing 
measured glucose and values across a wide range of critically ill patients. The progression 
ofthe model throughout the clinical trials has shown merit in the results, however, ideally a 
larger patient cohort will be subjected to the current model in order to further analyse its 
effectiveness and find areas in which improvements could be made. Overall, the system 
model presented was able to accurately capture essential dynamics of the system exhibited 
by the glucose and insulin driven metabolic responses in critically ill patients over both 
short-term and long-term periods. 
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1.4 PRIOR CONTROL RESEARCH 
1.4.1 The Need for Control 
While lCU patients are often sedated and in a highly monitored state, they are extremely 
diverse in the dynamics of their hyperglycemia. As a result, their response to a glucose 
input can vary significantly due to equally extreme variations in insulin levels, effective 
insulin utilization, glucose absorption and a variety of other factors. Therefore, fixed 
protocols can result in error, given the large variation in patient dynamics. Hence, this 
research represents a fairly extreme test of the ability of the models and control systems 
developed, and highlight the need for simplicity in a clinical environment. 
Automated treatment promises better control of blood glucose with higher consistency and 
an associated reduction in rclated complications. Existing insulin pumps and emerging non-
invasive and semi-invasive glucose monitoring systems may be easily interconnected to 
realise a closed loop system. Ultimately, the control unit should be able to automate 90 -
95% of the day-to-day insulin care. Therefore, the goal is to control the essential dynamics, 
rather than all ofthe dynamics and exceptional behaviours. 
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1.4.2 Practical Implementation of Control Systems 
Research undertaken by Lam et al (2002) outlined the requirements for practical 
implementation of a blood glucose controller for diabetic individuals based upon Bergman 
et aI's (1985) minimal model. The aim was to develop a control method for the automation 
of insulin infusion that linked emerging technologies in blood glucose biosensors with 
insulin infusion technology. The requirements of the controller were that it had to be able 
to account for variations in a patient's response to a glucose input and different sensor 
bandwidths, while maintaining a level of simplicity and robustness. A heavy derivative 
controller was employed, and simulations showed that a reduction in the sampling period 
provided a better control response (Chase, et aI., 2002; Lam, et aI., 2002). The trade-off's 
between sampling period, sensor lag, and various control regimes were considered by 
simulation, an example of which is shown in Figure 1.5. 
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FIGURE 1.5: TYPE 1 DIABETIC INDIVIDUAL RESPONSE TO AN OGTT USING 
BERGMAN ET AL'S (1985) MINIMAL MODEL AND VARYING CONTROL 
REGIMES BY LAM ET AL (2002) 
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The next step was to put this theoretical work into practice. This task was undertaken by 
Chase et al (2003; Doran, et aI., 2004a), and used the concepts developed by Lam et al 
(2002) to control blood glucose levels in critically ill patients. Initially, Bergman et aI's 
(1985) original model was reduced from three-compartments to two-compartments, as 
critically ill patients have a direct IV line, which bypasses the subcutaneous compartment 
described by Bergman et al (1985). A heavy derivative controller to manage blood 
glucose levels following an OGrr of75g (Chase, et aI., 2003; Doran, et aI., 2004a; 2004b). 
The test was conducted over two days, with the first day consisting of an OGrr with 
minimal or no insulin infusion, to determine patient specific model parameters. The second 
day consisted of applying the controller during an identical OGTT. The research succeeded 
in demonstrating tight, feedback controlled blood glucose regulation in response to a 
glucose input in critically ill patients using a heavy-derivative controller. The model was 
able to capture the insulin consumed to within 10%, and heavy derivative control was 
shown to result in reductions in glucose excursion of up to 89% and basal glucose 
reductions of up to 41 % (Doran, et aI., 2004a; 2004b). Figure 1.6 shows an example ofthe 
uncontrolled (day one) and controlled (day two) clinical trial. 
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FIGURE 1.6: CONTROLLED AND UNCONTROLLED RESPONSE TO AN OGTT IN 
A CRITICALLY ILL PATIENT (DORAN, ET AL., 2004A; 2004B) 
Albisser et al (1974) was the first researcher to explore clinical trials which showed the 
validity in reducing blood glucose levels using feedback control. Chee et al (2002) has also 
recently explored automation to manage blood glucose levels in critically ill patients. Chee 
et al (2002) developed a closed loop control system based on an existing 'sliding-scale' 
protocol, and was able to maintain blood glucose levels within the range 10 - 15 mmollL, 
but not to within 6 - 10 mmollL. Their reasoning for not obtaining lower levels was their 
conservativeness in insulin infusion rates to avoid hypoglycemic episodes. 
Other clinical trials in the literature have focused on clamp test data (e.g. Caumo, et al., 
1999; Cobelli, et al., 1998; 1999; DeFronzo, et al., 1979; Hanson, et al., 2000; Katz, et al., 
2000) and have been utilised for fitting a model (e.g. Hovorka, et al., 1998a) or 
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identification of parameters (e.g. Araujo-Vilar, et aI., 1998; Bergman, et aI., 1981; 
Hrebicek, et aI., 2002; McGuire, et aI., 1979; Radziuk, 2000). A number of the clinical 
trials are based upon the minimal model (Bergman, et aI., 1985), and some trials have 
found the minimal model to underestimate insulin sensitivity (e.g. Araujo-Vilar, et aI., 
1998; Avogaro, et aI., 1989; Caumo, et aI., 1999; Cobelli, et aI., 1998; 1999; McDonald, et 
aI., 2000; Radziuk, 2000; Vicini, et aI., 1997; 1999) as estimating this value is often the 
target of these clinical studies. 
Hovorka et al (2002) claim that this decreased insulin sensitivity value is due to too much 
modelled glucose, and modify the minimal model to a more complex model including two 
compartments representing the kinetics of D_[U_I3C] glucose, two compartments 
representing the kinetics of 3-0-methyl-D-glucose, and two compartments representing the 
kinetics of native glucose. In addition, Hovorka et aI's (2002) model includes three insulin 
compartments representing insulin's effect on glucose distribution and transport, glucose 
disposal, and glucose production, resulting in 19 parameters. 
Other less complex approaches based on the minimal model have used two glucose 
compartments (e.g. Cobelli, et aI., 1999; Vicini, et aI., 1999) splitting the glucose into hot 
and cold (traced and untraced) compartments, non-compartmental approaches (Mari, et aI., 
2001; Natali, et aI., 2000) or have focused on insulin kinetics, primarily saturation kinetics, 
without considering utilisation (e.g. Home, et aI., 1982; 1990; 1986; Thorsteinsson, et aI., 
1985). Of these trials, very few have used control algorithms or focused on developing a 
system model for a control application, focusing instead on fitting data retrospectively. 
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1.5 HARDWARE AVAILABLE FOR CONTROL IMPLEMENTATION 
1.5.1 Glucose Monitoring Technology 
The fundamental aspect of ongoing treatment regimes for diabetes involves self-monitoring 
of blood glucose levels. The standard for obtaining a blood sample is the finger prick 
method. The blood sample is applied manually to a test strip and, in conjunction with a 
portable meter, the blood glucose measurement is found. The subject must then use their 
prior knowledge and experience, along with a prediction of the exercise and glucose intake 
they expect to experience in the next few hours, to interpret the glucose measurement and 
provide the insulin necessary to control their glycemic level. Monitoring of blood glucose 
concentration is highly important to avoid hypoglycemic and hyperglycemic incidents, 
however, due to the pain, hassle, and expense of testing, a number of diabetic individuals 
do not monitor their glucose levels as often as would be preferred by health professionals. 
In addition, this approach is subject to error due to misuse resulting from poor ergonomics 
by the diabetic individual (Rogers, et aI., 2001). 
Alternative sites for blood glucose sampling have been proposed in less sensitive areas of 
the body and devices have been developed to take these measurements. Health and 
industrial workers are among the groups who have found the finger as a site for blood 
extraction less than desirable. The AtLast meter developed by Amira Medical is early 2000 
can be used in either the forearm or the thigh, whereas the Freestyle meter developed by 
TheraSense Inc in mid 2000 produces a "pin-head" sized blood sample painlessly from the 
forearm (Reynolds and Karounos, 2002). Lifescan and Abott have also introduced a 
number of options for alternative site testing (Johnson, et aI., 2001). It should be noted that 
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alternative site testing may result in bruising, and that the fingertip is preferable over the 
forearm or thigh for detecting rapid changes in glucose levels, and hence be used for 
confirmation if the subject is concerned (Johnson, et al., 2001). 
Beyond these choices, technological advances have lead to many options for sensmg 
glucose levels with less invasiveness and inconvenience. The main options available on the 
market are the Gluco Watch Biographer from Cygnus and the Medtronic MiniMed 
Continuous Glucose Monitoring System (CGMS) by Paradigm (Muir, 2003). In addition, 
there are emerging non-invasive technologies using infra-red sensing (Anscombe, 2003). 
Gluco Watch biographer 
The Gluco Watch biographer developed by Cygnus is one of the forerunners in the field of 
emerging glucose sensors, providing frequent, automatic and semi-invasive glucose 
measurements. It works by extracting glucose through the skin using a low level current 
passed between a cathode and an anode in a method known as reverse iontophoresis. 
Uncharged glucose molecules are carried in the stream of charged sodium ions heading for 
the cathode, and the amount of glucose extracted is correlated to the blood glucose levels. 
Glucose measurement is perfonned using an electrochemical biosensor which detects H20 2 
produced in the glucose/glucose oxidase reaction. 
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AutoSensor 
Glu(:oWatch 
FIGURE l.7: GLUCOWATCH AND AUTOSENSOR PADS 
The GlucoWatch has limitations, with data accuracy compromised in the presence of high 
electrical currents or noise, open or short circuits, and excessive perspiration. Incorporated 
in the GlucoWatch are skin temperature and conductance sensors to detect where 
perspiration may have affected the reading. Predetermined criterion on the temperature and 
conductance sensors, and the glucose measurement output cause nonconforming readings 
to be skipped. A study of 13,573 biographer readings resulted in only 3.1 % of skipped 
readings (Pitzer, et al., 2001) in semi-controlled use. 
Minimed Subcutaneous Sensor (CGMS System Gold) 
The Minimed system is more useful as a diagnostic tool than a day-to-day monitoring 
device, but can fulfil either role. The key components are an abdominal subcutaneous 
glucose sensor, and a small pager-type monitor (as shown in Figure 1.8), for diagnosis and 
analysis, a communication station and computer software is also required. The 
subcutaneous sensor can be worn for up to 72 hours, and the battery operated moni tor 
averages the 10 second samples to display a glucose output every 5 minutes, providing 288 
readings during a 24 hour period. The subject also has the option of manually entering 
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glucose data and event infonnation so that when the data is downloaded, the healthcare 
professional has greater background knowledge to apply to analysis (Medtronic Inc, 2004; 
Reynolds and Karounos, 2002). Limitations include premature sensor failure resulting in 
loss of data, calibration issues, and the hassle involved in relocating the sensor and in 
keeping an event diary. However, the data density delivered is excellent and could be 
useful in a cIitical care situation given the hands-off nature of its operation. 
FIGURE 1.8: MEDTRONIC CGMS GLUCOSE SENSOR UNIT (MEDTRONIC INC, 
2004) 
1.5.2 Insulin Infusion Technology 
Insulin pump therapy is now used by more than 200,000 people in the United States, and 
it's use is growing worldwide (Nadeau, 2003). Although some diabetic individuals are 
unable to use insulin pumps, the majority prefer it for its convenience, flexibility, and ease 
of use. A study by Raskin (2003) compared efficacy, safety and patient satisfaction of 
Continuous Subcutaneous Insulin Infusion (CSIJ) using an insulin pump with Multiple 
Daily Injection (MDI) therapy in 132 type 2 diabetic patients. The study showed CSIJ 
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therapy and MDl therapy had comparable safety and efficacy, but 93% of the CSII treated 
patients preferred it to the MDI therapy. 
In a clinical environment such as the ICU, drug delivery devices are commonplace and are 
used to give bolus or continuous infusions of multiple drugs. Currently, the insulin 
infusion is set by the nurse on the infusion pump, with the rate detennined from the history 
of GlucoCard readings, knowledge of feed details, expeIience and intuition. 
1.6 SUMMARY 
The need for glucose control in cIitically ill patients cannot be debated. Though it may not 
be the main cause of mortality, it has been shown that it may playa large factor and is 
controllable with insulin, and thus should be closely monitored. The level of existing and 
emerging technology allows a closed-loop automated system to be realised. Given the 
potential liability issues of an automated insulin infusion, it is likely that the first place the 
system will be implemented will be in a clinical environment. Hence, the clinical 
application of automated insulin infusion, and the lCU in particular, is the focus for the 
research presented. 
Feedback control has been trialled by a number of researchers, using methodology ranging 
from sliding-scale (Chee, et al., 2002; Van den Berghe, et al., 2001; 2003) to heavy 
deIivative control (Chase, et al., 2002; 2003; Doran, et al., 2004a; 2004b; Lam, et al., 
2002), with mixed results. Insulin infusion technology is widely accepted by both diabetic 
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individuals and clinical professionals and glucose sensing technology is emerging. The 
emerging glucose monitoring technology has been seen to have issues related to it's 
accuracy and efficacy (Muir, 2003; Pitzer, et aI., 2001), and hence, the clinical environment 
is seen to be the most likely location for the introduction of automated glucose regulation. 
Overall, the future promises the combination of blood glucose sensors and insulin infusion 
technology and with the addition of a control algorithm, the development of a closed-loop 
feedback automated controller is imminent. 
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2 
RETROSPECTIVE DATA AUDIT 
2.1 MOTIVATION 
Critically ill patients often experience stress-induced hyperglycemia and high levels of 
insulin resistance, even if they have no history of diabetes (Bloomgarden, 2003; Capes, et 
aI., 2000; Christensen, 2001; Coursin and Murray, 2003; Esposito, et aI., 2003; Finney, et 
aI., 2003; Krinsley, 2003; McCowen, et aI., 2001; Mizock, 2001; Ousman, 2002; Peck, 
2004; Umpierrez, et aI., 2002; Van den Berghe, et aI., 2001; 2003). The metabolic response 
to stress is characterised by major changes in glucose metabolism. Increased secretion of 
counter-regulatory honnones leads to a prominent rise in endogenously produced glucose 
and the rate of hepatic gluconeogenesis, as well as a reduction in insulin sensitivity. 
Nutritional support regimes with a high dextrose content often compound the counter-
regulatory response and do not suppress endogenous glucose production as a meal normally 
would (McCowen, et aI., 2001; Mizock, 2001; Patino, et aI., 1999; Weissman, 1999). 
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Inhibiting the response to increased glycemic levels are factors such as increased insulin 
resistance, absolute or relative insulin defIciency, and drug therapy. Although 
hyperglycemia can be a marker of severity of illness, it can also worsen outcomes, leading 
to an increased risk of further complications, such as severe infections (Bistrian, 2001), 
myocardial infarctions (Capes, et aI., 2000), polyneuropathy and multiple-organ failure 
(Van den Berghe, et aI., 2001). Tight glucose control has been shown to reduce Intensive 
Care Unit (lCU) patient mortality by as much as 45% (Krinsley, 2003; Van den Berghe, et 
aI., 2001; 2003). 
It is debated whether the reduction in glucose levels (Van den Berghe, et aI., 2001; 2003) or 
the administration of insulin (Annane and Melchior, 2003) is the main contributing factor 
for the reduction in mortality during the Van den Berghe trials. Annane and Melchior 
(2003) propose that the effects of insulin infusion during acute illness, such as decreased 
hepatic glucose production, increased immune function, and enhanced glucose transport to 
intracellular sites, are the reason for the reduction in the glycemic levels. However, Van 
den Berghe et al (2003) showed that the value of daily insulin dose was a positive, rather 
than a negative, risk factor for death in the patients studied indicating that it was not the 
amount of infused insulin that mediated the reduction of ICU mortality with intensive 
insulin therapy, although it is mentioned that this factor may be a contributor. Finney et al 
(2003) also found that it was the control of glucose levels rather than absolute levels of 
exogenous insulin infusions that accounted for the reduction in mortality in critically ill 
patients. 
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A retrospective data audit undertaken by Krinsley (2003) of 1826 critical care patients 
showed that even small increases in glycemic levels resulted in significant reduction in 
survival rates. Krinsley's (2003) findings showed that analysis of glucose values added 
predictive power above that achieved by APACHE II scores alone. McCowen et al (2001) 
also found a positive correlation between blood glucose values and APACHE II scores. 
This is a significant result as, unlike studies by Van den Berghe et al (2001; 2003) where 
most patients considered underwent cardiac surgery and are therefore a specific subset of 
critically ill patients. Both Krinsley (2003) and McCowen et al (2001) focused on large 
populations of heterogeneous critically ill patients. The difference between retrospective 
data audits, such as that by Krinsley (2003), and results of intensive insulin therapy, such as 
those by Van den Berghe et al (2001; 2003), is that retrospective data audits do not provide 
information as to whether hyperglycemia is causal of mortality, or merely a co-incidence. 
The mechanisms that correlate the increased values of glucose and the increased risk of 
mortality are not fully understood, and many reviewers are calling for more trials on this 
subject (Bistrian, 2001; Esposito, et aI., 2003; McCowen, et aI., 2001; Mizock, 2001; 
Robinson, 2002). Although hyperglycemia may not be the most important factor, in 
reducing ICU mortality, it is definitely a contributing factor. It is also comparatively 
treatable and avoidable through better design of nutritional and insulin infusion regimes. 
Therefore, there is definitely ground for improved insulin therapy leading to euglycemic 
control in critically ill patients. 
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2.2 STATISTICAL METHODS AND PATIENT DESCRIPTION 
2.2.1 Statistical Analysis 
Statistical analysis was performed using the StatXact package. Glucose values, insulin 
values, age, length of stay and APACHE II scores were compared between survivors and 
non-survivors using the exact Wilcoxon-Mann-Whitney 2-sided test. Fishers Exact 2-sided 
test was used for comparing study proportions between the Christchurch Hospital ICU and 
the Stamford Hospital ICU (Krinsley, 2003), checking the effect of gender on mortality, 
and comparing mechanical ventilation rates between survivors and non-survivors. 
Statistical significance was defined as P < 0.05 throughout. 
2.2.2 Study Outline and Methods 
Between lSI January 2003 and 3pt December 2003, 1164 patients were admitted to the 
Christchurch Hospital ICU. Of these, 237 adult patients had a stay greater than 3.0 days 
and were considered for analysis as Van den Berghe et aI's (2001) study did not show 
significant changes in mortality below this value. Of these patients, 36 had no recorded 
plasma glucose levels and were excluded. Plasma glucose values and insulin infusions 
from the bedside charts for the 201 patients were recorded, along with age, sex, APACHE 
II score, length of stay, ICU mortality, mechanical ventilation status and primary diagnosis. 
The patients were divided into the categories used by Krinsley (2003) depending on their 
primary diagnosis, as shown in Table 2.1. 
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TABLE 2.1: CHRISTCHURCH HOSPITAL ICU PATIENT SUBGROUPS 
SuBgroup No of Batients 070 of total 
Cardiac 32 16% 
Pulmonary 34 17% 
Sepsis 15 7% 
Other Medical 26 13% 
Neurologic 19 9% 
General Surgical 41 20% 
Trauma 34 17% 
TOTAL 201 100% 
Krinsley (2003) had a similar subset of patients, as shown in Table 2.2. The major 
difference between this data audit and the one undertaken by Krinsley (2003) is the size of 
the populations examined, as the spread across patient subsets is relatively similar. The 
Christchurch ICU had a smaller proportion of cardiac patients (16% compared to 30%, P < 
0.0001), as they considered both ICU and Cardiac ICU (CICU) patients, and a higher 
proportion of trauma patients (17% compared to 4%, P < 0.0001). 
Finally, the study generally referred to regarding the benefits of controlling blood glucose 
levels is that of Van den Berghe et al (2001; 2003). The data in Table 2.1 and Table 2.2 are 
a more heterogeneous subset of patients than those examined by Van den Berghe et al 
(2001) whose study population consisted of 63% cardiac surgery patients. 
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TABLE 2.2: STAMFORD HOSPITAL leU PATIENT SUBGROUPS (KRINSLEY, 
2003 
, ~ 
Subgroup No of Patients % of total 
I Cardiac 540 30% 
Pulmonary 289 16% 
Sepsis 92 5% 
Other Medical 272 15% 
Neurologic 241 13% 
General Surgical 313 17% 
Trauma 79 4% 
TOTAL 1826 100% 
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2.2.3 General Patient Description 
Table 2.3 gives an overview of the patient categories. The APACHE II score was 
calculated from the time at which their condition was at its worst during the first 24 hours 
of their stay in I Cu. APACHE II scores were available for 144 patients (72% of patients), 
and the average and range of values are for the APACHE II scores available. Length of 
Stay (LOS) is shown here in increments of 0.1, and the minimum length of stay is 3.0 days 
as patient records for those with less than 72 hours stay were excluded. The variables age, 
APACHE II score and length of stay are expressed as the mean, followed by the range in 
brackets. The survival status relates to the lCU discharge and was obtained from lCU 
discharge records. 
As shown in Table 2.3, survival rates were highest in cardiac, sepsis and trauma patients, 
and lowest in pulmonary patients. Cardiac patients tended to be older and have a shorter 
period of stay in the lCU. Pulmonary patients were less likely to require mechanical 
ventilation, while trauma patients tended to be younger, predominantly male, and require 
mechanical ventilation. Overall, patients were younger in the Christchurch Hospital study 
with an average of 55.6 years compared to 62.2 and 64.3 years (Van den Berghe, et al., 
2001) and 65.3 years (1(rinsley, 2003). Across all three studies, patients were more likely 
to be male (61 % compared to 71 % (Van den Berghe, et al., 2001) and 54% (Krinsley, 
2003)). 
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TABLE 2.3: GENERAL DESCRIPTION OF PATIENTS IN CHRISTCHURCH 
HOSPITAL ICU 
-
Subgl'OUp No of Age Female APACEHE Nfecli. ruIDS ICEN Patients (years) II Vent (days) Survival 
Cardiac 32 65.3 31% 22.1 78% 6.4 94% (30 - 85) (8 - 39) (3.0 - 21.8) 
Pulmonary 34 59.0 56% 25.5 38% 11.5 71% (18 82) (15 - 36) (3.1 - 36.0) 
Sepsis 15 55.4 47% 26.3 60% 12.0 93% (1 82) (21 30) (3.0- 39.9) 
Other 26 54.2 58% 25.6 54% 10.5 85% Medical (20 84) (17 36) {3.0-35.0 
Neurologic 19 54.1 42% 18.1 74% 8.5 84% (1 81) (7 24) (3.2 -43.8) 
General 41 64.6 32% 21.5 68% 10.6 88% Surgical (17 85 (l0 41) (3.0-42.5) 
Trauma 34 34.5 18% 17.2 85% 10.7 94% (15 83) (8 30) {3.0-60.0 
TIDTAL 201 55.6 39% 21.8 66% 9.9 87% (1 85) (7 41) (3.0 - 60.0) 
Age, APACHE II score and LOS are expressed as 'mean (range), 
2.2.4 Length of Stay 
Figure 2.1 shows the distribution of length of stay for the patients studied. Patients with a 
stay of 3 - 4 days made up 19.1% of the patient population studied, while patients with 3 -
9 days stay made up 62.4% of the population. The longest length of stay in the ICU during 
2003 was 60.0 days. 
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FIGURE 2.1: LENGTH OF STAY OF PATIENTS IN THE CHRISTCHURCH 
HOSPITAL ICU 
Patients with a length of stay in the ICU of less than 72 hours were excluded because in 
Van den Berghe et aI's study (2001; 2003) mortality increased significantly in patients that 
were in the ICU for greater than five days compared to patients with less than a five day 
stay (20.2% compared to 1.8% for the conventional treatment group). Mortality for those 
with tight glucose control did not begin to diverge from those without tight control in Van 
den Berghe et aI's (2001; 2003) study until 3 days, and hence the cut-off chosen here. As 
only patients with a stay greater than 3 days were recorded, this comparison was not able to 
be made with the Christchurch Hospital ICU patient population, however it was found that 
there was no significant difference between patients with 3-5 days stay and patients with 
greater than 5 days stay (14.5% compared to 13.7%). There was also no correlation 
between length of stay and APACHE II scores, as seen in Figure 2.2. 
44 Modelling and Control of Hyperglycemia in Critical Care Patients 
f! 
45 , ................................................................................................................................ . 
40~~~~~~~~~~--········································· ............................ --._ ........................... --~~--~~~--~~ 
35+··-+--------~--··························· -------------.----~--~~-- ................... -.~---~~ 
. 
. . . 
~ 25~~~~~~~~~~~~~~······································ ......... ----- ....... ~.----~~~--~ .. -~ 
t.Ll 
:r: 
~ 20~~~··--~--~~~········································------~------~~--~------ ---~~ 
~ . .. ..... . 
IO~~~--+············~~--~~~~-·············~~~············ ..................................... -~------.---~~-, 
10 20 30 40 50 60 70 
Length of Stay (days) 
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HOSPITAL ICU 
2.2.5 APACHE IIDistl'ibution 
The distribution of the 144 APACHE II scores calculated is shown in Figure 2.3, along 
with the associated risk of death (ROD) in each category. The APACHE II score is based 
on 12 routinely measured medical variables and predicts the severity of illness in critically 
ill patients. The calculation of the score is divided into two segments. The first is a 
physiology score representing the degree of acute illness based on the worst physiological 
values inculTed in the patient during the first 24 hours in the ICU. The second is a 
preadmission health evaluation indicating health status before acute illness. The score is a 
value between 0 71, with a positive cOlTelation between severity and APACHE II score 
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(Knaus, et aI., 1985). Figure 2.3 shows a relatively nonnal distribution of APACHE II 
scores with 26% of patients studied having an APACHE II score in the range of 20 - 24. 
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FIGURE 2.3: DISTRIBUTION OF APACHE II SCORES IN CHRISTCHURCH 
HOSPITAL ICU 
2.2.6 Effect of Gendel' 
Gender has no significant effect on mortality when compared across APACHE II 
categories, as shown by the high P values in Table 2.4. Intuitively, the P value shown is 
the probability of "similarity" in mortality between males and females in each APACHE II 
score category. Survival rates decreased as APACHE II scores increased and there was an 
87% survival rate across the 201 patients, as noted in both Table 2.3 and Table 2.4. 
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TABLE 2.4: EFFECT OF GENDER ON SURVIVAL IN CHRISTCHURCH 
HOSPITAL ICU 
A.PA.C!HE A.ssoc. 'Fotal Female male 
II ROD No of Survival No of Survival No of Survival Patients G%l Patients G%l Patients G%) 
0-14 ~4- 25 96% 7 100% 18 94% 15% 
15-24 ~25- 68 88% 30 90% 38 87% 40% 
25+ ~55- 51 80% 21 76% 30 83% 85% 
Excluded 57 86% 20 85% 37 86% 
'FO'FA.L 201 87% 78 86% 123 87% 
2.2. 7 Survivors and NOll-Survivors 
B 
value 
1.00 
1.00 
0.72 
1.00 
0.83 
Survivors were compared with non-survivors for each subgroup, and across the entire 
cohort, with the results shown in Table 2.5. There was no significant difference in age, 
APACHE II score, length of stay or mechanical ventilation rate between survivors and non-
survivors using the P < 0.05 statistical significance value. Generally, there was a trend 
towards younger survivors in the cardiac (P = 0.15) and pulmonary (P = 0.13) groups, as 
well as across all categories (P = 0.13). Survivors also tended to have a lower APACHE II 
score across all categories (P = 0.09). To better confinn significance in these subgroups, a 
larger cohort would be required. 
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TABLE 2.5: PATIENT PARAMETERS IN SURVIVORS AND NON-SURVIVORS IN 
CHRISTCHURCH HOSPITAL ICU 
Subgroup :lNoof Age APA<0HEII Mecli. EIDS patients (years) Vent (days) 
All 
Non-survivors 27 1 56.3 (10- 82) I 25.4(7-41) 1 74% 111.3 (3.1 - 36.0) 
Survivors 174 1 54.8 (1 - 85) 1 21.4 (8 - 36) 1 66% 1 9.8 (3.0 - 60.0) 
Cardiac 
Non-survivors 2 I 57.5 (55 - 60) 1 31.0 (23 - 39) 1 100% T 3.5(3.1-3.8) 
Survivors 30 1 65.8 (30 - 85) 1 21.4 (8 - 36) 1 80% 1 6.6 (3.0 - 21.8) 
Pulmonary 
Non-survivors 10 1 63.7 (24 - 82) 1 22.0 (20 - 26) 1 50% 1 13.0 (4.7 - 36) 
Survivors 24 1 57.0(18-79) 126.5(15-36) 1 33% 110.8 (3.1 - 24.8) 
Sepsis 
Non-survivors 1 I 49.0 1 27.0 1 100% 1 12.8 
Survivors 14 1 55.9 (1 - 82) 1 26.2 (21 - 30) 1 57% 1 11.9 (3.0 - 39.9) 
Other Medical 
Non-survivors 4 1 66.0 (47 - 84 1 27.7 (25 - 33) 1 75% 1 9.0 (3.4 - 22.3) 
Survivors 22 1 52.0 (20 - 84 I 25.2 (17 - 36) T 50% T 10.8 (3.0 - 35.0) 
Neurologic 
Non-survivors 3 1 64.3 (53 -78) 1 15.7 (7 - 20) T 67% 1 5.6 (3.5 -7.1) 
Survivors 16 I 52.1 (1-81) 118.7(11-24) 1 75% I 9.1 (3.2 - 43.8) 
General Surgical 
Non-survivors 5 1 69.2(59-77) 127.0(18-41) T 80% 116.1 (3.6 - 32.2) 
Survivors 36 1 63.9 (17 - 85) 1 20.4 (10 - 35) 1 67% 1 9.8 (3.0 - 42.5) 
Trauma 
Non-survivors 2 I 23.0 (20 - 26) 1 25.0 1 100% 1 6.5 (4.5 - 8.4) 
Survivors 32 1 35.2 (15 - 83) 1 16.8 (8 - 30) 1 84% 1 11.0 (3.0 - 60.0) 
Age, APACHE II score and LOS are expressed as 'mean (range)' 
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2.3 EFFECT OF BLOOD GL UCOSE LEVELS 
Detennining the level of blood glucose and its effect on mortality was the primary 
objective of this retrospective data audit. However, upon observation of the data, it was 
found that glucose measurement was often far less frequent than ideal, with multiple days 
with no glucose values recorded for a number of patients. ICU protocol suggests that a 
patient's blood glucose levels should be measured, at minimum, every four hours, and more 
frequently when blood glucose levels are in a hyper- or hypoglycemic range. The glucose 
values recorded had varying sample-times within a patient's stay, thus reducing the ease 
with which a statistically valid mean glucose value could be calculated. 
Of 3652 blood glucose measurements over all patients, the majority (34%) were in the 6 - 8 
mmolf1-., category, as shown in Figure 2.4. There were also 116 (3%) hypoglycemic values 
recorded by 81 patients, as shown in Figure 2.4 and Figure 2.5. In this case, the 
hypoglycemic threshold is set at 4 mmollL for these hyperglycemic patients, representing a 
significant drop from their elevated glucose level. Figure 2.5 shows that 38 patients (19%) 
had at least one blood glucose reading greater than 15 mmol/L and that of these patients, 13 
(6%) had at least one blood glucose reading greater than 20 mmollL. These values show 
that the blood glucose control in the Christchurch Hospital ICU is less than ideal. 
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Table 2.6 shows the measurement frequency, maximum and range of blood glucose values 
within the patient categories and overall. The number of measurements per day is an 
average value obtained by dividing the total number of blood glucose measurements by the 
length of stay. The maximum blood glucose value is the highest recorded blood glucose 
value, and the range is the difference between the highest and lowest recorded blood 
glucose values. The number of measurements per day was higher in non-survivors (P = 
0.03), suggesting the frequency of blood glucose measurement was associated with patients 
with a higher risk of death. The reason for this result is probably that Christchurch Hospital 
ICU protocol recommends that blood glucose should be measured more frequently at 
hyperglycemic levels. Interestingly, the protocol that suggests blood glucose levels be 
measured every 4 hours (6 times per day) has not been followed in many patients, as shown 
by the average number of measurements per day in Table 2.6. 
The maximum value of blood glucose along with the range of blood glucose values was 
higher in non-survivors (P = 0.001 and P= 0.003, respectively), suggesting that the level of 
deviation from basal blood glucose values has a negative impact on survival in critically ill 
patients, especially in trauma patients (P = 0.04 and P = 0.05, respectively). The maximum 
values of blood glucose correlate well with those found at Stamford Hospital ICU for both 
survivors (10.8 mmollL compared to 9.8 mmo1/L) and non-survivors (14.1 mmollL 
compared to 14.3 mmo1/L). This finding suggests that limiting the maximum and range of 
blood glucose, and hence the level of deviation, may be more important in the clinical 
situation. 
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TABLE 2.6: EFFECT OF FREQUENCY, MAXIMUM AND RANGE OF BLOOD 
GLUCOSE MEASUREMENTS ON SURVIVAL IN CHRISTCHURCH HOSPITAL 
ICU 
No of NumBer of Maximum Blood Blood mlucose SuBgroup patients Measurements mlucose Range per day; (mmoJiI0) (mmoItI0) 
All 
Non-survivors 27 I 4.7 (0.2 - 13.0) I 14.1 (7.1 - 22.2) I 8.4 (1.5 -15.7) 
Survivors 174 I 3.1 (0.1 - 16.2) I 10.8 (3.9 - 28.9) I 6.1 (0 - 26.7) 
Cardiac 
Non-survivors 2 I 10.3 (8.8 - 11.9) I 15.9 (14.7 - 17.1) I 12.6 (9.7 - 15.4) 
Survivors 30 I 4.4 (0.2 - 9.6) I 12.1 (8.2 - 19.8) I 7.6 (2.2 - 16.0) 
Pulmonary 
Non-survivors 10 I 4.3 (0.4 - 8.0) I 12.0 (6.9 - 18.3) I 7.8 (1.5 - 13.3) 
Survivors 24 I 3.2 (0.1 -7.9) I 11.1 (6.0 - 17.6) I 6.5 (0.0 - 14.8) 
Sepsis 
Non-survivors 1 I 7.2 I 11.5 I 9.7 
Survivors 14 I 3.5 (0.1 - 8.0) I 11.5 (4.6 -17.6) I 7.4 (0.0 -14.3) 
Other Medical 
Non-survivors 4 I 7.9 (1.4 -13.0) I 16.6 (12.9 - 22.2) I 12.0 (8.1 - 16.7) 
Survivors 22 I 4.7 (0.1 - 11.2) I 14.3 (6.0-28.9) I 9.5 (0.0-26.7) 
Neurologic 
Non-survivors 3 I 4.4 (0.5 - 7.2) I 13.7 (7.2 -18.4) I 6.5 (1.7 - 11.7) 
Survivors 16 I 2.4 (0.1 - 10.0) I 9.2 (3.6 - (18.4) I 3.9 (0.0 - 14.3) 
General Surgical 
Non-survivors 5 I 2.0 (0.2 - 5.0) I 11.1 (7.8 - 13.8) I 6.4(3.0-10.1) 
Survivors 36 I 2.7 (0.1 - 10.3) I 10.0 (5.4 - 18.9) I 5.4 (0.0 - 14.7) 
Trauma 
Non-survivors 2 I 0.6 (0.6 - 0.7) 113.9(12.4-15.4) I 7.4 (5.1- 9.7) 
Survivors 32 I 1.2 (0.1 - 16.2) I 8.3 (4.5 -16.6) I 3.1 (0.0 - 13.9) 
#/day, maxImum and range are expressed as 'mean (range)' 
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2.3.1 Calculating the Blood Glucose Mean 
Calculation of mean blood glucose values for this irregularly sampled data required the use 
of the trapezoidal rule together with a random walk model to bridge the gaps between data 
so that confidence intervals can be determined for the means. 
Method/or Determining Trapezoidal Mean 
Let x), ... , Xm be the blood glucose measurements, in mmol/L, recorded at times tJ, ... , tm, in 
hours. Set t] = 0, tm = T, and T to the smallest time interval between measurements across 
all patients, which in this case is one hour. The length of the data is expressed by n in 
terms of T, n = TIr, and the length of the intervals between each measurement is defined 
C; = t;+! -t; for i = 1 to m-l 
T 
(2.1) 
The parameters Ci, ti, Xi and T are shown schematically in Figure 2.6, which shows a series 
of blood glucose measurements with different sample times. When a linear line joins the 
points, as shown for the values Xl, ••• , X9, the area under the graph divided by the length of 
the series, T, is the trapezoidal mean. The nomenclature renames the measurements, time 
and sample times using Xi, ti and Ci, respectively. 
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FIGURE 2.6: TRAPEZOIDAL MEAN CALCULATION NOMENCLATURE 
Assuming that the blood glucose readings are ergodic, and using the trapezoidal rule as 
shown in Figure 2.6, an estimate of the patient's mean blood glucose for the duration [0,1] 
is defined (Burden and Faires, 1989): 
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Method for determining Mean Confidence Intervals 
Using the method described for determining the trapezoidal mean for the data, it is assumed 
that if blood glucose had been measured between two measured points, then it would lie on 
the linear line between those two points. However, this assumption may not hold. 
Therefore, a method for estimating the range within which this imaginary blood glucose 
measurement lies is required. 
As the smallest time interval between measurements is one hour, it will be taken as the new 
sample time. A measurement gap occurs whenever the length of the measurement interval 
is greater than one hour, Ci > 1 hour. One way to obtain an estimate for sample times when 
no measurement was taken is to "bridge" the measurement gaps using an appropriate 
random process model. Here, because of the sparseness of the data, a random walk 
constrained to the measurements at both ends will be used, forming a continuous data series 
between the first and last measurements taken at one hour intervals. 
Consider a measurement gap with length k, and let x~ and x; denote the measurements at 
the beginning and end of the gap. For the length of the measurement gap, i = 0, ... , k, the 
bridging process is given by 
(2.3) 
where the simple random walk, Zi, starts from x; and takes random steps WI, W2, .. . Wk 
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(2.4) 
Thus, the bridging process is a modification of the simple random walk so that the 
constraints at the ends are met. The bridging process can be expressed directly in tenns of 
. _ (k -i)" (i) * (k -i)~ _ (i) ~ X.- Xo+ xk + ..L... W . ..L...W. 
I k k k j~l J k j=i+l J (2.5) 
where x; is a simple linear interpolation of the end-points, x; and x;, perturbed by a 
weighted sum of WI, .. . ,Wk. 
To complete the definition of the bridging process, an appropriate distribution must be 
selected for randomly determining the Wi values. Since these weighted sum values are 
independent and identically distributed, a convenient choice would be a distribution that 
results in x; also belonging to the same distribution family. Two distributions that fit this 
description are the Normal distribution and the Cauchy distribution (Evans, et aI., 1993). 
To determine which of these two distributions was a better representation of the data, the 
differences in blood glucose measurements that were taken one hour apart from all patients 
are considered. Figure 2.7 shows the differences in blood glucose measurements taken one 
hour apart across all patients receiving insulin, and are compared to the Normal and Cauchy 
distributions. 
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The Cauchy distribution with location 0 and scale, / = 0.76, provides a better fit than the 
normal distribution to the data obtained (P = 0.03 compared to P < 0.0003 using the 
Kolmogorov-Smimov goodness-of-fit test). The value of the scale, /, in the Cauchy 
distribution was estimated by the maximum likelihood method. The one-hour differences 
of the bridging process must have a scale that matches /, since the distribution of the 
random walk between actual measurements, Xi, must match the Cauchy distribution. 
• • 1 • • (k-l) 1 " Xi -Xi-! =1(Xk -xo)+ -k Wi -I ~ Wj Ie le·~ .~. J~l, ... ,1 1,I+l, ... ,k (2.6) 
(2.7) 
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If the distribution of the weighted sum values, Wi, matches the Cauchy distribution, then the 
scale, s*, is defined: 
• 2{k-l) 
S =---8 
k 
(2.8) 
Let s; be the scale of the measurements, x;, then using the expression for x; in terms of 
the weighted sum values, Wi, the scale becomes: 
2i(k-i) i{k-i). 
---'---'-s = s 
k II' (k-I) (2.9) 
Therefore, the contribution of this measurement gap to the (1 - a)% confidence interval for 
the mean, P.n is 
q ,\--1 
s: _ al2 "" • uk --LAS; 
n ;=1 
*k{k+l) 
i) = ---'-----
6n 
(2.l 0) 
where qa/2 is the {al2)-quantile of the Cauchy CO, 1) distribution. For example, to achieve 
a 90 % confidence interval, qO.05 = 6.314. If there are M measurement gaps of lengths, 
k}, ... ,kM , , then an approximate (I - a)% confidence interval for the mean, Px is 
(2.l1) 
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In summary, the blood glucose mean is determined using Equation (2.2) with a 90% 
confidence interval determined using Equation (2.11). 
2.3.2 Blood Glucose Mean Values 
Similar studies (Krinsley, 2003) do not explain their method for calculating the mean blood 
glucose level, and may have calculated simple mean values. This method only gives a true 
representation of the mean when the sampling interval is constant for all measurements. 
Krinsley (2003) mentions that the number of glucose values obtained for each patient 
correlated significantly with the patients length of stay (R 0.870, P < 0.001), and hence it 
is assumed that the samples taken have a relatively consistent sampling time. However, in 
the case of samples obtained by medical staff at the Christchurch Hospital ICU, the 
sampling time was definitely not consistent and hence the method of using trapezoidal 
means was devised. 
The trapezoidal means were calculated using Equation (2.2) for the subset of 86 patients 
that were on insulin at any stage during their stay. This subset was chosen as they were 
most likely to have a greater density of data. Table 2.7 shows the effect of the mean blood 
glucose, estimated by the trapezoidal mean on survival in each of the patient sub-groups of 
those patients on insulin. Overall, the mean blood glucose was higher in non-survivors 
than in survivors (P 0.014). This result was also the case in cardiac patients (P 0.016). 
Insufficient data is likely the reason that mean blood glucose values were not significantly 
higher in the other subgroups. 
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TABLE 2.7: EFFECT OF BLOOD GLUCOSE TRAPEZOIDAL MEANS OF 
PATIENTS ON INSULIN ON SURVIVAL IN CHRISTCHURCH HOSPITAL ICU 
Subgroup Nooi' Trapezoidal Mean Blood patients <:ilucose (mmol/E) 
All 
Non-survivors 16 I 9.3 (6.5 -14.1) 
Survivors 70 I 7.9 (4.5 -12.2) 
Cardiac 
Non-survivors 2 I 9.8 (9.5 -10.1) 
Survivors 12 I 7.5 (5.9 - 9.9) 
Pulmonary 
Non-survivors 6 I 8.0 (7.0 - 9.9) 
Survivors 12 I 7.6 (4.9 - 9.6) 
Sepsis 
Non-survivors 1 I 7.4 
Survivors 8 I 8.2 (6.1 - 10.0) 
Other Medical 
Non-survivors 3 I 10.7 (6.5 -14.1) 
Survivors 13 I 8.4 (6.9 - 10.9) 
Neurologic 
Non-survivors 2 I 11.6 (10.2 - 13.0) 
Survivors 4 I 9.1 (7.2 - 12.2) 
General Surgical 
Non-survivors 2 I 9.0 (8.1 - 9.9) 
Survivors 11 I 7.5 (4.5 - 9.8) 
Trauma 
Non-survivors - I -
Survivors 1 I 9.7 
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2.3.3 Effect of Blood Glucose on Mortality 
Table 2.6 shows that the maximum and range of blood glucose levels are higher in non-
survivors than in survivors (P = 0.001 and P = 0.003, respectively), however it does not 
show the relationship between the values obtained and survival. Table 2.7 shows that a 
higher mean value is also correlated with mortality (P = 0.014). The retrospective design 
of this study prevents conclusions about if a higher maximum, range or mean blood glucose 
value causes a decreased survival rate, or is just a marker of decreased survival. However, 
from Van den Berghe et aI's (2001; 2003) study, the assumption that elevated blood 
glucose may be the cause can be assumed. Even if the relationship is not causal, past 
studies (Krinsley, 2003; Van den Berghe, et aI., 2001; 2003) and the results from this study 
of the Christchurch Hospital ICU show that there is a strong association between glucose 
levels and mortality that should not be ignored. 
Table 2.8 shows the effect of the maximum recorded blood glucose level on survival for 
201 patients from the Christchurch Hospital ICU. Patients with a highest recorded blood 
glucose value less than 6 mmollL had the highest survival rate. Using the protocol set by 
Christchurch Hospital, those patients with a maximum recorded blood glucose in the range 
of 6 - 8 mmollL, had a reduced survival rate compared with those in the less than 6 
mmol/L category. The trend shows that as the maximum blood glucose increases, the 
chance of ICU survival decreases, as shown in Figure 2.8. Note that the low patient 
numbers in the categories 18 - 20 mmollL and >20 mmollL, although shown on the graph, 
have not been included in the trend line calculation. With a larger cohort, these values 
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may follow the trend more closely, although, the 18 - 20 mmol/L value lies almost on the 
trend line. 
TABLE 2.8: MAXIMUM BLOOD GLUCOSE VALUE AND ICU SURVIVAL IN 
CHRISTCHURCH HOSPITAL ICU 
Maximum Blood No. of Survival 
Glucose (mmoI/L) Patients (%) 
<6 14 100% 
6-8 37 92% 
8-10 48 96% 
10-12 34 85% 
12-14 20 70% 
14-16 27 78% 
16-18 9 78% 
18-20 6 67% 
>20 6 83% 
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FIGURE 2.8: MAXIMUM BLOOD GLUCOSE VS ICU SURVIVAL IN 
CHRISTCHURCH HOSPITAL ICU 
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Similar trends were seen for the range and trapezoidal mean of blood glucose, as shown in 
Table 2.9 and 2.10. If the range of greater than 20 mmol/L is disregarded due to 
insufficient data, then the highest survival rate is 96% in patients with a blood glucose 
range of less than 5 mmollL. The survival rate decreased 21 % if the patient's blood 
glucose range was 5-10 mmol/L. Similarly, the survival rate decreased 12% if the 
trapezoidal mean was in the 6 - 7 mmol/L category compared to the <6 mmollL category. 
The trend shows that as the trapezoidal blood glucose mean increases, the chance of ICU 
survival decreases, as shown in Figure 2.9. Although shown on the graph, the lumped 
together 10+ mmollL category has not been included in the trend line calculation due to its 
low patient population and potentially extreme result. Alternatively, the trend may not be 
linear. 
TABLE 2.9: BLOOD GLUCOSE RANGE AND ICU SURVIVAL IN 
CHRISTCHURCH HOSPITAL ICU 
Blood Glucose No. of Survival 
Range (mmollb) Patients (%) 
<5 90 96% 
5-10 63 76% 
10-15 36 83% 
15-20 5 60% 
>20 3 100% 
Retrospective Data Audit 63 
TABLE 2.10: BLOOD GLUCOSE TRAPEZOIDAL MEAN AND ICU SURVIVAL IN 
CHRISTCHURCH HOSPITAL ICU 
~ 
.~ 
C/l 
::> 
S2 
Blood Glucose No. of Survival Trapezoidal Patients ('Vo) Mean (mmoIlL) 
<6 4 100% 
6-7 16 88% 
7-8 32 88% 
8-9 10 80% 
9-10 19 84% 
10+ 7 29% 
100% 
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FIGURE 2.9: TRAPEZOIDAL BLOOD GLUCOSE MEAN VALUES VS ICU 
SURVIV AL IN CHRISTCHURCH HOSPITAL ICU 
and Control in Critical Care Patients 
2.3.4 Effect of Blood Glucose Measm'ement Intervals on Mean Calculatiol'l 
To put the mean glucose values into context, confidence intervals were calculated. 
However, it was found that the length of the intervals was far too long to be helpful, due to 
the scarcity of the data gathered. The effect of the time periods between measurements was 
then considered, and by plotting the half-width of the confidence intervals against the 
average period between blood glucose measurements, as shown in Figure 2.10, a largely 
linear relationship was found. The linear least squares fit shown in Figure 2.10 considers 
only patients with a half-width less than 6 mmol/L, and consequently a confidence interval 
length of less than 12 mmollL. This 12 mmollL value represents an extreme size for a 
confidence interval and would render the associated mean value useless. 
Using this relationship, researchers such as Van den Berghe et al (2001; 2003) who 
measure up to every four hours, may have uncertainty on their actual glucose value of up to 
4.68 mmol/L. This result means that patients in the control1ed group, with mean glucose 
levels between 4.4 and 6.1 mmollL, could actually have significantly more variable and 
higher mean glucose levels. Table 2.11 shows selected values from Figure 2.1 O. The 
potential variation of blood glucose with infrequent sampling makes a strong case for more 
regular measurements and the use of emerging blood glucose sensors in measuring and 
regulating blood glucose levels. 
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TABLE 2.11: AVERAGE PERIOD BETWEEN BLOOD GLUCOSE 
MEASUREMENTS VS CONFIDENCE INTERVAL HALF -WIDTH 
Average Period between Blood Certainty on 
Glucose Measurements (hrs) Measurement (mmoI/L) 
0.5 ±0.59 
1 ± 1.17 
2 ±2.34 
3 ± 3.51 
4 ±4.68 
5 ± 5.85 
6 ±7.02 
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2.4 EFFECT OF BLOOD INSULIN LEVELS 
It is debated (Annane and Melchior, 2003; Van den Berghe, et aI., 2001; 2003) whether it is 
the insulin infused or the tight management of blood glucose levels that leads to the 
reduction in mortality in critically ill patients. Hence, the average insulin infused per hour 
and the proportion of the patient's stay that they were receiving an insulin infusion were 
calculated to test the theory proposed by Annane and Melchior (2003) that it is the insulin 
infused, and not the lowered blood glucose values, that resulted in a lowered risk of 
mortality. 
When survivors are compared to non-survivors there is a negative correlation between 
average insulin infused and survival (P = 0.01) over all patients. More specifically, non-
survivors received more insulin on average than survivors. As the size of the patients 
subsets was small, it is feasible that there was a correlation overall, yet not within any of 
the subsets. 
Results were the same for the proportion of stay that a patient was on insulin, with the non-
survivors on insulin for a longer period during their stay (P = 0.02). These results confirm 
the findings of Van den Berghe et al (2003) that there is a negative relationship between 
insulin infused and survival rate. 
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TABLE 2.12: EFFECT OF INSULIN INFUSION ON SURVIVAL IN 
CHRISTCHURCH HOSPITAL ICU 
.iNoof ~verage Proportion of Subgroup patients Insulin Stay on Insulin Infused ~IJZh.r) 
All 
Non-survivors 27 I 1.1 ~O- 5.7) I 41% (0-97) 
Survivors 174 I 0.5 (0- 5.7) I 24% (0- 98) 
Cardiac 
Non-survivors 2 I 3.6 (3.4 - 3.8) I 90% (84-97) 
Survivors 30 I 0.8(0-3.7) I 41%(0-98) 
Pulmonary 
Non-survivors 10 I 0.7(0-2.1) I 41% (0-79) 
Survivors 24 I 0.4 (0- 2.4) I 27% (0- 94) 
Sepsis 
Non-survivors 1 I 1.2 I 89% 
Survivors 14 I 0.5 (0-1.9) I 27% (0- 83) 
Other Medical 
Non-survivors 4 I 2.6 (0- 5.7) I 67% (0- 93) 
Survivors 22 I 1.0 (0 - 5.7) I 43% (0- 97) 
Neurologic 
Non-survivors 3 I 1.0 (0- 1.8) I 45% (0-74) 
Survivors 16 I 0.4 (0 - 3.2) I 16% (0 - 90) 
General Surgical 
Non-survivors 5 I 0.2 (0- 1.0) I 13% (0 - 61) 
Survivors 36 I 0.3 (0-1.9) I 17% (0-90) 
Trauma 
N on-survi vors 2 I 0.0 I 0% 
Survivors 32 I 0.1 (0 - 1.6) I 2% (0-47) 
68 Modelling and Control of Hyperglycemia in Critical Care Patients 
2.5 SUMMARY 
This chapter analysed data from 201 patients that had a length of stay of greater than 72 
hours in the Christchurch Hospital ICU over a 1 year period. The proportion of patients in 
each subset was found to be similar to that of the Stamford Hospital ICU (Krinsley, 2003), 
but unlike that studied by Van den Berghe et al (2001; 2003) whose population was mainly 
cardiac patients. 
Unlike Van den Berghe et al (2001; 2003), the mortality and APACHE II scores did not 
seem to increase with length of stay. However, it is suspected that if all patients (rather 
than just those with a length of stay of 72 hours or more) were considered that this 
phenomenon may appear. It might also be due to the different patient cohorts. There was 
no significant difference in age, APACHE II score, length of stay or mechanical ventilation 
rates between survivors and non-survivors. 
The number of measurements per day was higher in non-survivors (P = 0.03), as was the 
maximum value of blood glucose and the range of blood glucose values (P = 0.001 and P = 
0.003, respectively), especially in trauma patients (P = 0.04 and P = 0.05, respectively). 
The trapezoidal mean of blood glucose, calculated in 86 patients who received insulin 
therapy at any time was higher among non-survivors than survivors (P = 0.014). Insulin 
infusion averages and proportion of stay were negatively correlated with mortality (P = 
0.01 and P = 0.02, respectively), confirming findings by Van den Berghe et al (2003). 
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The general trend was that survival decreased with increasing maximum blood glucose, 
range of blood glucose and trapezoidal mean of blood glucose, suggesting that these three 
parameters have a negative effect on the survival of an lCU patient. From the data 
presented, it is proposed that the maximum blood glucose level, and hence the range of 
blood glucose levels, may be the factor most detrimental to a patients lCU survival. 
However, further studies on a larger patient cohort would be required to prove this idea. 
The effect of the length of time between blood glucose measurements was considered, and 
it was found that the error in the mean blood glucose calculated increased linearly with 
time. Standard practice of measurements every four hours, such as outlined by the 
Christchurch Hospital lCU and Van den Berghe et al (2001; 2003) may not be appropriate 
for controlling glucose levels due to the large errors involved. This result further reiterates 
the use of glucose sensing technology and automated insulin infusion in critical care 
environments. 
Overall, it was found that the Christchurch Hospital lCU has sub-optimal management of 
blood glucose levels, both by Van den Berghe et aI's (2001; 2003) protocol and their own. 
Hence, the aim of the entire project, to develop an automated infusion system for tight 
glucose control in critically ill patients, is justified by the findings of this retrospective data 
audit. 
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3 
CONTROL MODELLING AND ALGORITHMS 
3.1 INTRODUCTION 
In 1921, a young surgeon, Frederick Banting, and his graduate student assistant Charles 
Best prepared pancreas extracts which lowered the blood glucose level in dogs. Within 
months, this new revelation meant that sickly children with diabetes were returned almost 
to normal health with the aid of two insulin injections a day (Joslin, 1985). In 1939, 
Himsworth and Kerr were the first to establish an approach to measure in vivo insulin 
sensitivity (Derouich and Boutayeb, 2002). 
3.1.1 Theoretical Solutions Proposed 
The integration of insulin and technology has meant that diabetes management has 
advanced greatly throughout the last century. With the ability to reduce blood glucose 
levels using insulin injections combined with the ability to measure blood glucose, plasma 
insulin and insulin sensitivity levels, the next step was to use mathematical models to 
estimate the relationships between glucose disappearance, insulin and insulin sensitivity. 
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These models capture the basic kinetics of glucose and insulin, enabling the development 
of management and control algorithms. 
The development of insulin infusion programs has typically advanced along one of two 
paths. Simultaneously, both open-loop and closed-loop controllers have been proposed and 
have evolved through the work of numerous researchers (e.g. (Fisher, 1991; Furier, et aI., 
1985; Kienitz and Yoneyama, 1993; Lam, et a1., 2002; Skyler, et aI., 1981; Trajanoski and 
Wach, 1998). Semi closed-loop controllers, a compromise between open and closed-loop 
controllers, have also found their path in development (e.g (Chisholm, et aI., 1984). Open-
loop control programs deliver a predetermined infusion of insulin and are the simplest of 
the control types. At the other end of the scale, closed-loop controllers require regular, 
frequent glucose measurement and aim to replicate the function of the beta cells and the 
pancreas in endogenously regulating blood glucose levels. Closed-loop controllers are 
often complex as a result. Semi closed-loop methods, based on discrete, non-continuous 
blood glucose measurements, are appealing because of their simplicity when compared to 
the closed-loop system and their accuracy when compared to the open-loop system. 
A number of researchers in the field of both diabetes and/or control systems have examined 
the possibility of automating insulin infusion using models (e.g (Bergman, et aI., 1985; 
Cobelli, et aI., 1998; 1999; Doyle, et aI., 1996; Fisher, 1991; Fuder, et aI., 1985; Kienitz 
and Yoneyama, 1993; Kraegen and Chisholm, 1984; Skyler, et aI., 1981; Trajanoski and 
Wach, 1998). The models presented range in complexity from the minimal model 
(Bergman, et al., 1985) 1 sl order system to a 19th order system model of the glucose-
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regulatory system (Parker, et aI., 1996) and use optimal control regimes such as H-infinity 
control (Kienitz and Yoneyama, 1993) and various structural controllers (Berger and 
Rodbard, 1991; Parker and Doyle, 2001). The need for continuous data or patient specific 
parameters has restricted the use of these models to computer simulations rather than 
clinical trials. However, the common priority has always been reduction in the absolute 
glucose excursion from basal, and the slope of the glucose excursion curve is typically 
neglected. 
The simple feedback control method simulated by Furler et al (1985), works on the sliding-
scale approach adopted in many hospitals and by many diabetics and clinicians, where 
insulin is delivered based on discrete blood glucose measurements. Lately, there has been a 
great deal of opposition to sliding-scale methods (Kletter, 1998; Radack, 1997; Sawin, 
1997). In Furler et aI's (1985) protocol, a linear relationship between the insulin demanded 
by the algorithm and the blood glucose value is determined to provide between 0.5 and 2.5 
U/hr over the blood glucose range of2 to 12 rnmollL, and is held at these limiting infusion 
values outside this range. This approach physiologically improves the research completed 
a year earlier by Chisholm et al (1984) who used the linear relationship between 0.5 and 2.5 
U/hr of insulin over a blood glucose range of 4 to 8 rnmol/L. 
Both Chisholm et aI's (1984) and Furler et aI's (1985) approaches are reviewed in Fisher 
(1991), with Furler et aI's (1985) being found to be superior in the control of elevated blood 
glucose levels. Fisher (1991) proposes that if the 3-hourly blood glucose is greater than or 
equal to 6 mrnollL the patient be given a bolus insulin injection proportional to the blood 
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glucose level squared, followed by a constant infusion independent to the blood glucose 
level. If the blood glucose is less than 6 mmol/L an unvarying infusion linearly 
proportional to the blood glucose measurement is maintained. These control regimes are 
shown in Figure 3.1. 
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FIGURE 3.1: CONTROL REGIMES BY CHISHOLM ET AL (1984), FURLER ET AL 
(1985) AND FISHER (1991) 
Both Fisher (1991) and Furler et al (1985) base their research on 3-hourly blood glucose 
measurements, but suggest that the stability of blood glucose control decreases as the 
sample interval is increased. This suggestion leads to the obvious enhancement of the 
equations by means of a smaller sample interval as proposed by Lam et al (Chase, et aI., 
2002; Lam, et aI., 2002), and clinically trialled (Chase, et aI., 2003; Doran, et aI., 2004a; 
2004b), where a 15 minute sample period is employed. This research, undertaken at the 
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University of Canterbury in conjunction with the Canterbury District Health Board, utilizes 
a heavy derivative control algorithm focusing on the slope of the glucose excursion curve 
as opposed to its absolute excursion from a target basal level, as shown in Figure 3.2. The 
advantage of focusing on the slope is that excursions can be minimized before they occur 
because the slope essentially predicts their occurrence. For example, a large positive slope 
on a blood glucose curve suggests the blood glucose will continue increasing and a larger 
insulin infusion rate is required. A small or negative slope suggests the blood glucose level 
is decreasing or changing direction, and hence only a small infusion or no infusion at all is 
required. 
This control approach leads to the same results suggested by Fisher (1991), where a bolus 
injection is followed by a smaller infusion. However, it is more advanced in it's 
determination of the smaller infusion by its use of a basic glucose-insulin regulatory system 
model to design the control gains. In addition, the optimal steady state control solution for 
this model results in a single bolus of the exact size and time required to hold glucose levels 
constant in the face of a glucose challenge (Chase, et aI., 2002; Lam, et aI., 2002). Finally, 
in contrast to proportional control approaches that focus on blood glucose magnitude, this 
approach does not add insulin when blood glucose is dropping (Chase, et aI., 2002; Lam, et 
aI., 2002). As a result, it is potentially much safer with respect to hypoglycemic episodes. 
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3.1.2 First Mathematical Model 
Bolie (1961) was first to propose a mathematical model encompassing the effects of insulin 
on blood glucose levels. The simple model consisted of 2 equations and 5 patient 
parameters and assumed that the glucose disappearance was linearly related to both glucose 
and insulin levels. The insulin secretion is proportional to the glucose and the insulin 
disappears in proportion to the plasma insulin concentration. Bolie's (1961) model was the 
basis for following work by Akerman et al (1965), Corte et al (1970), and Segre et al 
(1973). 
3.1.3 Bergman's 3 Compartment Minimal Model and Successors 
The 3 compartment minimal model developed by Bergman et al (1985) is the basic system 
for much of the further research in the use of controllers for diabetes management (e.g 
(Avogaro, et aI., 1989; Bergman, et aI., 1987; Caumo, et aI., 1999; Cobelli, et aI., 1998; 
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1999; De Gaetano and Arino, 2000; Pillonetto, et aI., 2002; Vicini, et aI., 1997; 1999). It is 
also the basis for many more advanced models with greater complexity (e.g. (Caumo, et aI., 
1999; Cobelli, et aI., 1998; Hovorka, et aI., 1998a) This model is comprised of 3 equations, 
modelling the exogenous glucose and it's interaction with insulin, insulin storage in a 
remote compartment, and insulin infusion and beta cell insulin production. Note that 
Bergman et al's (1985) original intent was to create a model to aid in the steady state 
determination of insulin sensitivity. However, it's simple kinetics capture the fundamental 
dynamics of the system relatively well and it is therefore ideal for control system design. 
The use of a semi-closed loop algorithm for the control of blood glucose levels in diabetics 
was proposed and analysed in conjunction with the minimal model. (Fisher, 1991; Furler, et 
aI., 1985) The analysis of the semi-closed loop algorithm by Fisher was verified by years 
of clinical experience when it predicted the best response to a meal input, was an insulin 
bolus followed by a continuous insulin infusion shown in Figure 3.1. Furler et al (1985) 
analysed a semi-closed loop system with an increased number of equations to include the 
effect of insulin-antibodies and removed the endogenous insulin secretion by the pancreas. 
Alternative patient specific parameter sets were also suggested and methods, by which the 
patient specific parameters could be found, using steady state analysis, were proposed. 
The minimal model first proposed by Bergman et al (1985) forms the basis for the research 
undertaken. This model is physiologically verified and utilizes the concept of a remote 
compartment for insulin storage to account for the delay between insulin injection and 
utilization. The minimal model was designed to model metabolic physiology and simulate 
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basic glucose dynamics in vivo, and to be sufficiently simple enough that the patient 
specific parameters can be estimated using data from a frequently-sampled intravenous 
glucose tolerance test (FSIGTI). The minimal model is defined: 
where: 
X -P2X+pi 
j -n(I +IB)+U~ 
G = concentration of the plasma glucose above the basal level (mmoI/L) 
GB = basal level for plasma glucose concentration (mmollL) 
X = normalised insulin in the remote compartment (min-I) 
I = concentration of the plasma insulin above basal level (mUlL) 
IB basal level for plasma insulin concentration (mUlL) 
P(t) exogenous glucose infusion rate (mmol/(L·min)) 
u(t) insulin infusion rate (mU Imin) 
P3 steady state insulin sensitivity parameter (LI (mUmin2)) 
VJ assumed insulin distribution volume (L) 
PI fractional clearance of glucose at basal insulin (min-I) 
P2 delay in insulin action (min-I) 
n = delay in subcutaneous transfer ofinsuHn (min-') 
(3.1) 
(3.2) 
(3.3) 
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Equations (3.1) and (3.2) describe the time course of plasma glucose concentration. The 
first equation encompasses glucose uptake dynamics dependent on the insulin 
concentration in the system and the introduction of exogenous glucose. The second 
equation expresses the insulin concentration dynamics of the remote compartment, and 
illustrates the time delay of distribution in the system. Equation (3.3) describes the time 
course of plasma insulin concentration and encompasses dynamics essential for defining 
insulin secretion by the p-cells in response to a glucose stimulus. Equations (3.1) and (3.2) 
- (3.3) were developed separately Insulin concentration is the outcome from the exogenous 
insulin infusion, u(t) , in Equations (3.2) and (3.3), and glucose input, P(t), is the forcing 
function in Equation (3.1). 
3.2 INTRAVENOUS MODEL DEVELOPMENT 
3.2.1 Reduction to Two Compartments 
Implementing tight glucose control in critically ill patients via a fully automated insulin 
infusion system requires a simple model of the glucose regulatory system that accounts for 
the relationship between IV infusion of exogenous insulin and the measured blood glucose 
level. Bergman's three-compartment model, as shown in Equations (3.1) - (3.3), utilises 
the concept of a remote compartment (likened to the subcutaneous layer) for the storage of 
insulin to account for the subcutaneous transportation delay between the subcutaneous 
infusion of insulin and its utilization to reduce blood glucose levels. 
Direct arterial/venous lines are typically available in critically ill patients for IV insulin 
infusion so that the system can be modelled using only two compartments. The first 
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compartment models insulin infusion and uptake into the blood, and the second models the 
blood glucose level and insulin mediated transport of glucose from the blood, as shown in 
Equations (3.4) and (3.5). 
where: 
(; = -PGG -SJI(G + GB ) +P(t) 
j =-n(I +IB)+U(% 
n = delay in interstitial transfer of insulin (min-I) 
pG = fractional clearance of plasma glucose at basal insulin (min-I) 
SI = insulin sensitivity (L/mU/min) 
(3.4) 
(3.5) 
The two-compartment model removes the remote compartment, X, as defined by Equation 
(3.2), and combines the delay in insulin action, P2, and the steady state insulin sensitivity 
parameter, P3, into the insulin sensitivity ratio, SJ = P3/P2' In this case, the inclusions of a 
single parameter, SI, helps reduce underestimation of insulin sensitivity (McDonald, et aI., 
2000). Note that this very simple system still captures the fundamental dynamics of blood 
glucose rise and fall. However, its first order dynamics definition means that subtler, faster 
behaviours may be neglected. Figure 3.3 presents a mathematical schematic of both the 
two- and three- compartment models, including closed-loop feedback control blocks. 
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FIGURE 3.3: MATHEMATICAL SCHEMATIC OF BERGMAN'S 3-COMPARTMENT 
MODEL (TOP) AND THE REDUCED 2-COMPARTMENT MODEL (BOTTOM), 
BOTH INCLUDING FEEDBACK CONTROL 
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Steady State Analysis Comparison 
An analysis was performed to show the equivalence of the two- and three- compartment 
models in the steady state. This analysis is presented in detail in Table 3.1, where a steady 
state value is denoted by the subscript 'ss'. In contrast, the steady state values that result 
from testing certain inputs in step 'ix' are denoted by the subscript '00'. The analysis shows 
that in the steady state, the models yield equivalent results for steady state plasma glucose, 
Gss, and steady state insulin, Iss, whenpl i- O. 
Furthermore, both models result in Goo = 0 in the absence of exogenous glucose input when 
PI = Pc i- O. This result indicates that someone with measurable endogenous glucose 
removal (non-Type 1 diabetic individuals) will eventually reach basal level without 
external input. Similarly, if the individual is a Type 1 diabetic individual (PI = pc = 0), then 
Goo = 00 if there is any exogenous glucose input, as might be expected and Goo = 0 if there is 
not. These results show the models are equivalent and, in the steady state, capture the basic 
dynamic trends of the glucose-insulin regulatory system. 
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TABLE 3.1: STEADY STATE ANAL YSIS FOR TWO- AND THREE-
COMPARTMENT MODELS 
1. 
11. 
iii. 
IV. 
Remote 
Compartment 
Insulin cs 
Plasma Insulin 
Dynamics 
Steady State 
Steady State 
v. Plasma Insulin 
Steady State 
Remote 
VI. Compartment 
Insulin 
(from ii. and v.) 
Steady State 
Vll. Plasma Glucose 
(from 1. and vi.) 
Assume no 
prandial input, 
V11l hence no 
IX. 
exogenous insulin 
From 
assumptions 
III Vlll. 
N/A 
pet) = ~s 
u(t) = uss u(t) = u ss 
1 =1 +Uss / 
55 B In~ 1 =1 +u
5S / 
5S B /n~ 
N/A 
G = -X5sGB +~s 
S5 X Pl + 5S 
Pa +~I'S 
~s p(t co) = 0 
X", =0 
G =0 if) 
Gif) 0 
o 
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3.2.2 Addition of Plasma Insulin Decay Dynamics 
During trials undertaken in 2002, utilising a heavy-derivative controller to control the rise 
of blood glucose following a glucose challenge of 75 g, it was found that Equations (3.4)-
(3.5) lacked some fonn of accumulation dynamics (Chase, et aI., 2003; Doran, et aI., 2004a; 
2004b). The initial two-compartment equations are linked solely by the insulin sensitivity 
constant, SJ, and hence at a given point in time it is assumed that the insulin in this 
compartment, I(t) , from previous time points is completely utilised and has no current 
effect. However, while it works in steady state analysis, this assumption is not accurate in 
transient dynamics. More specifically, the 2002 trials showed a so-called 'insulin 
accumulation dynamic', where the glucose level continued falling up to 180 minutes after a 
large insulin bolus-like infusion was given, clearly illustrating transient dynamics were 
missing from a model that could not capture this late drop. 
The assumption made in the fonnulation of Bergman's three-compartment equations and 
hence the two-compartment model is therefore inherently flawed for transient dynamic 
cases. An addition to the model was required that accounted for un-utilised insulin in the 
plasma (Guyton and Hall, 1996) or that had bound then unbound to cell walls, tissues or 
insulin receptors (Duckworth and Kitabchi, 1981). This addition would have a similar 
effect to splitting the insulin compartment into a slow path and a fast path, which indicates 
the existence of fast and slow absorption channels and the presence of local insulin 
degradation (CobeUi, et aI., 1999; Turnheim and Waldhausl, 1988; Wilinska, et aI., 2003). 
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Tumheim and Waldhausl (1988) studied the phannacokinetic modelling of intravenous 
insulin injection, and concluded that the concentration of plasma insulin following a bolus 
injection declines with at least two exponentials or two different rates. The first is a rapidly 
disappearing component of insulin represents elimination from the intravascular space, and 
the second is a more slowly disappearing component that reflects elimination from the 
interstitial fluid and the tissues that utilise insulin. These two components have half-lives 
of2.4 and 50 130 minutes, respectively. 
It should be noted that although insulin kinetics appear to be unchanged in diabetes mellitus 
patients, insulin removal may be retarded for cases with insulin antibodies or insulin 
resistance. leU patients are likely to be in one ofthese two categories, hence changing the 
half-life values. The two exponentials can be approximated by one exponential relatively 
accurately for the time period up to 30 minutes after an insulin bolus, as shown in Figure 
3.4, and hence for continuous infusions or for closely spaced bolus's, one exponential is 
sufficient in the model being developed, without significantly compromising physiological 
accuracy for minimised complexity. 
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FIGURE 3.4: SEMI-LOGARITHMIC GRAPH OF INSULIN CONCENTRATION 
MODELLED BY 2 COMPARTMENTS (TURNHEIM AND WALDHA USL, 1988) 
Therefore, to account for the transient kinetics and utilisation of insulin, the plasma insulin 
concentration, I, in Equation (3.4) is replaced with a convolution integral to capture this 
effect, while Equation (3.5) is unchanged. 
(3.6) 
where: 
k = Parameter controlling the effective half life of insulin (min-I) 
The convolution integral basically states that the removal of glucose as a result of the 
presence of insulin is a function of the currently available insulin, I(t) , as well as the 
remaining un-utilised insulin. 
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Available (Accessible) and Unavailable (Inaccessible) Glucose Compartments 
The model consisting of Equations (3.5) and (3.6) considers only available glucose, as the 
available glucose directly measured effects the plasma glucose levels, whereas the effects 
from unavailable glucose are less measurable. Work by Vicini et al (1997; 1999) and 
Caumo et al (1999) considers only labelled tracer glucose (called hot glucose) and is split 
into an accessible pool (denoted by the subscript 1) and a slowly equilibrilating pool 
(denoted by the subscript 2), as shown in Figure 3.5. The accessible pool is where insulin 
independent glucose disposal takes place and includes tissues in rapid equilibrium with 
plasma such as the red blood cells, central nervous system, kidneys and liver. The second, 
slowly equiliblilating pool includes insulin dependent tissues such as muscle and fat. The 
split of glucose between the two pools is 60:40 (Caumo, et aI., 1999). Guyton and Hall 
(1996) state that "ordinarily, only about 60 per cent of the glucose in the meal is stored ... 
in the liver and then returned later" which lines up with the 60:40 split made by Caumo, but 
may only be accurate in the zero input, steady state condition. 
PLASMA 
INSULlN-k• 
k12 
Irreversible Loss 
from Pool 2 
FIGURE 3.5: TWO COMPARTMENT GLUCOSE MODEL (CAUMO, ET AL., 1999; 
VICINI, ET AL., 1997, 1999) 
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This model is based on the minimal model, and hence is not too dissimilar to the current 
model presented. In the current model, the effect of glucose removal via the kidney, liver 
and central nervous system is lumped into the glucose clearance parameter, pG, and hence 
the system model considers the glucose to be all in the accessible compartment, a so-called 
'cold' model (Caumo, et a1., 1999). In addition, when the literature discusses the minimal 
model underestimating insulin sensitivity (Caumo, et al., 1999; Cobelli, et a1., 1998; 1999; 
Vicini, et al., 1997, 1999) the result should be expected, as the glucose is modelled as all 
accessible, and hence bigger than in Caumo et aI's (1999) work. As the product of the 
insulin sensitivity, S[, a glucose term, (G+GB), and an insulin term, I, are considered 
together in the model, if the glucose tenn, G, is increased, it follows that insulin sensitivity, 
S[, will be decreased. However, other reasons for this underestimation might include 
insulin saturation at large doses as the works described (Caumo, et al., 1999; Cobelli, et al., 
1998; 1999; Vicini, et a1., 1997; 1999) utilise clamp tests with high insulin doses. When 
the insulin doses given are lower, the result is an increased insulin sensitivity value, Sf 
(Prigeon, et al., 1996). More specifically, splitting into two glucose compartments based 
on a steady state glucose disposal ratio may not be the most physiologically justified 
modelling choice in capturing transient behaviours. 
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3.2.4 Omission of ElldogellOus Insulin Production 
It is unsure to what extent a hyperglycemic critically ill patient's endogenous insulin 
production is impaired or what its exact dynamics are. As the reasons for stress-induced 
hyperglycemia in ICU patients vary widely, so also do their primary metabolic responses. 
In particular, stress hormones such as adrenaline and cortisol inhibit endogenous insulin 
production (Mizock, 2001). As a result of their condition and treatment, it has always been 
difficult to quantifY a value for endogenous insulin production and plasma insulin basal 
level during trials to date (Doran, et aI., 2004a; 2004b). In Bergman's three-compartment 
model and the reduced two-compartment model, both exogenous insulin infusion, u(t), and 
endogenous insulin production, I(t), are included. Control regimes developed for this and 
related research include an endogenous insulin production value, Uo, which has generally 
been set to be equivalent to 1-2 Ulhr, and a basal insulin concentration, Is set to 15 mUlL 
(Chase, et aI., 2003; Doran, et aI., 2004a; 2004b; Lam, et aI., 2002). 
Initially, due to the difficultly in directly measuring these parameters, the assumed values 
for endogenous insulin production, Uo, and basal insulin concentration, Is, were removed 
from the model to minimise the unknowns and potential variability. In addition, it can be 
assumed that ICU patients with steady feeds and hyperglycemia are in a moderately steady 
condition with relevantly constant endogenous insulin production. Therefore, the basal 
insulin production can be assumed to be a 'static' offset and its effect lumped into the 
endogenous fractional glucose removal parameter, PG. Additionally, the insulin sensitivity 
parameter, Sf, is a relative value that already encompasses a number of physiological 
phenomena such as receptor sensitivity, losses in the bloodstream and effects of external 
92 Modelling and Control of Hyperglycemia in Critical Care Patients 
perturbations such as drug therapies, so this approach minimises complexity by keeping 
only two, now potentially time varying, parameters, pG and Sf, to govern glucose removal. 
Equation (3.7) defines the new rate of change of plasma insulin concentration. 
(3.7) 
However, in the case of no exogenous insulin input, endogenous insulin secretion is not 
suppressed. The model was modified to include the effect of basal endogenous insulin, 
which is required for periods of no exogenous insulin infusion, as when u(t) = O. 
. u(t) e<-II(1»IB 
1 = -nl + --+ ------""--
~ ~ 
(3.8) 
The endogenous insulin production is equal to the basal insulin value dispersed through the 
insulin distribution volume, 1 B for these periods. As the exogenous insulin infusion, u(t), 
VI 
is increased, endogenous insulin, iE, is suppressed, so hence large values of exogenous 
insulin infusions, u(t), Equation (3.8) becomes: 
• u(t) 
lr:::o-nl+-
V 
(3.9) 
However, unpublished trials using Equations (3.6) and (3.7) still did not accurately capture 
all transient dynamics. In addition, good data fits required extensive variation of patient 
specific parameters, PG and Sf, (50 - 100%) over short, umealistic periods of time (1 - 2 
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hours). Hence, additional insulin dynamics are still missing. In particular, dynamics that 
capture the reduced glucose decrement resulting from large insulin boluses or infusions are 
required to account for saturation effects. 
3.2.5 Insulin Saturation 
The concentration of insulin in the blood is a function of several variables. Once insulin 
has entered the human circulatory system, its distribution is likely to be uneven because of 
differences in blood perfusion, tissue binding, and permeability of cell membranes (Guyton 
and Hall, 1996). To add to this complexity, the insulin concentration at any time is 
dependent on its appearance in the circulation, binding to plasma proteins, distribution in, 
and exchange among, body pools, and irreversible disappearance from the circulation (Del 
Prato, et aI., 2002; Mari, et aI., 2001; Thorsteinsson, 1990). 
When insulin enters the human circulatory system, it initiates its effects on target cells by 
first binding, then activating a membrane receptor protein. It is the activated receptor, not 
the insulin, that causes the subsequent effects. Increased penneability to glucose is a result 
of insulin binding to receptor cells, and the effects of this binding are that approximately 
80% of the cells in the body become highly permeable to glucose and the rate of transport 
of glucose into the resting muscle cell is increased by a factor of at least 15 (Guyton and 
Hall, 1996). 
During the 1970's and 1980's a string of papers were published regarding the plasma 
insulin disappearance kinetics in humans. Many found flaws in the first order (linear) 
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assumptions of insulin disappearance that had been predominantly used in previous models 
(e.g. (Insel, et aI., 1974; McGuire, et aI., 1979; Sherwin, et aI., 1974; Toffolo, et aI., 1980). 
These flaws were assumed to be based on the narrow range of insulin levels studies, with 
the first results of a study which showed non-proportionality between plasma concentration 
and plasma disappearance rate first reported by S6nksen et al (1973), Hence, experimental 
studies were undertaken to determine whether the insulin disappearance rate was 
proportional to the plasma insulin concentration, by considering the concentrations 
resulting from a series of intravenous insulin infusions at different rates in both normal and 
diabetic subjects. 
The proposed models generally employed Michaelis-Menten saturation mechanisms. 
Michaelis-Menten kinetics are assumed for a variety of biological phenomenon, and stem 
from a set of assumptions about what may be occurring at the molecular level on a cell's 
surface (Edelstein-Keshet, 1988; Joslin, 1985). The saturation mechanism demonstrates 
that even though insulin in the system may be highly abundant, the number of insulin 
receptors determines the number of binding sites and hence the extent and rate of insulin 
action. Saturation via Michaelis-Menten kinetics is generally modelled: 
(3.1 0) 
where: 
K(C) = insulin action as a function of concentration 
Kmax = maximal insulin disappearance rate via a saturable pathway 
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Kn = plasma insulin concentration where insulin disappearance is half maximal 
C = plasma insulin concentration 
Fugleberg et al (1982) investigated a kinetic model of insulin disappearance in which 
insulin was assumed to be extracted from the plasma by two independent processes, one 
saturable and one non-saturable. This assumption was consistent with Franckson and 
Ooms' (1973; 1973) findings in normoglycemic dogs, and S6nksen et aI's (1973) findings 
in normoglycemic humans. However, interpretation of S6nksen et aI's (1973) findings 
showed that severe hypoglycemia had occurred during their experiment, so it is difficult to 
use these results as validation. Fugleberg et al (1982) concluded that the plasma insulin 
disappearance could be described by the proposed kinetic model, and likened the saturable 
pathway to hepatic insulin degradation, and the non-saturable pathway to renal clearance. 
Thorsteinsson (1990) reviewed three kinetic models including the saturable and non-
saturable pathway model. The three potential models are shown in Figure 3.6. The first 
model, identical to the one proposed by Fugleberg et al in 1986, considers the case where 
both saturable and non-saturable (linear) mechanisms exist, and is defined in Equation 
(3.11). The second model represents just the saturation kinetics by means of the Michaelis-
Menten saturation model, and is defined in Equation (3.12). The third model represents 
first order (linear, non-saturable) appearance of insulin, and is defined in Equation (3.13). 
96 Modelling and Control of Hyperglycemia in Critical Care Patients 
where: 
Insulin infusion rate (lex) 
P .. insulin cQncentration (C) 
FIGURE 3.6: KINETIC MODELS FOR INSULIN A V AILABILITY 
(THORSTEINSSON, 1990) 
lex exogenous infusion rate (pmollkglmin) 
lend endogenous infusion rate (pmollkglmin) 
C = steady state plasma insulin concentration (pmol/L) 
k\ = insulin clearance rate via a non-saturable pathway (Llmin) 
(3.11 ) 
(3.l2) 
(3J3) 
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k2 = maximal insulin disappearance rate via a saturable pathway (nmol/min) 
k3 = plasma insulin concentration at which the insulin disappearance rate via a 
saturable mechanism is half maximal (nmoI/L) 
Thorsteinsson (1990) concluded that the second model, using saturation kinetics alone, was 
superior to the other models for normal subjects at physiological and supraphysiological 
plasma insulin concentrations, and for diabetics at supraphysiological conditions. The 
appropriate model at physiological insulin concentrations for type 1 diabetic patients was 
that of first order kinetics alone, the third model. 
Generally, insulin appearance calculated using Michaelis-Menten kinetics were larger than 
those calculated using first order kinetics, and it is hypothesised that first order kinetics 
underestimates clearance rates by 20-30%. The effects of physiological and pathological 
conditions were considered using the saturation kinetics model. The effect of age, sex and 
relative body weight, within 80-130% of the ideal body weight, was minimal on insulin 
appearance. Insulin appearance has been found to be related to the relative muscle mass 
and inversely related to the size of adipose (fat) tissue in young healthy subjects of normal 
weight. In severely obese individuals, greater than twice the ideal body weight, the insulin 
appearance was normal or reduced. In addition, high levels of insulin antibodies can also 
increase the insulin clearance rate because infused insulin is rapidly bound to antibodies, 
resulting in a lower steady state plasma free insulin concentration and hence a greater 
metabolic clearance rate (Thorsteinsson, 1990). 
98 Modelling and Control of Hyperglycemia in Critical Care Patients 
Hence, the evidence is significantly in favour of adding insulin saturation to the model 
presented. As the saturation is on the appearance of insulin, the Michaelis-Menten 
saturation dynamics were added to the plasma insulin concentration compartment. The 
result is another revision to Equation (3.5). 
(3.14) 
where: 
af = Michaelis-Menten parameter for saturation 
Previously, insulin saturation effects were not included in the model and saturation effects 
were seen as reduced insulin sensitivity, Sf. By including insulin saturation, variations in 
the insulin sensitivity, Sf, should be reduced and more physiologically realistic. Hence, the 
cyclical and drug-induced effects on insulin sensitivity should be more clearly visible. 
3.2.6 Glucose Clearance Saturation 
Glucose clearance due to exogenous insulin is controlled primarily by the insulin sensitivity 
parameter, Sf, which links exogenous insulin and endogenous glucose levels. To improve 
model accuracy, the incorporation of the glucose response to varying doses was 
investigated. As the dose of exogenous insulin is increased insulin sensitivity, Sf, decreases 
(Prigeon, et aI., 1996). This result occurs because the effect of insulin saturation at the 
receptor, limiting utilisation (Natali, et aI., 2000). Hence, there is a need for a saturable 
mechanism in the model to account for this non-linear effect. Prigeon et al (1996) 
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concluded that as results were not consistent with the known saturation characteristics of 
insulin action on tissue, a second saturable site involving the transport of insulin from 
plasma to interstitium might also be a possibility. 
Using a Michaelis-Menten function of insulin concentration with a delay of tI/2, Natali et al 
(2000) added a saturation to insulin action on fractional glucose extraction in the 
circulatory model shown in Figure 3.7. Natali et al (2000) was able to obtain good fits to 7 
lean and obese patients, with limitations only occurring in the first 60 minutes, which was 
attributed to an irregular onset of insulin action during this initial phase. The glucose 
clearance for this research was defined: 
(3.15) 
where: 
Cl = Glucose clearance (mLiminlm2) 
Eb =basal glucose fractional extraction 
Emax = maximal glucose fractional extraction via a saturable mechanism 
ECso = plasma insulin concentration at which the glucose fractional extraction 
rate via a saturable mechanism is half maximal 
100 Modelling and Control of Hyperglycemia in Critical Care Patients 
III .................................. . 
(J' 
~ :ve 
c' ~: 
<11: 
Ill. 
o. 
(J. 
::J. 
m: 
1:. 
0: 
:;i. 
(J' Ill: 
1:. 
::J: 
Ill· 
1:' 
,- . 
a: 
Qi 
'0' 0: 
E 
III sid": nouS -side hearl·lungs arleri 
f"" tW{f·exponential tra1sit f-
I~ trrTlB U8J1$lt~t tunctlon sur ~~ .... npling .. ., 
periphery 
... four'OkpOnoJ'lial transit I-tftT1~ (km$i1~f ft..JocUcn 
(rra~lional extractiOn) 
controlled bylnsulin 
. - - - .. - ,. ~ - ~ . '"- ,. ... 
'" '" " ~ .~ " .. " " " M • '" 
- - - - - - - - - - - --- - - - - - - - - - - - - -
Michaelis-Menten function 
.'K= ~~ -,.-J::g iecs 
insuhn concentration 
g,£: J ~'~ (;:Ie D -
Imonoexponential delay 1 
T1/2 
t 
E~ J ~§ 0.. ~~ 
FIGURE 3.7: NATALI ET AL'S (2000) MODEL INCLUDING SATURATION OF 
GLUCOSE EXTRACTION 
The addition of a saturation term for the effect of exogenous insulin changes Equation 
(3.6). 
(3.16) 
(3.17) 
where: 
UG = Michaelis-Menten glucose clearance rate saturation parameter 
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3.3 FINAL FORM OF MODEL 
The model has been developed to account for non-linear saturation of exogenous insulin 
appearance rate and its saturable utilisation to reduce blood glucose levels. The reduction 
of the minimal model from three to two compartments accounts for IV infusion and is 
verified for the steady state. The addition of transient insulin kinetics via a convolution 
integral on exogenous plasma insulin concentration and its utilisation has accounted for the 
accumulation dynamic seen in prior clinical trials, and better matches physiological 
knowledge. This modelling approach also effectively splits the glucose compartment into 
fast and slow (or available and unavailable) compartments over a continuum rather than 
two discrete states (Caumo, et aI., 1999; Cobelli, et aI., 1999; Vicini, et aI., 1997). 
Removing endogenous insulin production from the model for periods of exogenous insulin 
infusions reduced model complexity and improved model parameter fits. The addition of 
insulin appearance and glucose clearance saturation are physiologically justified and added 
via Michaelis-Menten dynamics. The resulting non-linear model is now defined: 
(3.18) 
(3.19) 
n1 u(t) e(-II(t)) 1 
___ +_+ B 
l+aJ ~ ~ 
(3.20) 
which is equivalent to the three compartment model defined 
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(3.21) 
(2= -kQ+kI (3.22) 
._ nI u(t) e(-If(t))I
B 1-- +--+------"'--
l+aJ ~ ~ 
(3.23) 
where Q represents the effects of the insulin decay half-life in the plasma and is similar to 
the model found in Mari et al (2001). The tinal fonn of the non-linear model is shown in 
Figure 3.8. 
lI({J---------j1 '"'P"" ""I CONTROLLER ;"P"" Ga)1 ~.--------G({) 
Decay Satumlion 
FIGURE 3.8: MATHEMATICAL SCHEMATIC OF THE FINAL FORM OF THE 
CONTROL MODEL INCLUDING FEEDBACK CONTROL 
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The model developed, shown by Equations (3.19) - (3.21) and in Figure 3.8, is similar in 
overall form to the initial two-compartment model, shown in Equations (3.4) (3.5) and in 
Figure 3.3, but has a number of significant differences. The effect of exogenous insulin in 
the plasma in the time period following its infusion and the saturation of insulin appearance 
and glucose clearance have been added, while the endogenous insulin production, Uo, and 
basal level, IB, have been lumped into the endogenous glucose parameter,PG, removing two 
less well defined model parameters. In addition, non-linear saturation of insulin appearance 
and utilisation have been added, per results in the literature. Finally, the second 
compartment in Equation (3.21) has equal constants, k, preventing the undermodelling of 
insulin sensitivity, Sf (Caumo, et al., 1999). 
3.3.1 Steady State Analysis 
A steady state analysis was performed to show the equivalence of both of the two-
compartment models in the steady state. This analysis is presented in detail in Table 3.2. It 
should be noted that in the assumption of no exogenous insulin, the steady state insulin 
infusion, Uss, differs between the two models, as the final form assumes no endogenous 
insulin, Uss 0, and the two-compartment model assumes Uss = Uo. However, both 
assumptions lead to the same steady state value as shown in steps (ix) and (xi). 
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TABLE 3.2: STEADY STATE ANALYSIS FOR NEW MODEL AND ORIGINAL 
TWO-COMPARTMENT MODEL 
11. 
iii. 
IV. 
v. 
Vl. 
VB. 
... 
Vlll 
IX. 
x. 
XI. 
~- ~ 
Plasma Glucose 
Uptake Dynamics 
Plasma Insulin 
Decay 
Plasma Insulin 
Dynamics 
Steady State 
Steady State 
Plasma Insulin 
(from iii.) 
Plasma Insulin 
Decay Steady 
State 
(from ii. and v.) 
Steady State 
Plasma Glucose 
(from i. and vi.) 
Assume no 
prandial input, 
and no exogenous 
insulin 
From 
assumptions 
III VB1. 
Assume no 
exogenous insulin 
From 
assumptions 
mx. 
Final Form of Model 'lhvo-@ompartment Model 
Q=-kQ+k1 N/A 
G=/=O 
P(t) = ~s P(t) = ~s 
u(t) = USS u(t) = uss 
Q -/ ss - sS N/A 
G = - Sf/ssGB + ~s + aG/ss~s 
ss PG + SJss + aG/ssPG 
G = -SJssGB+~s 
ss PG +Sl.<s 
~s = P(t = rxJ) = 0 
lIss = u(t = rxJ) = 0 
Q,,=O 
Goo =0 
'ro 0 
uss = u(t = rxJ) = 0 
/ro =0 1", =0 
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4 
PARAMETER VALUES 
4.1 BACKGROUND 
The concentration of glucose and insulin in the blood is a result of many processes, such as 
endogenous insulin secretion, exogenous insulin and glucose inputs, insulin and glucose 
distribution in the body, glucose and insulin interaction and utilisation, and storage of both 
insulin and glucose by organs in the body. Once a model is developed to include all these 
processes, the values of patient specific model parameters are the key element in obtaining 
good model fits and predictions, and must be physiologically justified and computationally 
optimised. In most physiological studies, each portion of the glucose-insulin system is 
analysed individually, but for a control model each of these individual portions must be 
combined. 
The parameters used in the control model of Equations (3.19) - (3.20) are split into patient 
specific and generic parameters. For control modelling, patient specific parameters are 
determined by considering previously gathered data, either from the day before (Chase, et 
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aI., 2003; Doran, et aI., 2004a; 2004b), or immediately prior to fit, as presented later in this 
thesis. The patient specific parameters in the model make the generic system model unique 
to a particular patient. The generic parameters are based on reported results and held 
constant for all patients. This assumption reduces complexity in fitting, by assuming that 
the generic parameter is approximately the same throughout the population and does not 
significantly impact model performance. 
The difficulty in model prediction using these values lies in the variability of glucose 
clearance, PG, and insulin sensitivity, Sf, over time. Insulin sensitivity, Sf, can vary over a 
period of 3 - 24 hours (Wilinska, et aI., 2003) in Type 1 diabetic individuals, and it is 
unknown whether this phenomenon occurs in critically ill patients. Glucose clearance, PG, 
may also vary over time. In the critical care environment, the impact of a wide variety of 
pharmaceutical therapies, such as adrenaline-based vasopressors, must also be considered. 
4.2 FRACTIONAL CLEARANCE OF GLUCOSE, PG 
The parameter PG determines the rate at which glucose is cleared from the system at basal 
insulin. It is a parameter that originated from the minimal model proposed by Bergman 
(1985) and is often referred to as p j or SG. A number of researchers have used the minimal 
model to determine values for PG, either empirically (Avogaro, et aI., 1989; Bergman, et aI., 
1981; Cobelli, et aI., 1999; McDonald, et aI., 2000; Pillonetto, et aI., 2002) or theoretically 
(Bettini, et aI., 1995; Fuder, et aI., 1985; Vicini, et aI., 1999), and have produced a wide 
range of values. Of the theoretical values listed in Table 4.1, Furler et aI's (1985) estimates 
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encompass the entire range ofthose values proposed by others (0 - 0.028 min-I). However, 
it should be noted that the value proposed by Furler et al (1985) for PG in Type 1 diabetic 
individuals, PG = 0, results in instability in the minimal model as shown by the steady state 
analysis in Chapter 3. A zero value also implies absolutely no non-insulin mediated 
glucose clearance, which is not possible. 
The values for pG from clinical studies also have a reasonably large range, spanning from 
0.0059 min- l (Avogaro, et aI., 1989) to 0.0466 min-I (Bergman, et aI., 1981) and includes 
healthy, diabetic and obese individuals with varying levels of glucose tolerance. This range 
also encompasses ranges developed theoretically by a large margin. Unfortunately, the 
varying units and unknown assumptions made by Cobelli et al (1999), mean that converting 
their values to compare with other physiological values was not possible. 
Although, the glucose effectiveness, pG, may change over time, the variation is likely to be 
small compared with that of the insulin sensitivity, Sf (McDonald, et aI., 2000). The 
parameter for glucose effectiveness originated from the minimal model (Bergman, et aI., 
1985), and so it makes sense that use of the minimal model is most likely when determining 
a value for PG from the literature (e.g (Avogaro, et aI., 1989; Bergman, et aI., 1981; Bettini, 
et aI., 1995; Cobelli, et aI., 1999; McDonald, et aI., 2000; Pillonetto, et aI., 2002; Vicini, et 
aI., 1999). The alternate model developed in Chapter 3 may have different values, although 
they are expected to be similar given the similarity of this model term to the minimal 
model. For this research a conservatively lower value of pG = 0.01 min- l is assumed to be 
approximately normal for catabolic lCU patients, unless fitting dictates a different result. 
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TABLE 4.1: PHYSIOLOGICAL AND THEORETICAL VALUES FOR GLUCOSE 
CLEARANCE 
0.0059 0.0098 6 Healthy with Glucose (A vogaro, et aI., 1989) min-I 
Tracer 
0.012 0.033 6 Healthy Minimal Model (Avogaro, et at, 1989) min-I 
0.0075 0.0101 Minimal Model 
min-I 6 Healthy with Glucose (Avogaro, et aI., 1989) 
Tracer 
0.0071 - 0.0246 7 obese, low Minimal Model (Bergman, et aI., 1981) min-I tolerance 
0.0136 0.0217 3 lean, low Minimal Model (Bergman, et aI., 1981) 
min-1 tolerance 
0.0192 0.0464 5 lean tolerant Minimal Model (Bergman, et at., 1981) 
min-1 
0.0323 0.0466 3 obese tolerant Minimal Model (Bergman, et at, 1981) 
min- l 
0.0096 min- l Theoretical Meal ettini, et aI., 1995) Hot 
0.0098 min- l Theoretical IVGTT Minimal Model (Bettini, et aI., 1995) Hot 
0.0099 min- l Theo Minimal Model (Bettini, et aI., 1995) Cold 
0.0243 min- l Theoretical IVGTT Minimal Model (Bettini, et aI., 1995) Cold 
2.81 22 IVGTT Normal 2 compartment (Cobelli, et at, 1999) 
mLmin-1 -I Minimal Model 
4.27 ± 0.33 22 IVGTT Normal 1 Compartment (Cobelli, et aI., 1999) 
mLmin- l -1 Minimal Model 
Omin-] Type 1 proposed Minimal Model (Furler, et aI., 1985) 
values 
Normal/ Insulin 
0.028 min- I Resistant Proposed Minimal Model (puder, et aI., 1985) 
values 
0.008 - 0.038 56 lean and obese Minimal Model (McDonald, e 
min-I women 
0.0089-0.021 10NIDDM Minimal Model (Pillonetto, e min-] 
0.010140 Simulated Data Cold Minimal (Vicini, et aI., 1 
min- l 1 Model 
0.019864 Simulated Data Cold Minimal (Vicini, et aI., 1999) 
min- l -I Model 
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4.3 INSULIN SENSITIVITY, S, 
Two-day proof of concept clinical trials using heavy derivative control (Chase, et aI., 2003; 
Doran, et aI., 2004a; 2004b) showed the need for an optimised insulin sensitivity parameter, 
S1, that changed with time. Insulin sensitivity, Sf, is defined as the glucose responsiveness 
to the metabolic actions of exogenous and endogenous insulin and is the most important 
model parameter when automating insulin infusion. In-vivo insulin sensitivity may vary 
according to insulin concentration, exposure time, pulsatility and tissue delivery amoung 
others (Oenuth, et aI., 1998). The need for variation in insulin sensitivity is highly 
important in critically ill patients, as their physical state can often change quite quickly in 
response to stress of their condition, feeding, or medication. 
A number of techniques have been developed to quantify insulin sensitivity or a surrogate 
measure. These techniques range in complexity and time required to obtain them. The 
simplest are scalar ratios, such as the HOMA (Katsuki, et aI., 2001) and the QUICKI 
(Hrebicek, et aI., 2002), which are the combination of fasting blood insulin and glucose 
values. These values are simple diagnostic tools for the extent of insulin resistance and are 
usually measured over a large population for comparisons of subgroups. The minimal 
model has been used by a number of researchers to find values of insulin sensitivity (e.g 
(Araujo-Vilar, et aI., 1998; Avogaro, et aI., 1989; Bergman, et aI., 1981; 1987; Breda, et aI., 
2002; Caumo, et aI., 1999; Cobelli, et aI., 1999; Pacini and Bergman, 1986; Pillonetto, et 
aI., 2002; Prigeon, et aI., 1996; Vicini, et aI., 1997; 1999). It is a more complex method and 
generally requires the patient to undergo a fasting period then an OOTT, FSIVTT or similar 
test, the whole process taking 8 hours or more. Computer simulations are then required to 
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determine the value of insulin sensitivity. The minimal model, in some forms, has been 
shown to underestimate insulin sensitivity (Cobelli, et aI., 1999; Vicini, et aI., 1999). The 
'gold' standard for obtaining insulin sensitivity is the euglycemic clamp technique 
(DeFronzo, et aI., 1979), however this test is labour and time intensive for both patients and 
clinicians, and hence is only suitable for more specialised clinical studies. 
The majority of these methods calculate indices, which are used to indicate relative 
sensitivities, rather than an absolute value. Hence, while they are useful in comparing 
members of a clinical study and diagnosing insulin resistance or diabetes, they do not 
provide a value of insulin sensitivity, Sf, for the use in a control model. Only the intensive 
minimal model based methods and euglycemic clamp provide this physiological measure. 
Insulin sensitivity, Sf or lSI (Insulin Sensitivity Index), has been a widely researched 
parameter, especially in the empirical sense as shown by the selection of insulin sensitivity 
values shown in the literature and presented in Table 4.2A and 4.2B. 
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TABLE 4.2A: PHYSIOLOGICAL VALUES FOR INSULIN SENSITIVITY 
0.75 (Araujo-Vilar, Minimal Model et 
5.14 Modified (Araujo-Vilar, Minimal Model et al 
6 healthy 
1.71 - 5.87 x 10-4 1.71 - 5.87 (l01±1% Minimal Model (Avogaro, et aI., 
min-1 JlU-1 mL ideal body 1989) 
2.23 - 8.20 x 10-4 Minimal Model (Avogaro, et aI., 
min-1 JlU-1 mL 2.23 -8.20 with Glucose 1989) Tracer 
3.17 - 5.13 x 10-4 Minimal Model (Avogaro, et aI., 3.17-5.13 with Glucose 
min-1 JlU-1 mL Tracer 1989) 
Steil and 
7.83 ± 5.3 x 10-5 1.76 - 6.12 MINIMOD94 Bergman 94 in 
min-! (pmol L-1 rl (Araujo-Vilar, 
et al. 
5.1 ± 1.3 x 1 3.8- 6.4 min-! lmL 
4.9 ± 1.0 3.9- 5.9 odel (Bergman, et 
min-1 mL al. 1981 
5.5 ± 1.6 x 1 4.9-7.1 Minimal Model (Bergman, et 
min-1 lmL al. 1981 
2.0 ± 0.4 1.6-2.4 7 obese, low Minimal Model 
min-1 mL tolerance 
0.037 ± 0.007 10 normals Clamps dL min-l U-1mL unsure 
0.046 ± 0.008 10 normals FSIVTT (Bergman, et dLmin-1 U-I mL unsure at, 1 
11.67± 1.71 xl 22 IVGTT 2 Compartment (Co belli, et al., 
min-I -lmL unsure Normal Minimal Model 1 
8.68 1.62 x 1 22 IVGTT 1 Compartment 
min-I -I mL unsure Normal Minimal Model 
13.08±1.17 Hyperglycemic (DeFronzo, et 
mg min-1 kg-1 JlU unsure 11 normals 
mL-1 clamp aI., 1979) 
* Conversion is 0.1 44 xpmo1!L = mUlL 
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TABLE 4.2B: PHYSIOLOGICAL VALUES FOR INSULIN SENSITIVITY 
Sf or lSI 'Sf* (10-") (E.lmll.Ttmin) 
2.54 ± 2.74 0-5.28 IlU mL-! min-l 
4.41 ± 3.30 
IlU mL-1 min-! 1.11-7.71 
0.2 - 22.6 x 10-4 
min-! mU-! mL 0.2 -22.6 
4.3 ± 1.31 4.81-mL min-! m-2 L-1 
mU 9.02*** 
1.25 ± 0.07 2.28-mL min-! m-2 L-! 
mU 2.55*** 
8.12 ± 5.2 x lO-5 
min-! (pmol L-!r! 2.03 - 9.25 
0.6 - 2.1 x lO-4 
0.6 - 2.1 min-! mU-! mL 
4.8 ± 0.95 x 10-5 
min-!.lpM 4.62 - 6.90** 
3.56 ± 0.53 x lO-5 
min-!.lpM 3.64 - 4.91 ** 
2.42 ± 0.40 x 10-5 
min-!.lpM 2.42 - 3.38 
13.83 ± 2.54 x lO-L 
mL kg-! min-! IlU-! unsure 
mL 
12.98 ± 2.21 x lO-L 
mL kg-! min-! flU-! unsure 
mL 
* ConverSIOn IS 0.144xpmollL = mUlL 
** 12 L distribution volume assumed 
'Eype 
18 Normals 
18 Normals 
56 lean and 
obese 
women 
4 lean 
healthy 
3 obese 
healthy 
10NIDDM 
(Type 2) 
7 obese 
7 obese 
7 obese 
14 normal 
14 normal 
*** Using mean body surface area (m2) (Natali, et a1., 2000) 
How Who? @alculated? 
Minimal Model (Duncan, et aI., 
of FSIVGTI 2003) 
Minimal Model (Duncan, et aI., 
ofFSIVGTT after 2003) 
exercise 
(McDonald, et Minimal Model 
aI., 2000) 
Circul atory (Natali, et aI., 
Model 2000) 
Circul atory (Natali, et aI., 
Model 2000) 
(Pacini and 
Bergman, 1986) 
MINIMOD 86 in (Araujo-
Vilar, et aI., 
1998) 
Minimal Model (Pillonetto, et 
aI., 2002) 
Bolus Injection, (Prigeon, et aI., Peak Cone = 1996) 1167 ±156 pM 
Bolus Injection, (Prigeon, et aI., Peak Cone = 1996) 3014± 384 pM 
Bolus Injection, (Prigeon, et aI., Peak Cone = 1996) 6596± 547 pM 
2 compartment (Vicini, et aI., 
minimal model 1997) 
2 compartment (Vicini, et aI., 
minimal model 1997) 
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Theoretical values for insulin sensitivity, Sf, have also been proposed using the hot (with a 
tracer) and cold (no tracer) minimal model (Avogaro, et aI., 1989; Caumo, et aI., 1999; 
Vicini, et aI., 1997). A selection of these values are shown in Table 4.3. The theoretical 
values range from 1.97 x 10-4 to 5.2 x 10-4 LlmU/min, while the empirical values range 
from 0 to 22.6 x 10-4 LlmU/min, with the majority of values falling approximately in the 
range between 2 x 10-4 8 x 10-4 LlmU/min, as shown in Figure 4.1. It is interesting to 
note the wider empirical range, illustrating the significant variation encountered in clinical 
situations. 
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FIGURE 4.1: GRAPHICAL REPRESENTATION OF PHYSIOLOGICAL INSULIN 
SENSITIVITY VALUES 
Insulin sensitivity is generally reduced for obese and diabetic individuals, and vanes 
depending on the model or method used to obtain it. It should be noted, however, that 
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although insulin sensitivity varies, almost all values, excluding Araujo-Vilar et al (1998) 
and McDonald et al (2000), have the same order of magnitude. Finally, it should be noted 
that insulin sensitivity, Sf, exhibits a much larger range than the glucose clearance, PG, 
illustrating its heavier impact on model results and potentially greater variability over time 
(McDonald, et al., 2000). 
TABLE 4.3: THEORETICAL VALUES FOR INSULIN SENSITIVITY 
-
Sf 01* lSI Type How Wl1o? C'aleulated? 
eore Ica (Bettini, et al., 1995) 
min- i !lUi mL IVGTT Model 
328 x ]0 Th t Cold Mlmmal 
2.79 x 104 Theoretical Cold Minimal (Bettini, et aL, 1995) 
min-I !lUI mL Meal Model 
3.66 x 10-4 Theoretical Hot Minimal (Bettini, et aL, 1995) 
min-I flU-I mL IVGTT Model 
1.97 x 10-4 lbeoretical Hot Minimal (Bettini, et al., 1995) 
min-J flU I mL Meal Model 
2.9 - 3.3 x 10-4 Monte Carlo Cold Minimal (Caumo, et aL, 1999) dL kg-I min- I flU-I mL Simulations Model 
3.2 3.5 x 10-4 Monte Carlo Hot Minimal (Caumo, et aL, 1999) dL kg-I min-I flU I mL Simulations Model 
5.2 x 10-4 Normal and Proposed values 
min-1 mU-1 L Type 2 for Minimal (Furler, et al., 1985) Model 
2 x 10-4 Proposed values 
min-I mU-1 L Type 1 for Minimal (Furler, et aL, 1985) 
Model 
2.4 x 10-'1 Simulated Cold Minimal (Vicini, et aL, 1999) 
min-I flU I mL Data Model 
3.6 x 10-4 ulated Hot Minimal (Vicini, et aL, 1999) 
min-I !lUi mL Data Model 
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4.4 INTERSTITIAL INSULIN TRANSFER DELAY, 11 
The values for interstitial insulin transfer are calculated by considering the half-life of 
insulin as it travels through the interstitial fluid. The half-life, t1/2 is easily converted to the 
interstitial insulin transfer delay, 1'1, as shown in Figure 4.2. 
(4.1) 
where: 
1'1 delay in interstitial transfer of insulin (min-I) 
11/2 half-life of insulin in the interstitial space (min) 
o Time (min) 
FIGURE 4.2: HALF-LIFE DECAY CURVE 
A literature search for physiological values revealed the half-lives shown in Table 4.4. The 
intravascular space (i.e. in the blood vessels) has a much faster clearance, as shown by a 
lower half-life, than the interstitial space (i.e. in the small spaces between tissues and 
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organs). As expected, insulin infused intravenously was cleared faster than that infused 
subcutaneously. Initial trials used n = 5/54 min-I, a value obtained from Bergman et al 
(1985), which is equivalent to a half-life of approximately 7.5 min, which also falls within 
the range given by Thorsteinsson (1990) of a half-life of 4.6 - 8.3 min. From the 
physiological values of half-lives following an IV injection in Table 4.4 and advice from 
medical professionals the value of n has been increased to n = 0.16 min-I, giving a half-life 
of approximately 4.3 minutes. 
TABLE 4.4: PHYSIOLOGICAL VALUES FOR INTERSTITIAL TRANSFER HALF-
LIFE 
tm (min) Il Wherefrom? Following Who? (min-I) 
Low Affinity After 12 hour infusion, 
1.5 0.46 Insulin Binding bolus given, so insulin (Nestler, et aI., 1988) 
Sites concentration is 10-8 M 
Silvers (1974) and 
2.3 -2.4 0.29 - Intravascular IV injection Sherwin (1969) in 0.30 space (Turnheim and 
Waldhausl, 1988) 
2.4 0.29 Intravascular IV injection (Turnheim and 
space Waldhausl, 1988) 
4.6 - 8.3 0.083 - Plasma IV injection (Thorsteinsson, 1990) 0.15 (Interstitial) 
7.5 0.09 (Bergman, et aI., 1985) 
High Affinity 140 min after 12 hour 0.09 - infusion, bolus given so 6-8 0.12 Insulin Binding insulin concentration is (Nestler, et aI., 1988) Sites 10-9 M 
Silvers (1974) in 
14 0.04 Interstitial fluid IV injection (Turnheim and 
Waldhausl, 1988) 
8 - 24 0.03 - Pool 1 to Pool 2 SC infusion (Kraegen and 0.09 Chisholm, 1984) 
0.02 - Plasma 20mU/m
L/min for 0-100 
25 ±9 min, then 200mU/m2/min (Natali, et aI., 2000) 0.04 (Interstitial) for 100-200 min (SC) 
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4.5 INSULIN DECAY HALF-LIFE, k 
The values of interstitial insulin transfer are calculated by considering the half-life of 
insulin as it is removed from the interstitial fluid. The half-life, t1/2 is easily converted to 
the insulin decay half-life, k. 
(4.2) 
where: 
Ie = parameter controlling half-life of insulin decay (min-I) 
t1/2 = half-life of insulin removal from the interstitial space (min) 
The effect of changing Ie is seen in Figure 4.3, where t1/2 = 50 min corresponds to Ie = 
0.0139 min-I, tl/2 = 100 min corresponds to Ie = 0.0069 min-I and tl/2 = 150 min corresponds 
to Ie = 0.0046 min-I. It can be seen that as the half-life increases and Ie decreases, that the 
rate of insulin removal is reduced, as expected . 
.... ,' 
., ........ , 
" .••. 1-. •. __ • __ .J . __ ._ ... ~ .... 
50 Jon J50 
time (minj 
FIGURE 4.3: DECAY CURVES SHOWING THE EFFECT OF CHANGING INSULIN 
DEC A Y HALF-LIFE 
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TABLE 4.5: PHYSIOLOGICAL VALUES FOR INSULIN DECAY HALF-LIFE 
tm 
" 
WHere From? Following? WHo? ~min) ~ . -I) mm 
53 0.0103 Diabetics CSII 3U/hr for 1 hour (Kobayashi, et al., 1983) 
62 0.0112 1 OmU/kg/min for 12- (Nestler, et al., 1988) 16 hours 
70 0.0099 From Pool 2 SC rapid 5 min (Kraegen and infusion Chisholm, 1984) 
Radio labelled Joiner (l959) in 76 0.0091 insulin SC abdominal bolus (Kraegen and Chisholm, 1984) 
Radio labelled Binder (1969) in 87 0.0080 insulin SC abdominal bolus (Kraegen and Chisholm, 1984) 
Elimination from 
50- 0.0053 - the interstitial IV injection (Turnheim and 130 0.0139 fluid and tissues Waldhausl, 1988) 
that utilise insulin 
Radio labelled Karisto (l980) in 120 0.0058 insulin SC abdominal bolus (Kraegen and Chisholm, 1984) 
Silvers (l974) in 
133 0.0052 Tissues IV injection (Turnheim and 
Waldhausl, 1988) 
Values shown in Table 4.5 considered the removal from the interstitial space following a 
subcutaneously injected insulin bolus. As the model developed in Chapter 3 is based on 
intravenously injected insulin, the half-life values given for a subcutaneous bolus are too 
long. Kraegen and Chisholm (l984) suggested that the delay in the subcutaneous layer is 
approximately 20 minutes. Thus, the range for half-lives of 50 - 130 minutes, with many 
values between 50 and 90 minutes leads to a value of k = 0.0099 min-I being selected, 
corresponding to a half-life of 70 minutes. This value was chosen to reflect the centroid of 
the values from the literature survey in Table 4.5. 
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4.6 SATURATION ON INSULIN TRANSPORTATION, (II 
Saturation is assumed to follow Michaelis-Menten dynamics as discussed in Chapter 3. 
K(C) (4.3) 
where: 
K(C) = insulin action as a function of concentration 
Kmax = maximal insulin disappearance rate via a saturable pathway 
Kn = plasma insulin concentration where insulin disappearance is half maximal 
C = plasma insulin concentration 
In the model it is defined in Equation (3.14) and the specific term is repeated here. 
where: 
K(1) 111 
l+a,1 
K(1) = insulin action as a function of concentration 
11 delay in interstitial transfer of insulin (min-I), where 11 = Kmax ~ IK" 
aI Michaelis-Menten parameter for saturation, where a I = 1{ IAn 
1 plasma insulin concentration (mUlL) 
(4.4) 
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TABLE 4.6: PHYSIOLOGICAL VALUES FOR INSULIN TRANSPORT 
SATURATION 
!1(7max 'I~, ~Iearance IDose m~mel? ~liol? 
5.2 2.7 27.6 1-5 (Thorsteinsson, (4.0-9.1) (1.6-5.1) (17.3 - 47.9) mU kg-I min-I Normal 1990) 
nmol min-I nmol L-1 mLkg-1 min-I 
7.3 3.9 25.0 2-10 (Thorsteinsson, (6.6 - 8.9) (2.5 - 7.4) (18.6-47.1) mU kg-I min-I Normal 1990) nmol min-I nmol L-1 mL kg-I min-I 
9.4 7 18 2-10 (Thorsteinsson, (6 - 12) (3.6 - 13) (10- 23.7) mU kg-I min-I Type 1 1990) 
nmol min-I nmol L-1 mL kg-I min-I 
2 nmol L-1 Normal 
Jones (1984) in 
(Thorsteinsson, 
1990) 
, 0.0083 Kuehn, 1980 in 
-0.83# Nonnal (Thorsteinsson, 
nmolL-1 1990) 
28.1 ± 8.3 18 (Thorsteinsson, 
mL kg-I min-I Normal 1990) 
Shapiro (1987) 
28mLkg-1 Normal In . -I (Thorsteinsson, mIn 
1990) 
33.3 mLkg-1 0.2/0.5/0.9/1.8 6 Frost (1979) in 
min-I mU kg-I min-I Normal (Thorsteinsson, 1990) 
27.7 mL kg-l 2/4/6/8/10 6 (Thorsteinsson, 
min-I mU kg-I min-I Normal 1990) 
35.2 mLkg-1 112/3/4/5 4 (Thorsteinsson, 
min-J mU kg-I min-I Normal 1990) 
5.157/7/ nmol (Baura, et al., 
min-I 1993) 
6.15 ± 0.57 3.37± 24.9± 1.7 mL 112/3/4/5 8 (Ellemann, et 0.28 
nmol min-I 
nmol L-1 
kg-I min-I mU kg-I min-I Normal al., 1987) 
112/3/4/5 8 (Ellemann, et 
mU kg-I min-I Corti son a1.,1987) 
e 
19 0.13/0.2/0.4 Normal (Thorsteinsson, mL kg-I min-I mU kg-I min-I et al., 1986) 
# Assummg a 12 L dlstnbuhon volume, ## ConverSIOn from /-lU, nmoVmm = /-lU/min/(O.l44xlO 6) 
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Table 4.6 shows the values from the literature, which are mainly from Thorteinsson's work 
(1990). Table 4.7 shows the calculated values calculated using Equation (4.4). Note also 
that n is very similar to that shown in Table 4.4, despite the independent calculation. 
The range of physiological values for the insulin saturation parameter, aI, range from 
0.0005 - 0.0043 LlmU. The value used in this research is aI = 1.7 x 10-3 LlmU, which lies 
approximately in the centre of the ranges found by Thorsteinsson (1990) for normal 
subjects. It is currently unknown if a critically ill patient has a significantly different 
saturation level, and hence the value for normal subjects was chosen. 
TABLE 4.7: CALCULATED PARAMETERS FOR INSULIN SATURATION 
++ 
Kmax /(" + ( • -I) aI Type? Who? Il mill (B/mD) 
5.2 2.7 0.0026 (Thorsteinsson, (4.0-9.1) (1.6-5.1) 0.16 (0.0014 - Normal 
nmol min-1 nmolL-1 0.0043) 1990) 
7.3 3.9 0.0018 (Thorsteinsson, (6.6- 8.9) (2.5 -7.4) 0.16 (0.0009 - Normal 
nmol min-1 nmol L-1 0.0028) 1990) 
9.4 7 0.0009 (Thorsteinsson, (6 - 12) (3.6- 13) 0.11 (0.0005 - Type 1 
nmol min-1 nmol L-1 0.0019) 1990) 
2 nmol L-1 0.0035 Normal 
Jones (1984) in 
(Thorsteinsson, 
1990) 
6.15 ± 0.57 3.37 ± 0.28 0.15 0.0019 - 8 (Ellemann, et 
nmol min-1 nmol L-1 0.0022 Normal aI., 1987) 
+ AssUIllmg a dlstnbutlon volume of 12 L, ++ ConversIOn UmU = Unmo1l144 
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4.7 SATURATION ON FRACTIONAL CLEARANCE OF GLUCOSE, aG 
Although, the fractional clearance of glucose is primarily controlled by the insulin 
sensitivity parameter, SJ, which links exogenous insulin and endogenous glucose levels, a 
number of investigators (Duckworth and Kitabchi, 1981; Natali, et aI., 2000; Nestler, et aI., 
1988; Prigeon, et aI., 1996; Transberg, et aI., 1981; Turnheim and Waldhausl, 1988) have 
examined glucose response to varying insulin dose. Overall, as the dose of exogenous 
insulin is increased insulin sensitivity, SJ, decreases (Prigeon, et aI., 1996). This result 
occurs because of insulin saturation at the receptor site, affecting the rate of glucose 
clearance (Natali, et aI., 2000). 
Literature searches for levels of saturation showed that the number of researchers to 
investigate this phenomenon is reasonably small, as seen in Table 4.8. The Michaelis-
Menten value of saturation, o.G, is the value 1/Kn shown in Table 4.8, where Natali et al 
(2000) is the primary researcher. As Natali et al (2000) uses a circulatory model of glucose 
and insulin kinetics, their insulin sensitivity is based on tracer measurements, a hot index, 
and is consequently much larger than values of insulin sensitivity used for the minimal 
model. As there is a trade-off between the fractional glucose clearance saturation, o.G, and 
the insulin sensitivity parameter, SJ, an initial generic value of o.G = 0.04, was used across 
all patients. 
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TABLE 4.8: PHYSIOLOGICAL VALUES FOR GLUCOSE CLEARANCE 
SATURATION 
'It'max 'Nil ~leaJjanGe IDose rn~Ulle ~Ilo 
214 ± 29 Nonnal (Nestler, et al., 
mLm-2 min-1 1988) 
14- 35 8.2 - 43.3 Nonnal (Trans berg, et 
mL kg-1 min-1 mUkg-1 al., 1981) 
81 - 443 570 -771 20/200 4 Lean (Natali, et al., 
mUL- 1 mL m-2 min-1 mUm-2 min-1 2000) 
414- 536 -1332 201200 3 Obese (Natali, et al., 
1122 mL m-2 min-l mU m-2 min-l 2000) 
mUL-1 
700- 800 (Turnheim and 
mLmin-1 Waldhausl, 
1988) 
2 - 5 X 10- 1 (Duckworth and 
M Kitabchi, 1981) 
Following clinical trials and model validation with retrospective data, the initial estimate of 
(J.c = 0.04 was found to be too high, and hence saturating glucose clearance in the model 
when it was not saturating in the patient. The estimate was reduced to (J.c = 0.015 following 
additional literature searches revealing values in the range 0.015 - 0.025 (Caumo, et al., 
1999; Prigeon, et al., 1996; Rizza, et al., 1981). The lower end of this range was chosen as 
a conservative estimate as this choice improves patient safety when used for clinical 
control. More specifically, if the patient's glucose clearance saturates below this level the 
blood glucose will not drop as far for a given (saturating) insulin input. 
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4.8 SUMMARY 
The use of previously detennined parameters from an extensive literature search has 
reduced the number and range of clinical trials that have to be completed to detennine 
physiologically valid model parameters. The complexities of the glucose insulin system 
means responses have to be studied in smaller subsections and then combined to give the 
parameters required for a system model. The literature survey results outlined here fonn 
the basis of both ranges of patient specific models and initial estimates for generic patient 
values. These values are then refined through clinical studies and model fitting 
retrospectively to detennine their ability to allow the system model developed to effectively 
mimic the human glucose-insulin metabolism. 
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5 
PARAMETER IDENTIFICATION 
5.1 MOTIV A TI ON 
For the system model to be useful for real-time control, an efficient method of identifying 
patient specific parameters in clinical real-time is required. Objectives include low 
computation time, high accuracy for tracking changes in patient specific parameters, pG and 
Sf, and physiologically realistic values of optimised parameters. A method that is convex 
and not dependent on starting point, as with non-linear recursive least squares (Hovorka 
and Vicini, 2001), is also desirable. The model developed in Chapter 3 is presented here 
for review. 
(5.1 ) 
Q= -kQ+kI (5.2) 
(5.3) 
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5.2 METHOD 
Parameter values from the literature are presented in Table 5.1. The exogenous feed details 
are known, so the value of the exogenous glucose infusion, P(t), can be determined. The 
equilibrium glucose level, GE, can be estimated, either using the initial value for a short 
term trial or by averaging the glucose readings across the prior 12 hours for longer data 
fitting. 
TABLE 5.1: GENERIC SYSTEM MODEL PARAMETERS 
Parameter Value 
~ 12 L 
n 0.16 min-I 
Ie 0.0099 min-I 
o.G 0.04 
0.1 1.7 x 10-3 
Comparisons between gathered data and the system model output are done by minimising 
the L2 norm between measured data and model parameters. Initially, blood glucose data is 
approximated as a continuous series, using a simple linear approximation to form a 
piecewise linear curve, Gapprox. The patient specific parameters, PG and Sf, are then defined 
as piecewise constants over the time series of the measured data. 
N 
PG = L(PG;(H(t-120*(i-1)-H(t-120i)) (5.4) 
;=1 
N 
S1 = ~::<Sli(H(t-120*(i-1)-H(t-120i)) (5.5) 
;=1 
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where H(t - to) is the Heaviside function defined by H(t - to) = 0 when t is less than to, and 
H(t - to) = 1, when t is greater than or equal to to. Note that N in Equations (5.4) and (5.5) 
may be different depending on the number of hours per segment. For this research, the 
fractional clearance of glucose, pG, is held constant over two hour periods and the insulin 
sensitivity, Sf, varies every hour, creating piecewise constant time varying model 
parameters. Note that the variation in Equations (5.4) - (5.5) can also be defined as linear, 
or higher order, over these time periods for greater detail. 
The next step is to optimise the parameter values. For any glucose model output curve that 
is a solution to Equation (5.1), the following expression holds for any period of time 
between t and to: 
(5.6) 
Equation (5.6) can be re-written: 
It should be noted that the glucose level, G, is defined as the glucose level above the 
equilibrium glucose level, GE. Hence, the measured glucose level, G, is actually G + GE, 
resulting in a equivalent expression. 
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An important aspect of any parameter fit is the resulting error in the fit. Let Gill be the best 
fit from the model to the measured data, with corresponding piecewise constant functions 
for patient specific parameters, pgl and st. Consider also a time interval, [to, t], where for 
to < t < tl, the patient specific parameter values from the best fit to the measured data, 
pt and SJU, are constant over that period with values represented by PG and SJ' 
respectively. Then the best fit of the model is equal to sum of the simple linear 
approximation and an error term, crt): 
~ ~ 
Gill (t) = G"pprox(t) + c(t) (5.9) 
where the error term, c(t), falls within the interval, 0 ~I c(t) I~ 0 , for small o. The best fit 
of the model at any time, G.lII(t) , is calculated: 
= G"pprox(to) + PG(t-tO)Ge - PG f G"pprox(t)dt-SJ f G"pprox(t)Q(t)dt+ i P(t)dt+E(t) 
o {I (I 
where the error term, E(t), is defined: 
IE(t)I=lc(to)-PG l c(t)dt-SJ l c(t)Q(t) dt l 
~ I c(to) I + PG I L c(t)dt I +SJ I L c(t)Q(t)dt I 
~O + PG f Ic(t)ldt+SJ f Ic(t) IQ(t)dt 
I) I) 
~O + PGO(t-tO)+SJO f Q(t)dt 
(I 
=0(0) 
(5.1 0) 
(5.11) 
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Note than even if the time period, t - to, and the convolution integral, I Q(t)dt, are both 
tl 
large, then the piecewise patient specific parameter tenus, PGo(t-to) and S/o I Q(t)dt, 
H 
are small compared to the integral patient specific tenus, PG f G fit (t) dt and 
n 
S/ i Gfit (t)Q(t) dt , when it is assumed that the best fit to the glucose data is greater than 1, 
H 
G fit (I) > 1, since: 
PGo(t -to) < OCt -to) ° 
PG r G/it(t)dt r 1dt Ju Ji) 
(5.12) 
Q(t)dt ° i Q(t)dt 
1----"-----1 < (I ° i Q(t)dt 
" 
(5.13) 
Thus, for a general time period [to, t] an approximation can be used to represent the best fit, 
GfiI(t) , utilising integral functions. 
G,~::r (t) == Gapprox(to) I PG(Gapprox (t) - Ge)dt - I S/Gapprox (t)Q(t)dt + ! P(t)dt 
il 0 (I 
(5.14) 
Integral functions have the advantage that they are insensitive to noise in the measured 
glucose data effectively providing a low-pass filter in the summations involved in 
numerically integrating. 
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For example, when the length ofthe time period is chosen to be 120 minutes long, [to, to + 
120], the fractional clearance of glucose, PG, takes on one value, PGI, and the insulin 
sensitivity parameter, Sf, takes on two values, Sn and Sa, giving three unknowns for this 
time period. To find the values of these patient specific parameters that give the best fit to 
the measured glucose data in this time interval, six equations are proposed with a generic 
form: 
G~ ( 20·) G~approx( 20·) - 0 approx to + I - fil to + I - , i =1...6 (5.15) 
To show the form that ensues the first and last ofthese equations, i = 1 and i = 6, are given: 
- J"+20 ~ J"+20 +SJ] GapPl'ox(t)Q(t)dt- P(t)dt=O 
(I \) 
(5.16) 
where the integrals in Equations (5.16) and (5.17) can be quite easily evaluated 
numerically. The unknowns in these equations are PGI, and Sn and Sa. Therefore, for i = 
1 ... 6, Equation 5.15 defines a simple least squares system of six linear equations with three 
unknowns. 
To illustrate, blood glucose measurement data recorded for a critical care patient over 6.5 
days is shown by the dots and error bars in Figure 5.1. This data is then broken into 120 
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minute intervals producing 462 equations with 231 unknowns. The equilibrium glucose 
level, GE, is recalculated every 12 hours. The 462 equations for all these intervals are 
solved by constrained linear least squares in MATLAB where the patient specific 
parameters, pG and Sf, are limited to within the ranges, 0.01 ~PG ~ 0.02 and 0.00001 ~ Sf ~ 
0.0025, respectively. The values of the patient specific parameters, pG and Sf, are used to 
solve the differential equation shown in Equation (5.6) over the 6.4 day interval. The line 
in Figure 5.1 shows a very close model fit to the data, however the insulin sensitivity, Sf, 
shown in Figure 5.2 has undesirable, non-physiological sudden jumps. This result is due to 
noise in the glucose measurements which is transferred, via the model and fit, to noise in 
both pG and Sf. To further reduce the noise, each pG and S/ value is replaced by its 3-point 
moving average value, filtering out the impact of noise and possibility of erroneous 
measurements, such as the very low minimum value at approximately t = 1.75 days. 
The fit using smoothed patient parameters shown in Figure 5.3 is an excellent fit over the 
6.4 days the patient was studied. This accuracy shows that the dynamics in the model are 
easily capable of capturing patient dynamics for extended periods with physiologically 
realistic conditions and the fitting approach based on the use of integration, reduces the 
noise in the data. By using linear regression, the resulting equations are a well-posed, 
convex problem that is easily solved and is not starting point dependent like the commonly 
used non-linear recursive least squares method (Hovorka and Vicini, 2001). The result is a 
numerically simple optimisation routine suitable for use in clinical situations, particularly 
where real-time control applications are required. 
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Using the smoothed patient specific parameters, pG and S], the resulting model fit is shown 
in Figure 5.3. This fit is still well within the error bands created by the data. In addition, 
the patient specific parameters, pG and Sf, as shown in Figure 5.4 and Figure 5.5 are less 
noisy and hence more valid. 
18 
16 
2 
OL-------~------~------~------~------~------~~ 
o 234 5 6 
FIGURE 5.3: AN EXAMPLE PATIENT'S BLOOD GLUCOSE DATA AND 
SMOOTHED FIT 
Note that the resulting plot for pG, shown in Figure 5.4, is approximately constant. When 
the constraints on the model glucose clearance, pG, were relaxed, there was no change in 
the insulin sensitivity, Sf. Also when the magnitude of pG was changed by changing the 
constraints, there was no significant change in insulin sensitivity or the overall model fit. 
Hence, the model is insensitive to variation in glucose clearance, pG, similar to the results 
reported by McDonald et al (2000). 
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The insulin sensitivity, Sf, following smoothing, as shown in Figure 5.5 appears to be 
oscillatory, with periods of approximately two days and smaller oscillations on top of that 
at approximately 16 - 20 hours. This result shows the possibility of a diurnal variation in 
this patient. If the insulin sensitivity was held constant, this change in the patient's 
physiological parameter dynamics may have been missed and resulted in significant model 
error. The diurnal variation in insulin sensitivity, although thought likely in healthy 
individuals (Wilinska, et aI., 2003), is an idea that has not been considered in much depth in 
critically ill patients. 
5.3 SUMMARY 
Patient specific parameters require an optimisation or fitting method to assign patient 
specific values for a patient. More specifically, as both glucose clearance and insulin 
sensitivity are expected to vary with time, the parameters calculated by the proposed 
identification technique require physiological verification. Physiological verification in 
this case, comes from limiting both the range and variation of the optimised values to 
realistic, reported ranges. 
The use of linear regression in the optimisation of patient parameters is numerically simple 
and hence requires much less computation. It also avoids the problem posed by starting 
point dependent methods, such as non-linear recursive least squares, where multiple 
starting points are required. Overall, the use of this parameter identification method gives 
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excellent fits, as discussed later, which allow metabolic changes to be reflected accurately 
in patient specific parameters. 
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TARGETED GLUCOSE REGULATION 
6.1 INTRODUCTION 
To apply the control model developed in a clinical environment, it has to be combined with 
a sensor and feedback controller. The overall objective is safely reducing elevated blood 
glucose levels or maintaining an acceptable blood glucose level. Adaptive control is used 
to monitor the physiological status of a critical care patient, allowing tight glycemic control 
to be achieved in proof of concept trials. Step-wise targeted reduction of blood glucose 
levels reduces blood glucose safely and allows the patients progress and metabolic state to 
be closely monitored. 
The proof of concept clinical trials span five hours and begin with an insulin challenge over 
a one hour period, followed by four hours of tight blood glucose control. Each hour the 
controller uses bolus injections to achieve a target blood glucose value. Target blood 
glucose levels are selected 10- 20% below the current blood glucose levels, with the drop 
dependent on the extent of the patient's elevated blood glucose level and a minimum target 
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of 4.5 mmollL. During the trial, patients are subjected to a constant, nasal-gastric feed of 
1000 calories of glucose per day, which is the standard protocol in the Christchurch 
Hospital lCU. Ethical consent for these trials was obtained from the Canterbury Ethics 
Committee. 
6.2 TRIAL PROCEDURE 
6.2.1 Patient Selection 
The selection criteria are designed to include stable, hyperglycemic patients, but also to test 
the control algorithm across a range of patients with varying injuries, illnesses and 
physiological states. Patients had to be older than 16 years with random blood glucose 
levels greater than 8 mmol/L. They also were required to be on a constant nasal-gastric 
feed and have an arterial cannula. Exclusion criteria included patients that were not 
expected to survive 72 hours, patients receiving neuromuscular blockade, or patients with 
morbid obesity (body mass index greater than 35 kg/m2). 
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6.2.2 Trial Outline 
Between 0700 hours and 1000 hours, the patient's insulin infusion is turned off. A constant 
nasal-gastric feed of 70 mllhr (0.0918 mmol/(L- min) assuming a 12 L distribution volume) 
of Isosource™ is maintained throughout this period and the duration of the trial. Paired 
blood glucose measurements are taken hourly to detennine the patient's equilibrium blood 
glucose level using a bedside Glucocard™ Test Strip II glucose testing kit with an absolute 
error of 7% (Arkray Inc. 2001). At 1000 hours, the patient receives a 1.5 U insulin 
challenge bolus via an intravenous cannula using a GrasebyTM 3500 syringe pump. Paired 
blood glucose measurements are taken at 15 minute intervals until 1100 hours. 
At 1100 hours, the first estimate for the patient specific parameters, GE, pG and Sj, are made 
using the data collected in the hour following the insulin challenge. An insulin injection 
frequency of thirty minutes or one hour is detennined by the controller according to the 
predicted patient blood glucose regulatory system behaviour. Paired blood glucose 
measurements are taken every 30 minutes, and patient specific parameters are re-evaluated 
each hour using the prior two hours of data. Following each re-evaluation of patient 
specific parameters, pG and Sj, the insulin injection bolus size to achieve the sub-target is 
detennined by the controller. Blood glucose level sub-targets are set for 1200, 1300, 1400 
and 1500 hours using the prior two hours of data. The goal is a reduction of 10 - 20 % in 
blood glucose level per hour. The overall approach is therefore a bolus driven adaptive 
control method that utilises recently obtained data to update the patient specific parameters. 
The control method is summarised in Figure 6.1. 
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To lower a hyperglycemic patient's blood glucose level to a desired target, the 
identification of patient specific parameters, pG and Sf, is critical. Gradient based 
optimisation routines have proven difficult due to the infrequent noisy measurements and 
non-convex parameter dependent problem defined (Chase, et aI., 2002; 2003; Doran, et aI., 
2004a; 2004b). In addition, prior efforts have also shown that these parameters vary over 
time. By frequently checking and recalculating these values, the controller aims to, first, 
find accurate parameter values and, second, capture any variation in the patient's metabolic 
state due to external perturbations to the system. 
In model terms, the equilibrium blood glucose level is the value a patient's blood glucose 
reaches when there are no external inputs. Although critically ill patients have elevated 
equilibrium glucose levels, determining this level for a patient is difficult, as it requires the 
patient to be fasted, potentially restricting their ability to fight illness or injury. Fasting also 
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requires additional effort and monitoring by medical staff. However, a good approximation 
of the equilibrium glucose level, GE, is important to being able to determine an optimal 
bolus size. Hence, the basal, or equilibrium, glucose level is assumed to be the same as the 
1000 hours blood glucose measurement, which follows three hours of constant feed with no 
insulin infusion. The assumption is that this level represents a steady state equilibrium 
value. 
Another challenge in determining the optimal insulin bolus is the extent of endogenous 
insulin production. Endogenous insulin production is often impaired due to both stress of a 
patient's condition and concurrent drug-therapy. The identification of endogenous insulin 
production is a relatively complex and time-consuming procedure, often utilising a clamp 
technique. For the control algorithm presented to find its way into mainstream clinical 
practice, simplicity is essential. Hence, a value for endogenously produced insulin must be 
estimated. Past clinical trials, such as those by Hovorka et al (2002), have not required 
estimations of endogenous insulin as they focus on Type 1 diabetic individuals who are 
unable to produce insulin. These trials initially assume that the majority of endogenous 
insulin production is suppressed by the exogenous insulin infusions. 
Patient specific parameters, PG and SJ, are identified before each insulin infusion bolus, 
using the past two hours of data. Fitting less than two hours of data would be inadequate as 
not enough data would be available. A period longer than two hours would potentially 
miss dynamics such as the variations described by Wilinska et al (2003). More 
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importantly, variations due to insulin inhibiting or enhancing drug-therapy might also be 
excluded. 
The effective half-life of insulin in the plasma, k, is defined as a generic parameter, but the 
current model gives the opportunity to change the half-life, at any hour. Insulin sensitivity, 
SJ, should be roughly constant over a five hour period, with changes occurring gradually. If 
the plot of insulin sensitivity, Sf, is taking on a saw-tooth profile, it indicates that the half-
life may be incorrect. By decreasing the half-life, and hence increasing k, the time 
immediately following the insulin bolus is accentuated, and the insulin sensitivity, does not 
have to vary linearly over each hour to compensate for the differences between insulin 
availability in the model and the patient. 
The trials conducted show the progression of the model and controller. The first four trials 
use the model based on that developed by Doran et al (2004a; 2004b), as shown in 
Equations (3.5) and (3.6). The following two trials use the model that includes both insulin 
appearance and glucose clearance saturation, as shown in Equations (3.21) - (3.23). The 
clinical trials verify the need for these new saturation dynamics, and the data from the first 
four trials can be used to rerun trials virtually, further verifying the model dynamics. 
6.3 RESULTS AND DISCUSSION FROM CLINICAL TRIALS 
6.3.1 Unsaturated Trials 
The first two clinical trials were undertaken to verifY the glucose kinetics in the model in 
Equations (3.5) and (3.6). Hence, saturation effects were not included and the model 
employed is defined: 
where: 
I 
G=-pGG S/(G+GE)k fI(r)e-k(,-r)dr + P(t) 
o 
j = -n{1 + I
B
)+ u(t) 
~ 
G = concentration of the plasma glucose above the basal level (mmoI/L) 
GE = equilibrium level for plasma glucose concentration (mmollL) 
I = concentration ofthe plasma insulin above basal level (mUlL) 
IB = basal level for plasma insulin concentration (mUlL) 
P(t) = exogenous glucose infusion rate (mmol/(L·min» 
u(t) = insulin infusion rate (mU Imin) 
Vi assumed insulin distribution volume (L) 
pG fractional clearance of glucose at basal insulin (min- l ) 
S1 insulin sensitivity (LI(mU'min» 
n first order decay rate constant for insulin in plasma (min-I) 
Ie parameter controlling the half life of insulin (min- l ) 
(6.1) 
(6.2) 
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The insulin infusion equation includes endogenously produced insulin, Uo = n VrIE, as well 
as exogenously infused insulin, u(t}. For these trials, critically ill patients were assumed to 
have their endogenous insulin production suppressed by the elevated counter-regulatory 
hormones present (Rizza, et aI., 1981). The effective half life of insulin, k, is set to 70 
minutes based upon the 50 - 120 minute range given for sub-cutaneous insulin in Kraegen 
and Chisholm (1984) and Tumheim and Waldhausl (1988), as discussed in Chapter 4. The 
generic variable values used in these trials are shown in Table 6.1. 
TABLE 6.1: GENERIC PARAMETERS USED IN TRIAL 1 AND 2 
Parameter Value 
IE 15 mUlL 
P(t} 0.0918 mmol/(L·min) 
Uo 16.7mU/min 
~ 12 L 
n 0.093 min-1 
k 0.0099 min-1 
The results from the first two trials showed that improvements needed to be made. The 
assumption of suppressed endogenous insulin production was shown to be inaccurate. 
Figure 6.2 and Figure 6.3 show the comparison between the original endogenous insulin 
assumption and post-trial analysis where all endogenous insulin was assumed to be present. 
This change dramatically improved the model fit to the measured data. Note that the 
sudden jump in Figure 6.3 is due to a 10g glucose IV infusion to treat a hypoglycemic 
episode. 
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6.3.2 Improved Unsaturated Model Trials 
The next two trials used the same control model as trials 1 and 2, but no infusion was made 
to account for suppressed endogenous insulin , as was done in the first two trials. The 
number of parameters determined by optimisation was also increased. Both the equilibrium 
glucose level, GE, and the endogenous insulin production, Va, were optimised hourly, along 
with the patient specific parameters from the first trial, pc and S1. There was also scope to 
change the assumed value of the plasma insulin basal level, lB, if the fit was not ideal, 
followed by refitting the equilibrium glucose level, GE, and the endogenous insulin 
production, Va. The remaining generic parameters are shown in Table 6.1. 
Trial 3 
Patient 3 was a 62 year old male suffering from pneumonia, and the trial was completed on 
the fifth day of the patient's stay. The patient's initial glucose value was 8.5 mrnollL, 
however the optimisation procedure found an equilibrium glucose value, GE, of 7.5 
mrnollL. As both the initial and equilibrium glucose values showed only moderate 
hyperglycemia, the sub-targets were designed to reduce blood glucose by 10% each hour. 
This patient was found to have a very low level of endogenous insulin production, as 
shown by a Va value of 0.0008 mU/min. The measured glucose data, model simulation and 
insulin infusion values for trial three are shown in Figure 6.4. The circle marked data 
indicates a target set the hour previously and a point the model predicted it would hit at that 
time. 
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The results of the third trial showed the patient to be highly insulin resistant, as shown by 
the low insulin sensitivity value fitted and shown in Figure 6.5. Therefore, significant 
insulin infusion boluses were required to reduce blood glucose levels, as shown in Figure 
6.4. It should be noted that although, an insulin bolus of 6 U may seem extremely large, 
these patients are also on a constant feed. For safety during these proof of concept trials, the 
recommended insulin infusion is displayed and then manually infused, placing a human 
check in the control loop, When the injection size determined by the controller exceeds 6 
U, a saturation of 4 U and then 6 U is enforced, ensuring patient safety by safeguarding 
against hypoglycemic episodes. This procedure was required for trial three, as shown in 
t: 
'e 
::l 
E. 
E 
::J 
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Figure 6.4, with the 4 U insulin bolus saturation put in place at 120 minutes, and the 6 U 
insulin bolus saturation in place at 180 and 240 minute infusions. In this case, the 4 U 
saturation resulted in the measured glucose being slightly higher than the desired target, 
though still within the error bands. However, the 6 U saturation allowed the controller to 
reach its targets, strongly suggesting the presence of metabolic saturation at these levels of 
insulin infusions. 
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FIGURE 6.5: VARIATIONS IN PATIENT SPECIFIC PARAMETERS FOR TRIAL 3 
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The advantage of the re-evaluation and recalculation used in the controller is shown in 
Figure 6.4 and Table 6.2, as the targets were reached more accurately as the trial 
progressed. After 120 minutes, the controller had captured the high insulin resistance 
found in this patient, as seen in Figure 6.5, and insulin boluses following this were more 
effective, as shown in Figure 6.4. Further injections might have shown greater effect on 
lowing blood glucose if the trial was continued past its five hour period. 
TABLE 6.2: COMPARISON BETWEEN TARGET AND ACHIEVED GLUCOSE 
LEVELS FOR TRIAL 3 
Time (min) Target Glucose Achieved Glucose Error (mmoIlL) (mmoIlL) %(abs) 
120 7.84 9.15 17%(1.31) 
180 8.92 9.25 4 % (0.33) 
240 8.40 8.50 1 % (0.10) 
300 7.73 7.90 2 % (0.17) 
Trial 4 
Patient 4 was a 71 year old male with a subarachnoid haemorrhage and secondary 
aspiration pneumonia, in his fourth day in the lCU. The initial blood glucose level of 13.4 
mmollL is high, but not uncommon in lCU settings, and the equilibrium blood glucose 
level, GE, was found to be 12.88 mmollL. Sub-targets were assigned to reduce blood 
glucose by 20% per hour. Unlike the patient in the third trial, this patient was found to 
have a relatively high level of endogenously produced insulin, Uo = 56.56 mU/min, which 
is over three times higher than normal (Bergman, et aI., 1985; Furler, et aI., 1985). The 
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measured glucose data, model simulation and insulin infusion values for trial three are 
shown in Figure 6.6. 
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FIGURE 6.6: TRIAL 4 RESULTS SHOWING GLUCOSE DATA AND MODEL 
SIMULA TION AND INSULIN INFUSION VALUES 
Very good approximations of the patient specific parameters, pG and Sf, were obtained 
immediately after the 60 minute insulin challenge period, as shown by the consistency in pG 
and S/ over the following 120 minutes in Figure 6.7. At the end of the 120 minutes, an 
insulin bolus solution could not be found to achieve the intended target of 7.9 mmollL at 
180 minutes, as shown by the diamond mark in Figure 6.6. The failure to find a solution 
for the insulin bolus led to the use of a standard 0.55 U bolus and re-adjustment of the 
target value to 9.3 mmol/L. By setting a less difficult target, solutions for the patient 
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specific parameters were obtained, and additional data was gathered to assist in the bolus 
calculation to meet the target at 240 minutes. The inability of the program to find 
physiologically valid, patient specific values indicated the need for the improved 
identification algorithms discussed in Chapter 5. 
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FIGURE 6.7: VARIATIONS IN PATIENT SPECIFIC PARAMETERS FOR TRIAL 4 
After the trial, a potential cause of the non-convergence at 240 minutes displayed in Figure 
6.6 was found. The patient was given Metoprolol™, a ~-blocker that enhances the effect of 
insulin, at approximately 120 minutes into the trial. MetoproloFM is a fast acting drug with 
an effective life of 2 to 3 hours (Cruickshank and Plichard, 1994). At 240 minutes into the 
trial, it is thought that the effect of the MetoproloFM was diminishing, as reflected by the 
controller identifying a reduction in both pG and Sf at 240 minutes in Figure 6.7. In 
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addition, the errors in Table 6.3 increased at this time while the adaptive control model 
began to adjust to this sudden externally induced change in behaviour. 
TABLE 6.3: COMPARISON BETWEEN TARGET AND ACHIEVED GLUCOSE 
LEVELS FOR TRIAL 4 
Time (min) Target Glucose Achieved Glucose Error % (mmoIlL) (mmoIlL) (abs) 
120 9.55 9.10 5 % (-0.45) 
180 9.70 9.40 3 % (-0.30) 
240 7.20 7.75 8 % (0.55) 
300 6.70 6.12 9 % (-0.58) 
The desired stepwise reduction in blood glucose is clearly seen in the fourth trial, reducing 
the patient's blood glucose level from 13.4 mmol/L to 6.7 mmol/L over four hours, in four 
succinct steps. The responsive nature of the controller was shown to be advantageous in a 
clinical environment where patients are often subjected to external perturbations, such as 
drug therapy, which may affect their metabolic response to insulin doses. Changes in the 
metabolic response due to drug therapy in critically ill patients can also be likened to 
metabolic changes in ambulatory diabetic individuals during or after exercise (e.g. 
(Derouich and Boutayeb, 2002; Duncan, et aI., 2003), illustrating the advantages of 
adaptive control in both a clinical environment and potentially in day to day life. 
163 
6.3.3 VerifYing the Addition of Saturatioll 
The data gathered from Trials 3 and 4 was used to verify the addition of glucose clearance 
and insulin saturation to the model. The literature survey completed for Chapter 4 showed 
merit in the use of these two saturation modes, but before it could be used in clinical trials 
the new saturation model needed to be tested in simulation. By adding saturation, the 
amount of insulin utilised by the body could be compared to the amount infused. The goal 
is to ensure the controller uses insulin more efficiently and does not allow insulin to 
accumulate. 
The results presented show the same measured blood glucose data, blood glucose targets 
and insulin bolus sizes as in Figure 6.4 and Figure 6.6. The difference is the model used 
and the method in Chapter 5 was used to find patient specific parameters, pG and Sj. Both 
trials were re-evaluated using the parameters in Table 6.4. 
TABLE 6.4: GENERIC PARAMETERS USED FOR RERUNNING THE MODEL IN 
TRIALS 3 AND 4 
Parameter Value 
-
P(t) 0.0918 mmol/(L·min) 
f7[ 12 L 
n 0.16 min-I 
k 0.0099 min-I 
o.G 0.015 
0.1 1.7 x 10-3 
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Trial 3 Re-evaluated with Saturation Model 
The effect of the saturation in the model can be seen by comparing the original model 
output in Figure 6.4 to the saturated model output in Figure 6.9. The saturated model 
output captures each of the measured blood glucose points with greater accuracy. This 
increased accuracy is especially apparent in the final hour of the trial, where the saturation 
model captures the glucose rise between 240 and 300 minutes. 
The effect of saturation on delayed insulin in the blood is shown in Figure 6.8, where the 
area between the two lines represents the insulin unable to be utilised due to saturation. By 
adding saturation, future trials will not infuse insulin that cannot be utilised, hence 
decreasing insulin infused for the same metabolic reaction. Saturation also decreases the 
fitted parameter values as seen in Figure 6.1 0 where the glucose clearance, pG, ranges from 
1.996 x 10-2 to 2.017 x 10-2 min-J and the insulin sensitivity, Sf, ranges from 2.337 x 10-4_ 
14.619 x 10-4 LI(mU·min). Hence, the patient specific values should be a better 
representation of the actual values. 
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FIGURE 6.9: TRIAL 3 RESULTS SHOWING GLUCOSE DATA AND MODEL 
SIMULATION WITH THE ADDITION ON SATURATION AND INSULIN 
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FIGURE 6.1 0: VARIATIONS IN PATIENT SPECIFIC PARAMETERS AFTER 
SATURA TION IS ADDED TO THE MODEL FOR TRIAL 3 
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Trial 4 Re-evaluated with Saturation Model 
The effect of the saturation in the model in trial 4 can be seen by comparing the original 
model output in Figure 6.6 to the saturation model output in Figure 6.12. The saturation 
model was much more effective at capturing the measured glucose data points, and once 
again, patient specific parameters were reduced, as shown in Figure 6.13, where the glucose 
clearance, pG, ranges from 1.694 x 10-2 to 1.990 x 10-2 min- J and the insulin sensitivity, Sf, 
ranges from 9.167 x 10-4 to 21.466 x 10-4 L/(mU'min). The effect of saturation on delayed 
insulin in the blood is shown in Figure 6.11. As can be seen in Figure 6.8 and Figure 6.11, 
as the delayed insulin increases in magnitude, the proportion of insulin that is not utilised 
increases dramatically. 
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FIGURE 6.11: DELAYED INSULIN IN TRIAL 4 SHOWING THE EFFECT OF 
SATURATION 
Targeted Glucose Regulation 167 
u 
~ ")I-H ................... ! 
E-
o; 
i: 
...J ;( 
~ . 
::: 
" (; 
-g 6 
Q 
Cli 
f-------;-----i--------T-----f------j---.--.;-----------Ifj(,,)O 
.- :;(10fl~ 
<I(tOrl 'e 
2.((10 §. 
?(Il)(J -=-
:I 
o(.L, ----f~(:-, l--b-~L---C"~'G -~L,d.20(::-' -----:,,h''}(!,.------.l---=::;:~,jIs::JO ===='::1 
Time (min) 
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FIGURE 6.13: VARIATIONS IN PATIENT SPECIFIC PARAMETERS AFTER 
SA TURA TION IS ADDED TO THE MODEL FOR TRIAL 4 
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6.3.4 Saturated Model Trials 
The final clinical trials were undertaken using the saturated model developed in Chapter 3, 
which is presented here for review. 
(6.3) 
Q=-kQ+kI (6.4) 
(6.5) 
The main differences between this model and the model used in previous clinical trials are 
the addition of saturation on insulin appearance and glucose clearance, and the removal of 
endogenous insulin production. The values for generic parameters used in the fifth trial are 
shown in Table 6.5. The glucose equilibrium value, GE, is assumed to be the average of the 
paired blood glucose samples at 1000 hours, for simplicity. New procedures for 
determining patient specific parameters, Pc; and Sf, as described in Chapter 5, were also 
utilised, reducing computation time and giving more optimal values for the parameters. 
TABLE 6.5: GENERIC PARAMETERS USED IN TRIAL 5 AND 6 
Parameter Value 
P(t) 0.0918 mmol/(L·min) 
VI 12 L 
n 0.16 min-1 
Ie 0.0099 min-1 
ac; 0.04 ---t 0.015 
af 1.7 x 10-3 
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TrialS 
Patient was a 76 year old male in the leu as a result of respiratory failure secondary to 
mediastinal sepsis, heart failure and post coronary artery bypass surgery. The patient had 
spent approximately three months in and out of the leU following cardiac surgery in 
December 2003, but when the trial was undertaken, he had been in the leu for 33 days. 
The equilibrium glucose level showed only moderate hyperglycemia, and blood glucose 
levels were targeted to drop only 10% per hour. The measured glucose data, model 
simulation, insulin infusion values and remaining insulin in the plasma for trial five are 
shown in Figure 6.14 shows the patient specific parameters found during the trial. 
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FIGURE 6.14: TRIAL 5 RESULTS SHOWING GLUCOSE DATA, MODEL 
SIMULATION, AND INSULIN INFUSION VALUES 
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FIGURE 6.15: VARIATIONS IN PA TIENT SPECIFIC PARAMETERS FOR TRIAL 5 
The new model correlated very well with measured glucose data. Table 6.6 shows the 
accuracy with which target levels were achieved. The average error is 4.25 %, which is 
within the measurement error. 
TABLE 6.6: COMPARISON BETWEEN TARGET AND ACHIEVED GLUCOSE 
LEVELS FOR TRIAL 5 
Time (min) Target Glucose Achieved Glucose Error (mmoI/L) (mmoI/L) %(abs) 
120 6.78 6.35 6 % (-0.43) 
180 6.23 6.13 2 % (-0.10) 
240 5.70 6.00 5 % (-0.30) 
300 5.20 4.90 6 % (-0.30) 
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The inability of the model to capture the dip in blood glucose levels between 240 and 300 
minutes is interesting. The insulin bolus prescribed by the controller was lower than it 
would have been in the model used in the first four trials as it accounted for the effect of 
saturation on glucose clearance. In post-trial analysis, the effect of lowering the saturation 
on glucose clearance by reducing the parameter o.G from 0.04 to 0.015, as used by Natali et 
al (2000), allowed the model to more closely follow the blood glucose measurements 
between 240 and 300 minutes, without compromising the fits leading up to this period. 
Throughout this trial, insulin sensitivity, S" took on a saw-tooth shape, as seen in Figure 
6.1 5. An explanation for the saw-tooth shape shown is that the half-life for insulin 
disappearance, defined by k, was too long. When the half-life is reduced, insulin in the 
model is cleared more quickly, and the insulin sensitivity parameter, Sf, fitted did not have 
to compensate. When the insulin disappearance parameter, k, was doubled or tripled 
(reducing the half-life from 70 to 35 minutes or 23 minutes), the saw-tooth shape and large 
variance was lost. Given that the glucose clearance, pG, was still virtually constant, this 
result also highlights the relative independence and insensitivity of the glucose clearance 
parameter,PG, to changes in insulin sensitivity, Sf, in this model 
As an example, Figure 6.16 shows the effect of tripling k, and reducing o.G from 0.04 to 
0.015. Note how the dip between 240 and 300 minutes is captured more effectively, as a 
result of the decreased half-life and reduced impact of glucose clearance saturation. The 
variation in insulin sensitivity has also been reduced. Post-trial analysis showed that an 
even better fit and lowered insulin sensitivity (1.30 x 10-3 - 1.90 x 10-3 LI(mU'min)) was 
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found with no saturation on glucose clearance and a half-life of 35 minutes, suggesting this 
patient was not achieving a level of insulin high enough to induce glucose clearance 
saturation in their system. 
Glucose Concentration 
FIGURE 6.16: TRIAL 5 RESULTS SHOWING GLUCOSE DATA, MODEL 
SIMULATION, INSULIN INFUSION VALUES AND REMAINING INSULIN IN 
THE PLASMA WITH REDUCED HALF-LIFE AND GL UCOSE CLEARANCE 
SATURATION 
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Trial 6 
Patient 6 was a 77 year old female suffering from sepsis, and the trial was completed on the 
30th day of the patient's stay. The equilibrium glucose level showed only moderate 
hyperglycemia, and blood glucose levels were targeted to drop by 15 % per hour. The 
measured glucose data, model simulation, insulin infusion values and remaining insulin in 
the plasma for trial six are shown in Figure 6.17. Figure 6.18 shows the patient specific 
parameters found during the trial. 
16~-------,--------~---------,--------,---------,-----~==~~~~~ 
!.J 
010 
E g 
a; 
;u 
...I 8 
'" 1/1 o 
U 
::J 
c:; 
-g 6 
o 
iii 
-----------------------,-----------
------------------.----,-----.-------------
. . . 
-----------------------r-----------------------r------------------------1-----------------------
____ p ________ u ______ u __ _ 
[ [ ?ontrolled insuli~ Input 
41----------j---------t--------T------~T--------r_----~=t==::::==~6000 
muumum_uu_uj ______ uu _____ m ____ u __ r ___ uu_uu __ um __ m_jummuuu--u.~0ur------------m-uuuu-l-u---uummu--1 -, Injection size I 5000';:; 
-----------------------<--------------------------f--------------------------:--------------- ---------f-------------------------,-------------------------+---------------------- 4000 's 
, ,~j<>'~i:~ti< ••• ;r>~t ••••• ·· •• ·•••••• ::: I 
°0L-------~~------~~~----~15~O----~--2~O~O------~2~50~~L---~30~0------~358 
Time (min) 
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Time (min) 
FIGURE 6.18: VARIATIONS IN PATIENT SPECIFIC PARAMETERS FOR TRIAL 6 
This trial showed the impact of changing the insulin effective half-life, k, during a trial. 
The data collected from the first two hours resulted in a saw-tooth shape for insulin 
sensitivity, as shown in Figure 6.18, similar to that in trial 5. Due to modifications before 
the trial began, the effective insulin half-life was manually updated to 35 minutes, half of 
the original value, at 120 minutes into the trial. The effect of this change is seen in Figure 
6.18 where Sf loses its variability after 180 minutes and becomes more physiologically 
realistic. 
The 'scalloped' shape of the glucose profile following an insulin bolus seen in Figure 6.17, 
resulted in the time between boluses being reduced to 30 minutes at 240 minutes into the 
trial, and hence 2 targets for that hour are shown instead of one. Table 6.7 shows the error 
between the targets and the achieved glucose values. Although the controller was effective 
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at reaching this half-hourly subtarget, the targets on either side were poor fits in 
companson. 
TABLE 6.7: COMPARISON BETWEEN TARGET AND ACHIEVED GLUCOSE 
LEVELS FOR TRIAL 6 
Time (min) Target Glucose A.chieved Glucose Error (mmoIlL) (mmoIlL) %(abs) 
120 9.82 9.10 7 % (-0.62) 
180 8.34 8.75 5%(0.41) 
240 7.09 6.00 15 % (-1.09) 
270 6.52 6.85 5 % (0.33) 
300 6.00 7.20 20 % (1.20) 
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6.4 CLINICAL TRIAL CONCLUSIONS 
The clinical trials presented show the efficacy of the control algorithm and system models 
in achieving targeted glucose control across a wide range of critically ill patients. The 
progression of the model throughout the trials has shown merit in each change made to the 
model and control method. Ideally, a larger patient cohort will be tested using the current 
model to further analyse its effectiveness and find areas in which additional improvements 
could be made. Overall, the system model presented was able to accurately capture the 
essential dynamics exhibited. 
The first two trials demonstrated the use of the system model and enhancements proposed 
by Doran et al (2004a; 2004b) and Chase et al (2003). The next two trials showed 
improved results and were able to achieve glucose targets more effectively, with target 
errors of 1 - 17 % (0.10 - 1.31 mmo]/L). The robustness of the model and its ability to 
deal with unknown external perturbations was shown in the fourth patient. Finally, both 
trials showed the model's adaptive learning as the trial progressed, with errors between 
actual and predicted glucose levels reducing over time. 
The fifth trial showed the largest improvement in model and control performance, with the 
addition of insulin appearance and glucose clearance saturation. The results showed almost 
perfect fits for the first four hours of the trial. The difference between targets and actual 
glucose values achieved ranged from 2 - 6 % or 0.10 - 0.43 mmollL, which shows very 
tight targeted control with errors within the measurement error of 7 % (Arkray Inc. 2001). 
From this trial, the validity of the insulin appearance saturation was justified, however 
glucose clearance saturation seemed to inhibit the model's ability to achieve a good fit to 
measured data, and so additional trials are required to better estimate this model parameter 
value. 
The sixth trial showed good accuracy, but was unable to successfully achieve two of its 
targets, missing by 15 and 20 %. The addition of a manual adjustment to the effective half-
life, suggested by the outcome of trial 5, was shown to be effective and removed the non-
physiological saw- tooth shape from the fitted insulin sensitivity profile. Future work 
should consider the optimisation of the effective half-life, k, as well as the glucose 
clearance,PG, and insulin sensitivity, Sf. 
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7 
LONG-TERM MODEL VERIFICATION 
7.1 MOTIVATION 
Using data gathered in the retrospective audit of blood glucose levels in the Christchurch 
Hospital ICU gave the opportunity to verifY the model, fitting procedure and patient 
parameters across a wide range of p~tients and over a longer time period than that used in 
/ 
the targeted control trials in Chapj6r 6. It also allowed closer observation of the variation 
of the patient specific parameters, pG and Sf, over time. 
If the model dynamics can match the data with physiologically realistic parameter values 
over longer time periods, its use for control will be further validated. Any critically ill 
patient that requires glycemic control will likely need it for at least a couple of days. 
Hence, the controller and the model must be capable of realistically capturing a wide 
variety of patient dynamics over long time periods during which patient condition and 
parameters may vary significantly. 
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7.2 SYSTEM MODEL 
Long tenn data fitting is perfonned using the model defined in Equations (3.19) (3.21). 
This model includes the effect of endogenous insulin when the exogenous insulin infusion 
is low. The patient specific parameters, pG and Sf, are found using the identification routine 
described in Chapter 5. The bounds on the patient specific parameters, PG and Sf, are 0.01 
< PG < 0'()2 and 0.0000] :; S/ :; 0.0025, respectively based on data in Chapter 4. The 
generic parameters are outlined in Table 7.1. 
TABLE 7.1: GENERIC PARAMETERS FOR LONG-TERM DAT A FITTING 
Parameter :\[alue 
VI 12 L 
11 O,J6 min-1 
k 0.0099 min-I 
(J.G 0.04 
0./ 1.7 x 10-3 
The exogenous glucose input, P(t), in Equation 3.21 changes with time, and is calculated 
from the feed details recorded on the patient's bedside chart. The exogenous insulin 
infusion, u(t), in Equation 3.23, is also obtained from the patient's bedside chart. 
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7.3 PATIENT SELECTION 
A random selection of patients from the 201 patient data audit with a period greater than 
one day with intervals between measured data points of three hours or less were used for 
the long-term data fitting. The data density of three hours was selected to ensure enough 
measurements to enable a good model evaluation. The entire length of stay was not always 
considered, as many patients only had a shorter period of data that fitted the criteIia. 
TABLE 7.2: PATIENTS SELECTED FOR LONG-TERM DATA FITTING 
Patient Medical APACHE Age Sex Mortality Diabetes Number Subgroup II Score 
24 Other 25 47 M Y Type 1 Medical 
87 Other 26 62 F Medical 
130 Trauma 11 21 M Type 1 
229 Cardiac 15 73 F 
289 Cardiac 18 70 M 
468 General 32 76 M Surgical 
484 Other 34 30 F Medical 
486 General 22 76 F Type 2 Surgical 
519 General 29 69 M Type 2 Surgical 
"--
Other 554 Medical 26 20 F Type 1 
666 Cardiac 8 44 F Type 2 
847 Other 17 67 F Medical 
1016 General 20 37 F Type 2 Surgical 
1025 Pulmonary 36 48 M Type 2 
1090 General Unknown 37 F Surgical 
1099 Pulmonary Unknown 24 M Y 
1125 Other Unknown 72 F Y Medical 
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The medical subgroup, APACHE II score, age, sex, mortality and diabetic classification are 
shown in Table 7.2. Due to the density of data required, eight of the seventeen patients 
selected turned out to be diabetic individuals. Patients with a pre-described condition of 
diabetes are likely to have their blood glucose levels monitored more closely. Most of the 
patients are from the 'General Surgical' or 'Other Medical' subgroups, and there is a wide 
range of APACHE II scores and ages (8 - 36 and 20 76, respectively). Overall, this 
subset broadly represents the cross section seen in the lCU. 
7.4 ERROR METRIC 
The percentage error between the fit and the data was calculated for each data point. 
7.1 
Table 7.3 shows the mean and standard deviation of the percentage error calculated using 
Equation 7.1 for each patient. It also shows the time interval used for modelling and the 
number of measurements in this interval. The average percentage error was 4.39 % and the 
average standard deviation was 4.45 %. Patient 1090 had the smallest percentage en'or and 
standard deviation, while patient 289 had the largest standard deviation and the second 
largest percentage error. Even the highest percentage fitting error of7.6 % is still relatively 
low compared to the 7 % measurement error of the GlucoCard™ (Arkray Inc. 2001). 
There was no correlation between there is no correlation between mean fit elTor and 
frequency of measurement for this regularly sampled cohort. 
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TABLE 7.3: ERROR IN DATA FITTING 
Patient Mean Percentage Time Number of Measurements 
Number Percentage Error Standard Interval Error ~o,4) Deviation ~%) ~days} Total Per Day 
24 4.78 6.90 2.0 32 . 1.6 
87 2.38 2.70 6.4 48 7.5 
130 7.62 6.07 1.4 31 22 
229 5.83 9.75 10.0 78 7.8 
289 7.75 1.7 13 7.7 
468 3.17 3.03 1.7 17 10.0 
484 2.53 2.00 1.7 18 10.6 
486 3.17 3.03 1.6 16 10.0 
519 3.08 2.52 12.3 82 6.7 
554 5.24 4.56 2.3 40 17.4 
666 3.68 2.28 1.6 15 9.4 
847 4.68 4.32 1.5 12 8 
• 1016 4.11 5.17 1.6 13 8.1 
1025 4.26 4.05 1.7 15 8.8 
1090 1.03 0.93 1.6 10 6.3 
1099 4.70 3.82 1.6 14 8.3 
1125 3.61 2.89 ! 1.7 11 6.5 
ge 4.39 4.45 I 3.1 27.4 12.6 
.~~ 
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7.5 PATIENT FITTING EXAMPLES 
7.5.1 Low Fitting Error Cases 
Patient 1090 had the lowest fitting error and standard deviation of those patients 
considered, representing the best overall fit. Over the 1.6 days considered ofthe patients 7~ 
day stay, the insulin infused was constant at 1 U/hr, and the feed was constant at 0.0247 
mol/(L' min). Figure 7.1 shows a relatively constant nonnoglycemic profile over this time 
with low variations in insulin sensitivity, Sf, showing that the patient was very stable and 
hence, not overly difficult to fit. 
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Patient 87 had a length of stay of 35 days, and over six consecutive days had sufficient data 
measurements the model fitting. Unlike the patient 1090, the glucose level is much more 
variable, leading to a higher variability and range in the insulin sensitivity, SI. The glucose 
clearance, pG, is stable over most of the time considered at 0.01 min-I, but does reach values 
of up to 0.015 min-I. These values are well within the physiological range expressed in the 
literature, and show a change in the metabolic responses at these time periods. Over the six 
days shown in Figure 7.2, the insulin infusion is shown in Figure 7.2 and the feed varied 
between a very low rate and the standard feed of 0.0918 mmol/(l: min) as shown in Figure 
7.3. Figure 7.2 shows some fonn of cyclical response, with a cycle occurring with a period 
of just over two days, overlaid with a smaller cycle period of approximately six hours. 
There does not appear to be any consistent correlation between SJ and the feed or insulin 
profiles. 
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The ability of the model to have very low eITors on these two very different patients is 
promising. The 1.6 and 6.2 day periods also represent very long stretches for model fitting 
compared to the few other published results (Hovorka, et al., 2002). Finally, the average 
error of 1.7 % represents a very good fit given the measurement error. 
7.5.2 High Fitting Error Cases 
The worst fits have an average en'or of 7.6 %. While this number is still acceptable for use 
in clinical situations, the reasons for poorer fit should be examined. Patient 130 is a Type 1 
diabetic individual, and hence had glucose measurements taken almost every hour as shown 
in Figure 7.5. This patient had relatively low insulin sensitivity and large and continuous 
insulin infusions were required to achieve nonnoglycemic over one day, as shown in Figure 
7.6. 
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11me (days) 
FIGURE 7.6: INSULIN INFUSION PROFILE OVER DATA FITTING PERIOD FOR 
PATIENT 130 
Although the model captures the large majority of blood glucose measurements throughout, 
it does miss a few data points at the peaks and troughs of the blood glucose profile. The 
blood glucose measurement of 12.3 mmollL at 1.04 days was at first thought to be an error, 
but is probably the result of the insulin infused changing from 6 U/hr to 3 U/hr and back 
again during this time. Another problem in the data gathered is that the hourly blood 
glucose readings and insulin infusions, may not actually have occurred on the hour as is 
assumed in the model fits. The bedside charts give the nurses one space for each half an 
hour to record the blood glucose measurement and insulin infusion, and in the recording for 
the retrospective data audit, blood glucose and insulin infused were recorded hourly. Thus 
the values assumed to occur on the hour, might actually have occurred at any time during 
that hour, leading to discrepancies between modelling and actual data. Despite these 
problems, it can be seen that the larger error for patient 130 is largely due to 2-4 
measurements with large errors over the 1.3 days fitted. 
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Patient 289 showed a less volatile glucose response curve, but still had a reasonably high 
percentage elTor. The main area of en-or occUlTed at the sudden blood glucose drop at 0.88 
days. The model was unable to capture the drop from 8.8 mmollL to 3.4 Imnol/L in four 
hours then back to 6.6 mmollL two hours later. This 5.4 mmollL drop was the result of 
increased insulin infusion fi-Oln 1 to 2 U/hr immediately following the 8.8 mmollL 
measurement. The infusion was then turned off following the possible hypoglycemic 
episode, resulting in glucose cycling and poor management. The feed stayed relatively 
constant during this time. However, the model still captured the basic trend in this area, 
and the large percentage elTor is a result of the smoothing of patient specific parameter fits 
to avoid sudden non-physiological changes. 
Overall, the fits at both ends of the scale are very good. Where larger elTors are seen, so 
too are larger standard deviations, indicating the presence of a few measurements with 
larger elTors, as seen in Figure 7.7. Finally, there is always the possibility that some 
measurements are contaminated or otherwise in error where some of the larger elTors occur, 
particularly if the measurement is a relatively high or low value for the patient. However, it 
bears repeating that tall fits over this diverse group were at or within measurement error, 
indicating that the very simple model defined is capable of capturing the dynamics 
observed. 
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7.6 MODEL PREDICTION 
It is not enough to capture dynamics by fitting, the model must also be able to predict 
upcoming behaviour and trends at least 1 - 2 hours ahead for use in central. A model that 
fits observed dynamics well and provides good predictions is well verified for clinical 
control applications presented. 
Patients 24, 130 and 554 were used to test prediction capabilities of the model. These 
patients were chosen because they had a number of measurements one hour apart to 
measure predictive quality at any point. To make a forward prediction from a given point, 
the model fit from the data of the previous eight hours was used. Note that predictions are 
insensitive to the length of time fitted prior to prediction as long as it is greater than two 
hours or 3 4 measurements. The prediction is made by holding the current patient 
specific parameters, pG and Sf, and the equilibrium glucose level, GE, constant over the next 
four hours. The model value is then compared to the actual data for the.'Ie four hours and 
the percentage error, ej, is calculated at one, two, three and four hours 
e. = 
I 
-G (t) 
dala i X 100 
Grlt/ta(ti) 
(7.2) 
These time periods are chosen to represent the range of time over which control might be 
exerted without measurement. 
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7.6.1 Patient 24 Prediction Results 
Figure 7.8 shows an example of one of the predictions made from an eight hour window. 
As this patient's blood glucose was decreasing and the patient specific parameters, pO and 
SI, were held constant as shown in Figure 7.9, the general trend has been missed by the 
model in this prediction. The data between 1500 and 2700 minutes was used for making 
predictions, and the prediction errors calculated using Equation (7.2) were dependent on the 
variability of the glucose data. 
Table 7.4 shows the average prediction errors one, two, three and four hours ahead, and 
their standard deviations, for 16 sets of predictions obtained fi'om each hour between 1500 
and 2460 minutes. The prediction error increased with increasing prediction time interval 
as expected, and shown in Table 7.4. The errors range from 6.77 % to 14.56 %. 
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FIGURE 7.9: PATIENT 24 SPECIFIC PARAMETERS FOR PREDICTION, 
GLUCOSE CLEARANCE (LEFT) AND INSULIN SENSITIVITY (RIGHT) 
TABLE 7.4: PATIENT 24 PREDICTION ERRORS 
Prediction Prediction Average Error Standard 
Error Time (hours) Prediction Deviation (%) Error (%) 
el 1 6.77 4.68 I 
e2 2 7.34 6.67 I 
e3 3 14.15 7.77 
I 
e4 4 14.56 11.71 I 
7.6.2 Patient 130 Prediction 
195 
Patient 130 had a more variable glucose profile than patient 24 during the eight hour 
window leading up to the prediction period shown as an example in Figure 7.1 O. The 
variability was high throughout the 720 to 1740 minutes used for prediction testing, and 
this variability is reflected by higher error values and standard deviations in Table 7.5. 
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TABLE 7.5: PATIENT 130 PREDICTION ERRORS 
Prediction Prediction .Average Error Standard 
Error Time (hours) Prediction Deviation (%) Error (%) 
el 1 10.92 10.02 
e2 2 15.87 15.46 
e3 3 19.55 15.34 
e4 4 22.97 19.33 
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7.6.3 Patient 554 Prel/ictioll 
Patient 554 also had a reasonably vmiable glucose profile throughout the 2.3 days fitted, as 
shown by the relatively high errors and standard deviations in Table 7.6. Figure 7.11 
shows a peIiod of the 1200 minutes used for prediction that has relatively small en'Ol'S due 
to the stability in the glucose profile at that time. 
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TABLE 7.6: PATIENT 554 PREDICTION ERRORS 
Prediction Prediction Prediction Error Standard 
Error Time (hours) Error(%) Deviation (%) 
el 1 10.73 9.79 
e2 2 16.90 12.69 
e3 3 18.88 15.45 
e4 4 22.13 18.21 
8 hour window of modellin 
I 
t (hours) 
FIGURE 7.11: PATIENT 554 PREDICTION EXAMPLE 
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lbe average prediction errors shown in Table 7.4, Table 7.5 and Table 7.6 are close to the 
measurement error for the first hour. By holding the patient specific parameters, PG and Sf, 
constant when there is a known variation in insulin sensitivity, a compromise between 
insulin sensitivity rising and falling is made, reducing the worst case error of prediction 
from a trend. Overall, the predictive ability demonstrated is acceptable for tight control 
only over the first hour. 
7.7 CYCLICAL VARIATION IN INSULIN SENSITIVITY 
A number of researchers have explored the idea of variation in insulin sensitivity in 
ambulatory diabetic and normal individuals (e.g. Arasaradnam, et aI., 2002; Radziuk, 2000; 
Wilinska, et aI., 2003). To the author's knowledge, little is known about variations of 
insulin sensitivity in critically ill patients. By using the insulin sensitivity profiles from 
long-term data fitting of the 17 patients considered, any cyclical variations may be 
observed. 
To find the period of a cycle in these patients, the average oscillation period of insulin 
sensitivity, Sf, must be detennined. This value is obtained by finding the inflection points 
in the insulin sensitivity curve, S,(t), and averaging the distance between every second 
inflection point. An inflection point is where the second derivative is zero. To find 
inflection points in this noisy data, the insulin sensitivity curve, S,(t), is low pass filtered, as 
shown in Figure 7.12, where every second inflection point is shown by a '0'. Patient 519 in 
199 
Figure 7.12 has a mean cycle length of 0.49 days (approximately 12 hours), and a standard 
variation of 0.1 0 days (approximately 2 -- 3 hours). 
The mean and standard deviations of the cycle lengths for each patient are found in Table 
7.7, along with the number of cycles found in their data. The range in cycle length is 0.23 ~ 
0.54 days (5.5 ~ 13.0 hours). Taking into account the number of cycles for each patient, the 
average period over all the patients is 0.45 days (l0.8 hours) which is very close to half a 
day, suggesting a half day cycle in critically ill patients. 
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TABLE 7.7: CYCLICAL VARIATIONS IN INSULIN SENSITIVITY 
ICU Patient Mean Cycle Cycle Standard Number of 
, Number Period (days) Deviation (days) Cycles 
24 0.54 0.17 3 
87 0.50 0.]2 12 
130 0.23 0.03 2 
229 0.42 0.16 23 
289 0.40 0.10 3 
468 0.43 0.17 3 
484 0.40 0.10 3 
486 0.52 0.03 2 
519 0.49 0.10 24 
554 0.46 0.l1 4 
666 0.46 0.11 3 
847 0.35 0.15 2 
1016 0.42 0.07 3 
1025 0.29 0.06 2 
1090 0.54 0.06 2 
1099 0.46 0.06 2 
1125 0.32 0.02 3 
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7.8 CONCLUSIONS 
The long-term fitting results show great promise, as the model was accurately able to 
capture the measured data to within the measurement enol' of the sensor. The strength of 
this model is that it has been able to capture the observed dynamics to within a small error 
across a wide range of patients, including Type 1, Type 2 and non-diabetic individuals, as 
well a wide range of injuries and illnesses. Using mainly generic parameters and only two 
patient specific parameters the results show the power of this simple, non-linear model. 
Predictions are to within 11 % in the first hour, and up to 23 % over four hours. This result 
is comparable to the ranges expected for 1 - 4 hour glucose variation obtained using the 
statistics presented in Chapter 2. Basically, if a measurement is to be accurate to within 10 
%, it should be measured every hour. The prediction is more successful when the patient's 
glucose levels are in steady state, and hence the patient specific parameters, pG and Sf, are 
unlikely to change much. If the patient's glucose metabolism is changing as a result to an 
external perturbation to the system or their condition, then the predictions will not be as 
accurate, as expected 
From this limited research, there appears to be a twice daily variation in insulin sensitivity 
in critically ill patients. An oscillatory period of between 0.42 and 0.54 days was observed 
over most of the 17 patients with an average of 0.45 days. Additional research is required 
to confirm this phenomenon and determine its cause. 
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CONCLUSIONS 
8.1 THE NEED :FOR CONTROL 
The retrospective data audit of 201 patients that had a length of stay of greater than 72 
hours in the Christchurch Hospital lCU over a 1 year period has shown the validity of 
developing a closed-loop control algorithm for clinical situations. The study showed that 
of the critically ill patients considered, 19 % had at least one glucose measurement above 
15 mmol/L, which is potentially harmful. It was shown that a reduced mean, maximum 
and range of blood glucose levels were associated with reduced mortality so survivors were 
more likely to have lower values of these metrics than non-survivors (P 0.014, P = 0.001 
, and P = 0.003, respectively). 
The proportion of stay and average insulin infused both had a negative effect on mortality 
(P = 0.02 and P 0.01, respectively). Hence, it is suggested that it is the reduction of 
glucose levels, not the insulin infusion that is beneficial to survival. As a result, future 
work will consider regulating hyperglycemia by controlling the dextrose input Finally, 
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from retrospective observation ofthe glucose and insulin infusion data in these patients, the 
combination of intuitive control and the sliding scale protocol employed, leads to glucose 
cycling, which could be also eliminated by use of well-designed control. 
The Christchurch Hospital protocol of measuring and recording blood glucose at least 
every four hours was often not followed. This result could occur because the clinical staff 
were too busy or did not see controlling blood glucose levels as a priority for the patient. 
The advance of blood glucose sensing devices will allow coupling glucose data with an 
insulin infusion system and control algorithm, freeing the clinical staff from some 
responsibility in this area to focus on . other aspects of the patient's health. The fact that 
measurements were taken more frequently in non-survivors than survivors (P 0.03) 
suggests that those patients in worse health were monitored more closely. 
8.2 MODEL DEVELOPMENT 
The model was developed from a simple two-compartment model to a more complex, yet 
more physiologically justified, non-linear model. lbis model accounts for non-linear 
saturation of exogenous insulin appearance rate and its saturable utilisation to reduce blood 
glucose levels. The addition of delayed insulin utilisation via a convolution integral has 
accounted for the accumulation dynamic seen in prior clinical trials, and better matches 
physiological knowledge. 
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Removing endogenous insulin production from the model reduced model complexity and 
improved model parameter fits in cases where exogenous insulin was infused. However, 
where there was no exogenous insulin the basal endogenous insulin term is still required. 
The addition of insulin appearance and glucose clearance saturation are physiologically 
justified, but require more clinical testing is required to detennine whether the glucose 
clearance saturation is justified. The objective of keeping complexity to a minimum has 
been aehieved, and the model has been shown to be proficient in both short-tenll and long-
tenn fitting, as well as in clinical adaptive control applications. 
8.3 PARAMETER VERIFICATION 
An extensive literature review found a wide range of parameter values detennined by many 
different methods. The challenge came in converting the values found in the literature into 
useful values or ranges for use in the system model. Patient specific parameters, PG and SI, 
that are known to change over time, were assigned constraints in the fitting process of the 
system model to keep them within physiological ranges found in the literature, resulting in 
constraints of 0.01 :S PG :S 0.02 and 0.00001 :S Sf :S 0.0025. Estimates for generic 
parameters, such as aI, aG, k and n, were obtained, and later verified using both short-term 
and long-tenn retrospective data, as well as during clinical trials. 
A novel method for identifYing patient specific parameters is presented. This method 
utilises the integral of the glucose deri vative equation to find the unknowns, PG and Sf. The 
result is a convex, computationally simple, linear, least squares solution. 
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8.4 TARGETED CONTROL 
The clinical trials showed the efficacy of the adaptive control algorithm and system models 
in achieving targeted control across a range of critically ill patients. Targets were achieved 
in the final two trials with an average error of 4.25 %, which is well within the 
measurement error. Ideally, a larger patient cohort will be subjected to the current model in 
order to further analyse its effectiveness and find areas in which improvements could be 
made. The resulting model and controller must have high levels of robustness, and 
accurately capture the essential dynamics of the glucose-insulin metabolic system across a 
number of patients with various levels of insulin resistance and glucose intolerance. 
8.5 LONG TERM DATA FITTING 
The parameter identification method developed shows great promise for drug therapy 
control algorithms. The model was accurately able to capture the dynamics in the 
measured data to within the 7 % measurement error of the sensor. From this limited 
research, there also appears to be an oscillation in insulin sensitivity in critically ill patient 
with a period of approximately half a day. Additional research may be required to confirm 
this phenomenon. 
Predictions are to within 11 % in the first hour, and up to 23 % over four hours. The 
predietion is more successful when the patient's glucose levels are in steady state, and 
hence the patient specific parameters, pG and Sf, are unlikely to change much. Overall, the 
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predictive ability demonstrated by the model and parameter fitting is acceptable for tight 
control only over the first hour. 
8.6 SUMMARY 
This research has successfully quantified hyperglycemia in critically i1I patients showing 
the need for glucose control in critically ill patients. The relatively simple system model 
developed effectively captures the essential dynamics of the glucose~insulin metabolism, 
over short and long tenn periods, and provides a foundation for developing semi~automated 
control protocols. The level of existing and emerging technology allows a closed~loop 
automated system to be realised for tight glycemic control in closely monitored clinical 
situations. Overall, the research presented is a significant step towards fully automated 
adaptive control of hyper glycaemia in critically ill patients. 
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9 
FUTURE WORK 
9.1 INTRODUCTION 
Although the thesis presented has covered a wide range of modelling, literature reviews, 
data analysis and clinical trials, it has not been extensive enough to cover a number of the 
questions and objectives proposed. The ultimate objective of the research is to develop a 
medical control system that can be used to control glycemic levels in both clinical 
situations and ambulatory patients. To achieve this goal, extensive modelling and testing is 
required, justifying the models and eontrol methods utilised. 
9.2 MODEL DEVELOPMENT 
Modelling of the glucose regulatory system should have a greater focus on patient 
variability and robustness, while maintaining the simplicity that ensures its use in clinical 
situations and that minimal computational power is required. A range of clinical and 
retrospective trials should be used to verify model improvements. It is also hoped that the 
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model can be extended to include other metabolic processes, both within and outside the 
glucose-insulin response system. 
The existing intravenous two-compal1ment model could be used in conjunction with 
Markov simulations to detelmine the impact of the valiability of patient specific 
parameters, pG and Sf. By using Markov simulations, the tendency of one event to be 
followed by another is analysed, and hence Markov simulations can be used to find the 
extent of the variation in patient specific parameters using retrospective data. The addition 
of a stochastic component to the glucose clearance and insulin sensitivity parameters, pG 
and Sf, will create models that more 'accurately capture these variations, resulting in an 
increased robustness in the controller that will increase it's accuracy across a wider 
population of patients. The overall goal of this eff0l1 would be to design models and 
controllers with broader applicability a 'one size fits all' goal. 
The same model could also be used as a basis for control1ing glycemic levels by varying 
glucose, rather than insulin, infusions. Although the system model already accounts for an 
external glucose input, P(t), the accuracy of the dynamics involved in transp0l1ation and 
loss of glucose have not been closely examined using this model. Parameters such as 
external glucose input, P(t), glucose clearance, PG, and glucose clearance saturation, aG, 
will have to be scrutinised, and the trade-offs between glucose clearance, pG, and insulin 
saturation, Sf, will probably become more apparent. 
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The model wi]] need to be extended for use in both ambulatory patients and clinical patients 
without arterial lines. It will therefore need to consider transp0I1ation delays and losses of 
insulin through the sub-cutaneous layer. As a result, the two-compat1ment model used for 
intravenous insulin infusions may be converted back to a three-compartment model similar, 
but with increased complexity, to that of Bergman et al (1985). Both ambulatory patients 
and clinical patients are likely to be receiving glucose as a meal input with a variety of food 
that break down into glucose in different ways, unlike the majority of critically ill patients 
that receive an almost constant feed infusion, and so the log-nonnal glucose input, P(t), 
proposed by Lam et al (2002) and used by Doran et al (2004a; 2004b) and Chase et al 
(2003) in clinical trials will have to be re-evaluated. 
Finally, as the glucose-insulin system model is vely similar to those in a variety of 
phannacodynamic systems, the general modelling and control methods developed in the 
proposed research may be extended to these similar systems. Such systems may include 
the agitation-sedation cycle in sedated JCU pqtients and the administration of certain 
antiviral drugs. 
9.3 CONTROLLER DEVELOPMENT 
Controllers employed to date in conjunction with this model have included heavy 
derivative control (Chase, et aI., 2002; 2003; Doran, et al., 2004a; 2004b; Lam, et al., 2002) 
and sub-target control (work unpublished) using intravenous insulin infusions. It is 
envisioned that future work may employ both these control regimes and invol ve the 
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development of others. The main aim of control development is to produce an efficient 
controller that is highly robust to v31iations between patients. The adaptive controller, as 
used in this thesis to achieve sub-targets, is likely the method that will be used for control 
in the near future. This method will be tested with both retrospective data and in a clinical 
environment, probably in the ICU. 
This year will also see the introduction of varying glucose infusions as a method to achieve 
set sub-targets. Research has shown that enteral feeding in critically illpatientsofien gives 
excess to requirements (Patino, et aL, 1999; Weissman, 1999; Woolfson, 1980), and by 
using a constant insuEn infusion and changing the input of dextrose int!? the human 
glucose-insulin system, the method of control has been reversed. The results of both 
insulin and glucose controlled glycemic levels may well be used in conjunction in the 
future to achieve optimal control of blood glucose levels in critically ill patients. 
9.4 CLINICAL TRIALS 
It is expected that the research focus in the future will remain on critically ill patients, as 
due to the technology development and legal issues, it is likely that a clinical enviromnent 
is the first place an automated glucose control unit will be implemented. The results 
obtained from both clinical trials and retrospective data on ICU patients can easily be 
extended to other hospital situations, such as cardiac, paediatric and post-operative critical 
care, as well as for diabetic patients in the wards. 
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The data gathered from the retrospective audit of the Christchurch Hospital ICU over one 
year, gives a wealth of patient data for use in model and parameter verification. Future 
work may include the addition of more retrospective data to this subset, from both the 
Christchurch Hospital lCU and other hospitals, as a number of other researchers are 
considering similar retrospective trials. 
As well as hyperglycemic critically ill patients, future work should also consider supra-
glycemic diabetic keto-acidosis patients (DKA's). These patients are admitted to hospital 
in a coma-like state as a result of extremely high glucose levels, and due to their sensitive 
nature, the glucose control is best done in steps over a period of time. This situation is 
ideally suited to the sub-target adaptive controller already in use in clinical trials, and is a 
potential future application for the work developed here. 
To test the addition ofthe effects of subcutaneous insulin infusion, retrospective data is also 
available from the Christchurch Hospital Lipids and Diabetes Research Group. This data is 
from OOTI's on Type 1 and Type 2 diabetic individuals. There may also be scope to test 
the subcutaneous model and parameters developed on ambulatory patients. 
9.5 COMMERCIAL VIABILITY 
The future of this research all ends in a final commercial product. As well as the research 
to be undertaken, there are a number of other factors involved in getting a product to 
market. The glucose controller mechanism will have to go through stages such as design 
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prototyping, reliability testing and market research. The commercial viability in both 
clinical and ambulatory situation will obviously need to be considered in research 
development models in future. 
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